JP2006056884A - Medicinal composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicinal composition containing a new medicinally useful pyrazolopyrimidine compound having an excellent SK (small conductance Ca<SP>2+</SP>-activated K<SP>+</SP>) channel-blocking activity, as an active ingredient. <P>SOLUTION: This medicinal composition contains a compound expressed by general formula [I] [wherein, R<SP>1</SP>is (A) a substituted aryl, (B) a nitrogen-containing aliphatic heterocyclic single ring group which may be substituted, (C) a substituted cyclic lower alkyl, (D) a substitutable amino or (E) a substituted heteroaryl; R<SP>2</SP>is (a) a substitutable heteroaryl or (b) a substitutable aryl; Y is a single bonding hand, a lower alkylene or a lower alkenylene; Z is CO, CH<SB>2</SB>, SO<SB>2</SB>or a group expressed by formula [II]; Q is a lower alkylene; and (q) is 0 or 1] or its pharmacologically acceptable salt as an active ingredient. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

The present invention relates to a pharmaceutical composition comprising a novel pyrazolopyrimidine compound or a pharmacologically acceptable salt thereof as an active ingredient, which has an excellent small conductance Ca ²⁺ -dependent potassium (SK) channel blocking action and is useful as a pharmaceutical. Related to things.

Ca ²⁺ -dependent potassium channels are classified into at least three types: large (BK), medium (IK) and small (SK). These potassium channels are activated by increasing intracellular Ca ²⁺ concentration. BK and IK channels are sensitive to changes in membrane potential in addition to intracellular Ca ²⁺ , but SK channels are not characterized by significant membrane potential sensitivity. The SK channel is also characterized by its low single channel conductance (6-20 pS) and high sensitivity to apamin.

  SK channels are present not only in excitable cells such as nerves and muscles but also in a wide variety of cells such as liver and blood cells, and are involved in cell functions such as release of chemical mediators, muscle contraction, and secretion.

  As a selective blocker for the SK channel, apamin is well known, and its pharmacological action includes enhancement of the motor transport function of the gastrointestinal tract (Non-Patent Document 1) and improvement of learning and memory impairment (Non-Patent Document 2). ) And shortening of the immobility time in the forced swimming test (Non-Patent Document 3) have been reported. In patients with myotonic dystrophy, the presence of a specific binding site of apamin in skeletal muscle and symptom reduction by administration of apamin have been reported (Non-patent Document 4). Furthermore, it has been reported that mice in which SK3, which is one of the SK channel subtypes, is forcibly expressed, develop respiratory dysfunction under low oxygen partial pressure (Non-patent Document 5).

  As a compound exhibiting a SK channel blocking action, Patent Document 1 discloses 1,1 ′-(α, α′-para-xylene) -3,3 ′-(α, α′-meta-xylene) -bis (benzimidazo). Bis (benzimidazole) derivatives such as Lithium) are disclosed in Patent Document 2 in 7,18-diaza-3,4 (1,4) -dibenzena-1,6 (1,4) -diquinolinacyclooctadecaphane. Cyclophane derivatives such as 3 trifluoroacetic acid hydrate are cross-linked to Patent Document 3, such as 1,4-bis- (2-methyl-quinolin-4-yl)-[1,4] -diazepane. Bisquinoline derivatives are disclosed. Patent Document 4 discloses a compound having a spirocyclohexane-1,1 ′ (2′H) -isoquinoline skeleton as a compound having an SK channel blocking action.

International Patent Publication WO00 / 01676

International Patent Publication No. WO97 / 48705 US Pat. No. 5,866,562 International Patent Publication No. WO02 / 79189 S. A. Waterman and M. Costa, J. Physiology 477, 459-468, 1994; N. Spencer et al., J. Physiology 517, 889-898, 1999 S. Ikonen et al., Eur. J. Pharmacol. 347, 13-21, 1998; C. Ghelardini et al., Br. J. Pharmacol. 123, 1079-1084, 1998 N. Galeotti et al., Br. J. Pharmacol. 126, 1653-1659, 1999 J.F.Renaud et al., Nature 319, 678-680, 1986; M.I.Behrens et al., Muscle & Nerve 17, 1264-1270, 1994 C. T. Bond et al., Science 289, 1942-1946, 2000

  An object of the present invention is to provide a pharmaceutical composition comprising a novel pyrazolopyrimidine compound having an excellent SK channel blocking action and useful as a pharmaceutical as an active ingredient.

  The present invention relates to general formula [I]:

(Wherein R ¹ is
(A) a substituted aryl group,
(B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group,
(C) a substituted cyclo-lower alkyl group,
(D) an optionally substituted amino group, or (E) a substituted heteroaryl group,
R ² is
(A) an optionally substituted heteroaryl group, or (b) an optionally substituted aryl group,
Y is a single bond, a lower alkylene group or a lower alkenylene group,
Z is —CO—, —CH ₂ —, —SO ₂ — or the following formula:

A group represented by
Q is a lower alkylene group,
q represents 0 or 1)
Or a pharmacologically acceptable salt thereof as an active ingredient.

In the compound [I] which is an active ingredient of the present invention, when R ¹ is (A) a substituted aryl group, the substituent on the aryl group is as follows:
(I) hydroxyl group;
(Ii) a halogen atom;
(Iii) a lower alkyl group;
(Iv) a lower alkyl group optionally substituted with a hydroxyl group, a lower alkoxy lower alkyl group, an amino lower alkanoyl group (the amino part of the group is a lower alkyl group, a lower alkoxycarbonyl group or the following formula:

(Wherein R ³¹ represents a lower alkyl group)
A mono- or di-lower alkylamino lower alkyl group, a mono- or di-lower alkylcarbamoyl group, a lower alkanoyl group optionally substituted with a hydroxyl group, a cyclo-lower alkylcarbonyl group, a lower group An alkoxy lower alkanoyl group, a lower alkoxy lower alkoxycarbonyl group, a cyclo lower alkyl lower alkyl group, a lower alkyl sulfonyl group, an aryl lower alkyl group (the aryl portion of the group may be substituted with a mono- or di-lower alkylamino group) , A lower alkenoyl group, a thiocarbamoyl group optionally substituted with a lower alkyl group, a heteroarylcarbonyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower Alkanoyl group, arylsulfonyl group Aryl moiety of the group may be substituted with a mono- or di-lower alkylamino group), the following formula:

(Wherein R ³² represents a lower alkoxy group)
An amino group optionally substituted with one or two groups selected from a group represented by the above and a nitrogen-containing aliphatic heteromonocyclic group optionally substituted with a lower alkyl group;
(V) an amino group (the group may be substituted with a group selected from a lower alkyl group and an aryl lower alkyl group), a heteroaryl group optionally substituted with a lower alkyl group, and a lower alkyl group; A lower alkoxy group which may be substituted with a group selected from nitrogen-containing aliphatic heteromonocyclic groups which may be
(Vi) a lower alkyl group, lower alkanoyl group, mono- or di-lower alkylamino lower alkyl group, mono- or di-lower alkylamino lower alkoxycarbonyl group, lower alkoxy-lower alkanoyl group, mono- or di-lower optionally substituted with a hydroxyl group Alkylcarbamoyl group, lower alkoxy lower alkoxycarbonyl group, lower alkoxy lower alkyl group, cyclo lower alkylcarbonyl group, aryl lower alkyl group, cyclo lower alkyl group, cyclo lower alkyl lower alkyl group, nitrogen-containing aliphatic heteromonocyclic group substitution Lower alkoxycarbonyl group and the following formula:

(Wherein R ³³ represents an amino group, a mono- or di-lower alkylamino group, or a mono- or di-lower alkylamino lower alkylamino group)
An amino lower alkyl group optionally substituted with a group selected from the groups represented by:
(Vii) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group optionally substituted with a group selected from a hydroxyl group, a lower alkyl group optionally substituted with a hydroxyl group, a lower alkoxy lower alkyl group and a carbamoyl group;
(Viii) a carbamoyl optionally substituted by a group selected from a lower alkyl group, a mono- or di-lower alkylamino lower alkyl group, a heteroaryl group-substituted lower alkyl group and a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group Group;
(Ix) a nitrogen-containing aliphatic heteromonocyclic group which may be substituted with a lower alkyl group (the nitrogen-containing aliphatic heteromonocyclic group may be bonded to the aryl group moiety through an oxygen atom) ;
(X) a nitro group;
(Xi) a cyclo-lower alkyloxy group optionally substituted with a mono- or di-lower alkylamino group;
(Xii) a lower alkenyl group optionally substituted with a group selected from a mono- or di-lower alkylamino group and a nitrogen-containing aliphatic heteromonocyclic group;
(Xiii) a lower alkynyl group optionally substituted with a group selected from a nitrogen-containing aliphatic heteromonocyclic group and a mono- or di-lower alkylamino group;
(Xiv) a lower alkylthio group optionally substituted with a mono- or di-lower alkylamino group; and (xv) a cyclo-lower alkyl lower alkoxy group (the cyclo-lower alkyl portion of the group is a mono- or di-lower alkylamino lower alkyl group). May be substituted),
1 to 3 groups selected from the same or different.

In the compound [I] which is an active ingredient of the present invention, when R ¹ is (B) a nitrogen-containing aliphatic heteromonocyclic group which may be substituted, As the substituent, for example,
(I) a lower alkyl group;
(Ii) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkanoyl group;
(Iii) mono- or di-lower alkylamino lower alkanoyl group;
(Iv) a lower alkoxy lower alkyl group;
(V) a mono- or di-lower alkylamino lower alkyl group;
(Vi) a cyclo-lower alkyl group;
(Vii) a heteroaryl group;
(Viii) a nitrogen-containing group which may be substituted with a group selected from a lower alkanoylamino group, a lower alkyl group, a carbamoyl group and a lower alkoxy lower alkyl group, and which may have one or more double bonds in the ring An aliphatic heteromonocyclic group; and (ix) a lower alkyl group, a mono- or di-lower alkylamino lower alkyl group, a cyclo lower alkylcarbonyl group, a lower alkenoyl group, a heteroarylcarbonyl group, a lower alkoxy lower alkyl group, a lower alkanoyl group And an amino group optionally substituted with a group selected from a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group,
The group chosen from is mention | raise | lifted.

In the compound [I] which is an active ingredient of the present invention, when R ¹ is a (C) substituted cyclo lower alkyl group, the substituent on the cyclo lower alkyl group is:
(I) Lower alkyl group, mono- or di-lower alkylamino lower alkanoyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkanoyl group, mono- or di-lower alkylamino lower alkyl group, lower alkanoyl group, cyclo lower alkylcarbonyl group A lower alkenoyl group, a heteroarylcarbonyl group, an arylcarbonyl group (the aryl portion of the group may be substituted with a halogen atom), a lower alkylthiocarbamoyl group, a lower alkoxycarbonyl group, a cyclo-lower alkyl group,

(Wherein R ³⁴ represents a mono- or di-lower alkylamino group)
An amino group which may be substituted with a group selected from the group represented by: cyclo lower alkyl lower alkyl group and lower alkyl sulfonyl group;
(Ii) Lower alkyl group optionally substituted with a hydroxyl group, mono- or di-lower alkylamino lower alkanoyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkanoyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower Alkyl group, mono- or di-lower alkylamino lower alkyl group, heteroaryl group-substituted lower alkyl group, lower alkoxy lower alkyl group, lower alkanoyl group, heteroarylcarbonyl group (the heteroaryl part of the group is substituted with a lower alkyl group) Or a lower alkylcarbonyl group, an aryl lower alkyl group, a cyclo lower alkyl group, a cyclo lower alkyl lower alkyl group, a lower alkyl sulfonyl group, a lower alkoxy carbonyl group, a mono or di lower alkyl carbamoyl group, an aryl carbonyl group ( The group Lumpur moiety may be substituted with a group selected from a halogen atom and lower alkoxy group), amino which may be substituted by a group selected from lower alkoxy-lower alkanoyl group and a lower alkenoyl lower alkyl group;
(Iii) a nitrogen-containing aliphatic heteromonocyclic group optionally substituted with a group selected from a hydroxyl group, a lower alkyl group, a lower alkanoyl group and a lower alkoxy lower alkyl group;
(Iv) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group (the nitrogen-containing aliphatic heteromonocyclic group is a lower alkyl group, a carbamoyl (or thiocarbamoyl) group, a hydroxyl group, a lower alkoxy lower alkyl group, a lower group, They may be substituted with a group selected from an alkanoyl group and a mono- or di-lower alkylamino group, and may be condensed with a benzene ring);
(V) a mono- or di-lower alkylamino lower alkoxy group, and (vi) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group (the nitrogen-containing aliphatic heteromonocyclic group is substituted with a lower alkyl group) A carbamoyl group optionally substituted with a group selected from a mono- or di-lower alkylamino lower alkyl group and a lower alkyl group,
And a group selected from:

In the compound [I] which is an active ingredient of the present invention, when R ¹ is (D) an optionally substituted amino group, examples of the substituent on the amino group include a lower alkyl group.

In the compound [I] which is an active ingredient of the present invention, when R ¹ is a (E) -substituted heteroaryl group, the substituent of the heteroaryl group is as follows:
(I) an amino lower alkyl group optionally substituted with a group selected from a lower alkyl group and a lower alkoxy lower alkyl group;
(Ii) a group selected from a cyclo lower alkylcarbonyl group, a mono- or di-lower alkylamino lower alkyl group, a lower alkanoyl group, a lower alkenoyl group, a mono- or di-lower alkylthiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group and a lower alkyl group An amino group optionally substituted by:
(Iii) a carbamoyl group which may be substituted with a group selected from a lower alkyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group and a mono- or di-lower alkylamino lower alkyl group;
(Iv) a lower alkyl group which may be substituted with a halogen atom;
(V) a mono- or di-lower alkylamino lower alkoxy group;
(Vi) an oxo group; and (vii) the following formula:

(Wherein ring A may be substituted by a lower alkyl group, and a benzene ring fused with nitrogen-containing aliphatic optionally heteromonocyclic group, Y ^a is a single bond, lower alkylene group or a lower Alkenylene group, p represents 0 or 1)
A group represented by
The group chosen from is mention | raise | lifted.

In the compound [I] which is the active ingredient of the present invention, when R ² is (a) an optionally substituted heteroaryl group, examples of the substituent on the heterocyclic group include a lower alkyl group, The same or different 1 to 3 groups selected from a lower alkoxy group and a mono- or di-lower alkylamino group, and when R ² is (b) an optionally substituted aryl group, the aryl group Examples of the above substituent include a lower alkyl group, a halogen atom, a halogeno lower alkoxy group, a mono- or di-lower alkylamino group, a lower alkoxy group, a nitro group, a lower alkoxy lower alkyl group, a hydroxyl group, a lower alkoxycarbonyl group, and a lower group. Examples thereof include 1 to 3 groups which are the same or different and are selected from alkanoyl groups.

Examples of the aryl group in R ¹ and R ² include a 6- to 10-membered monocyclic or bicyclic aryl group such as a phenyl group or a naphthyl group.

The nitrogen-containing aliphatic heteromonocyclic group in R ¹ and R ² may have one or more double bonds in the ring, such as azetidinyl group, pyrrolidinyl group, imidazolidinyl group, pyrazolidinyl group, piperidyl group And a 4- to 8-membered nitrogen-containing aliphatic heteromonocyclic group such as a group, piperazinyl group, azepinyl group, diazepinyl group, azeocinyl group, diazeocinyl group, morpholinyl group or 3-pyrrolinyl group. Of these, a 5-membered or 6-membered nitrogen-containing aliphatic heteromonocyclic group is preferable.

Examples of the heteroaryl group in R ¹ and R ² include a heteroaryl group containing an atom selected from a nitrogen atom, a sulfur atom and an oxygen atom as a hetero atom. Examples of such heteroaryl groups include 5- to 14-membered, preferably 5- to 10-membered monocyclic or bicyclic heteroaryl groups, and specific examples include pyrrolyl, imidazolyl, and pyrazolyl groups. Oxazolyl group, thiazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, dihydropyridyl group, pyrazinyl group, pyrimidinyl group, tetrahydropyrimidinyl group, furopyrimidinyl group, pyridazinyl group, imidazolidinyl group, indolyl group, quinolyl group, isoquinolyl group, purinyl Group, 1H-indazolyl group, quinazolinyl group, cinnolinyl group, quinoxalinyl group, nitrogen-containing heteroaryl group such as phthalazinyl group or pteridinyl group, or furyl group, pyranyl group, thienyl group, benzofuryl group or benzothienyl group Heteroaryl group, and the like into the sulfur-containing or oxygen-containing.

  Examples of the lower alkylene group and lower alkenylene group represented by Y include a lower alkylene group having 1 to 8 carbon atoms such as methylene group, ethylene group or propylene group, and 2 carbon atoms such as vinylene group and propenylene group. -8 lower alkenylene groups and the like.

Among the compounds [I] which are the active ingredients of the present invention, preferred compounds include, for example, (a) Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is —CO—, and R ² is a lower alkyl group. , A phenyl group substituted with a group selected from a lower alkoxy group and a halogen atom, a lower alkoxy-substituted heteroaryl group or a lower alkyl-substituted heteroaryl group, a compound in which q is 0, or (A) Y is a single bond , Z is —CH ₂ —, R ² is a lower alkoxyphenyl group, and q is 0.

Among the compounds [I] that are the active ingredients of the present invention, more preferable compounds include, for example, a phenyl group in which R ¹ is substituted with a group selected from (1) (i) to (iii) below,
(I) a lower alkoxy group substituted with a group selected from a mono- or di-lower alkylamino group and a nitrogen-containing aliphatic heteromonocyclic group;
(Ii) a lower alkyl group substituted with a group selected from a mono- or di-lower alkylamino group and a nitrogen-containing aliphatic heteromonocyclic group; and (iii) a lower alkyl group, a cyclo-lower alkylcarbonyl group, a mono- or di-lower group. An amino group substituted with a group selected from alkylamino lower alkyl group and lower alkoxy lower alkoxycarbonyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group, lower alkanoyl group and lower alkenoyl group,
(2) a cyclo-lower alkyl group substituted with a group selected from the following (i) to (iii):
(I) an amino lower alkyl group substituted with a group selected from a lower alkyl group, a hydroxy lower alkyl group, a mono- or di-lower alkylamino lower alkyl group, a lower alkanoyl group, a cyclo lower alkylcarbonyl group and a lower alkoxy lower alkyl group;
(Ii) a nitrogen-containing aliphatic heteromonocyclic group optionally substituted with a hydroxyl group; and (iii) a lower alkyl group, mono- or di-lower alkylamino lower alkyl group, lower alkanoyl group, heteroarylcarbonyl group, lower alkyl An amino group substituted with a group selected from a sulfonyl group and a lower alkylthiocarbamoyl group, or (3) a nitrogen-containing aliphatic heteromonocyclic group substituted with a group selected from the following (i) to (iii):
(I) a lower alkyl group;
(Ii) an amino group substituted with a group selected from a lower alkyl group, a mono- or di-lower alkylamino lower alkyl group, and a cyclo-lower alkylcarbonyl group; and (iii) a nitrogen-containing aliphatic complex unit substituted with a lower alkyl group; Cyclic groups,
A phenyl group, a lower alkyl group-substituted heteroaryl group or a lower alkoxy group-substituted heteroaryl group, wherein R ² is substituted with a group selected from a lower alkoxy group and a halogen atom,
Examples include compounds in which Q is a methylene group.

Among the more preferable compounds [I], a more preferable compound is a group represented by the formula: R ^1- (O) _q -YZ- is 4- (mono- or di-lower alkylamino lower alkyl). Benzoyl group; 4- (pyrrolidino lower alkyl) benzoyl group; 4- (dilower alkylamino lower alkoxy) benzoyl group; 3- (dilower alkylamino lower alkoxy) -4- (dilower alkylamino lower alkoxy) benzoyl group; 4- [Piperidino lower alkoxy) benzoyl group; 4- [N-lower alkyl-N- (di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N-lower alkanoyl-N- (di-lower alkylamino lower alkyl) ) Amino] benzoyl group; 4- [N-lower alkenoyl-N- (di-lower alkylamino lower alkyl) L) amino] benzoyl group; 4- [N-cyclo lower alkylcarbonyl-N- (di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N- (lower alkoxy lower alkoxycarbonyl) -N- (di-lower) 4- (N-lower alkanoyl-N- (pyrrolidino lower alkyl) amino] benzoyl group; [1- (lower alkyl) piperidin-4-yl] carbonyl group; 4- [N -Lower alkyl-N- (di-lower alkylamino lower alkyl) amino] piperidinocarbonyl group; 4- [N-cyclolower alkylcarbonyl-N- (di-lower alkylamino lower alkyl) amino] piperidinocarbonyl group; 4-[(di-lower alkyl) piperidino] piperidinocarbonyl group; [1- (lower alkyl L) piperidin-4-yl] lower alkanoyl group; [1- (lower alkyl) piperidin-4-yl] lower alkenoyl group; 4- (di-lower alkylamino lower alkyl) cyclohexylcarbonyl group; 4- (mono- Or di-lower alkylamino) cyclohexylcarbonyl group; 4- [N-lower alkanoyl-N- (dilower alkylaminolower alkyl) amino] cyclohexylcarbonyl group; 4- [N-lower alkenoyl-N- (di Lower alkylamino lower alkyl) amino] cyclohexylcarbonyl group; 4- [N-heteroarylcarbonyl-N- (dilower alkylaminolower alkyl) amino] cyclohexylcarbonyl group; 4- [N-lower alkylthiocarbamoyl- N- (di-lower alkylamino lower alkyl) amino] cycloto 4- [N- (di-lower alkylamino lower alkyl) -N- (lower alkylsulfonyl) amino] cyclohexylcarbonyl group; 4-[[N-lower alkyl-N- (hydroxy lower alkyl) amino] ] Lower alkyl] cyclohexylcarbonyl group; 4-[[N-lower alkyl-N- (lower alkoxy lower alkyl) amino] lower alkyl] cyclohexylcarbonyl group; 4-[[N-lower alkanoyl-N- ( Di-lower alkylamino lower alkyl) amino] lower alkyl] cyclohexylcarbonyl group; 4-[[N- (cyclolower alkylcarbonyl) -N- (dilower alkylaminolower alkyl) amino] lower alkyl] cyclohexylcarbonyl Group; 4- (pyrrolidinyl) cyclohexylcarbonyl group; 4- (hydroxy Cypyrrolidinyl) cyclohexylcarbonyl group; or 4- (piperidino) cyclohexylcarbonyl group, and R ² substituted with 1 or 2 groups selected from ethoxy group and fluorine atom, phenyl group, ethoxypyridyl group, propyl Examples thereof include compounds that are a pyridyl group or a propylthiazolyl group.

Among the more preferable compounds described above, particularly preferable compounds include those in which R ² is 3-ethoxyphenyl group, 6-propylpyridin-2-yl group, 6-ethoxypyridin-2-yl group, 2-propyl-1, Examples thereof include compounds that are 3-thiazol-4-yl group or 3-ethoxy-2-fluorophenyl group.

Among the compounds [I] which are the active ingredients of the present invention, specific examples of particularly preferred compounds include, for example, 1- (3-ethoxybenzyl) -4- [4- [4- [2- (dimethylamino) ethoxy ] Benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- [2- (1-piperidyl) ethoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (dimethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (diethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (1-pyrrolidinylmethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N- (cyclopropylcarbonyl) -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-[(2-methoxyethoxy) carbonyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl ] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-isobutyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[(1-propylpiperidin-4-yl) carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [3- (1-isopropylpiperidin-4-yl) propionyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (dimethylaminomethyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[(E) -3- (1-isopropylpiperidin-4-yl) acryloyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] Pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [3- (dimethylamino) -2,2-dimethylpropyloxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4 d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4- [4- [3- (dimethylamino) -2,2-dimethylpropyloxy] benzoyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-acetyl-N- [2- (1-pyrrolidinyl) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3 , 4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (ethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4-((3S) -3-hydroxy-1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N- (2-furoyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazine-1- Yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- [N- (crotonoyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N- (methylthiocarbamoyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl ] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4- [4- [N-crotonoyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazine -1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (diethylaminomethyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- [N-isopropyl-N- (2-methoxyethyl) aminomethyl] cyclohexyl] carbonyl] piperazine-1 -Yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4- [4- [2,2-dimethyl-3- (dimethylamino) propyloxy] benzoyl] piperazine-1 -Yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (dipropylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4- (dipropylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (ethylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [3- [2- (diisopropylamino) ethoxy] -4- [3- (dimethylamino) -2,2- (dimethyl) propyloxy] benzoyl] piperazine -1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N- (cyclopropanecarbonyl) -N- [2- (dimethylamino) ethyl] amino] piperidinocarbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- (3,3-dimethylpiperidino) piperidinocarbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine ;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-ethyl-N- [2- (dimethylamino) ethyl] amino] piperidinocarbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N-ethylamino] methyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl) [Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl [Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) Ethyl] amino] methyl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (hydroxy) ethyl] amino] methyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N- (methanesulfonyl) amino] cyclohexyl] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N- (methanesulfonyl) amino] cyclohexyl] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N- (methanesulfonyl) ) Amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- [2- (dimethylamino) ethyl] -N-pivaloylamino] methyl] cyclohexyl] carbonyl Piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (cyclopropanecarbonyl) -N- [2- (dimethylamino) ethyl] amino] Methyl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N-propionylamino] cyclohexyl] carbonyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxy-2-fluorobenzyl) -4- [4-[(trans-4-piperidin-1-ylcyclohexyl) carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] Pyrimidine;
1- (3-Ethoxy-2-fluorobenzyl) -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl] cyclohexyl] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxy-2-fluorobenzyl) -4- [4- [4- (ethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxy-2-fluorobenzyl) -4- [4- [4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
Or a pharmacologically acceptable salt thereof.

When compound [I], which is an active ingredient of the present invention, has an asymmetric carbon atom on the substituent in R ¹ and / or R ² , a plurality of stereoisomers based on the asymmetric carbon atom (diastereoisomer isomerism) The active ingredient of the present invention includes any one of these stereoisomers or a mixture thereof.

  The pyrazolopyrimidine compound represented by the general formula [I], which is an active ingredient of the present invention, can be produced by the following method, but is not limited thereto.

(Method A)
Among the compounds [I] which are the active ingredients of the present invention, the general formula [IA]:

Wherein Z ^a is —CO—, —SO ₂ — or the following formula:

The other symbols have the same meaning as described above. )
The compound represented by the general formula [II]:

(In the formula, the symbols have the same meaning as described above.)
Or a salt thereof and a general formula [III]:
_{^{R 1 - (O) q -Y}} -Z a -OR 3 [III]
(In the formula, R ³ represents a hydrogen atom, a lower alkyl group or a benzyl group, and other symbols have the same meaning as described above.)
It can manufacture by making the compound or its salt shown by react.

When R ³ is a hydrogen atom, this reaction can be carried out in a solvent in the presence of a condensing agent, in the presence or absence of an activator, in the presence or absence of a base. Any solvent may be used as long as it does not affect the reaction. For example, methylene chloride, chloroform, dimethylformamide, dimethylacetamide, tetrahydrofuran, dioxane, toluene, benzene, 1,2-dichloroethane, 1-methylpyrrolidinone, 1, Examples include 2-dimethoxyethane. Examples of the condensing agent include dicyclohexylcarbodiimide (DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC.HCl), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), Diethyl cyanophosphonate (DEPC), diisopropylcarbodiimide (DIPCI), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), carbonylditriazole, N-cyclohexylcarbodiimide-N′-propyloxymethyl polystyrene (PS) -Carbodiimide), N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), hexafluorophosphate 2- (7-azabenzo) Triazol-1-yl) -1,1,3,3-tetramethyluronium (HATU), hexafluorophosphate 2- (1H-benzotriazol-1-yl) -1,1,3,3-tetra Methyluronium (HBTU), bromotrispyrrolidinophosphonium hexafluorophosphate (PyBroP), 2- (1H-benzotriazol-1-yl) -1,1,3,3-tetramethyluronium hexafluoroborate (TBTU), chloro-1,1,3,3-tetramethyluronium hexamer (ACTU), and the like. Examples of the activator include 1-hydroxybenzotriazole (HOBt), hydroxysuccinimide (HOSu), dimethylaminopyridine (DMAP), 1-hydroxy-7-azabenzotriazole (HOAt), hydroxyphthalimide (HOPht), penta Examples thereof include fluorophenol (Pfp-OH), 1-hydroxybenzotriazole-6-sulfonamidomethylpolystyrene (PS-HOBt) and the like. Examples of the base include pyridine, triethylamine, diisopropylethylamine, 4-methylmorpholine, 1,8-diazabicyclo [5,4,0] -undecene (DBU), and the like.

  In this reaction, the amount of compound [II] used can be 0.3 to 10 equivalents, preferably 0.5 to 2 equivalents, relative to compound [III]. The amount of the condensing agent to be used can be 1 to 10 equivalents, preferably 1.5 to 4 equivalents, relative to compound [II] or [III]. The amount of the base to be used can be 1 to 10 equivalents, preferably 2 to 4 equivalents, relative to compound [II] or [III]. The amount of the activator to be used can be 1 to 10 equivalents, preferably 1.5 to 4 equivalents, relative to compound [II] or [III]. This reaction can be carried out at -20 to 80 ° C, preferably 0 to 30 ° C.

In the general formula [III], when Z ^a is a group represented by —CO— and R ³ is a hydrogen atom, the compound is converted into a reactive derivative such as a corresponding acid halide or mixed acid anhydride. Then, the compound [IA] can also be produced by reacting the reactive derivative with the compound [II] in the presence or absence of a solvent in the presence of the above base.

In the general formula [III], when Z ^a is a group represented by —CO— and R ³ is a lower alkyl group or a benzyl group, this reaction can be carried out by subjecting the ester compound to conventional hydrolysis, hydrochloric acid It can also be carried out by treating the carboxylic acid compound and compound [II] in the same manner as described above after conversion to the corresponding carboxylic acid compound by acid decomposition with formic acid, trifluoroacetic acid or the like, or reduction reaction.

Furthermore, in the general formula [III], when Z ^a is a group represented by —CO— and R ³ is a lower alkyl group or a benzyl group, this reaction is carried out in a solvent or without a solvent in the presence of a base. The compound [II] can be directly reacted with the compound [III]. Any solvent may be used as long as it does not affect the reaction. For example, methylene chloride, chloroform, dimethylformamide, dimethylacetamide, tetrahydrofuran, dioxane, toluene, benzene, 1,2-dichloroethane, 1-methylpyrrolidinone, methanol, Examples thereof include ethanol and isopropanol. Examples of the base include triethylamine, diisopropylethylamine, 4-methylmorpholine, 1,8-diazabicyclo [5,4,0] -undecene (DBU), dimethylaminopyridine (DMAP) and the like.

  In this reaction, the amount of compound [III] used can be 0.3 to 10 equivalents, preferably 0.5 to 2 equivalents, relative to compound [II]. The amount of the base to be used can be 1 to 10 equivalents, preferably 1 to 4 equivalents, relative to compound [II] or [III]. This reaction can be carried out at 25 to 150 ° C, preferably 60 to 100 ° C.

(Method B)
Among the compounds [I] which are the active ingredients of the present invention, compounds in which Z is a group represented by —CH ₂ —, that is, the general formula [IB]:

(In the formula, the symbols have the same meaning as described above.)
The compound represented by the formula [II] and the general formula [IV]:
_{^{R 1 - (O) q -Y}} -CHO [IV]
(In the formula, the symbols have the same meaning as described above.)
Can be produced by reacting with a aldehyde compound (lower alkanal or aryl lower alkanal) represented by the above in the presence of a reducing agent in a solvent.

  Any solvent may be used as long as it does not affect the reaction. For example, methylene chloride, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, N, N-dimethylacetamide, 1-methylpyrrolidinone, tetrahydrofuran, Examples thereof include 1,2-dimethoxyethane, 1,4-dioxane, toluene, benzene, ethanol, methanol, isopropanol, acetic acid and the like. Examples of the reducing agent include macroporous triethylammonium methylpolystyrene cyanoborohydride (MP-Cyanoborohydride), sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride and the like. The amount of the reducing agent to be used can be 1 to 10 equivalents, preferably 1 to 4 equivalents, relative to compound [II].

  This reaction can be carried out at -20 to 100 ° C, preferably 0 to 40 ° C.

(Method C)
Among the compounds [I] which are the active ingredients of the present invention, the general formula [IC]:

Wherein R ¹¹ represents an amino group which may be substituted with a group selected from a lower alkyl group, a mono- or di-lower alkylamino lower alkyl group and a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group; Other symbols have the same meaning as above.)
For example, the compound represented by the general formula [V]:

(In the formula, the symbols have the same meaning as described above.)
And a carboxylic acid compound represented by the general formula [VI]:
R ¹¹ -H [VI]
(In the formula, the symbols have the same meaning as described above.)
It can also manufacture by making the amine compound or its salt shown by these react.

  This reaction can be carried out in a solvent in the presence of a condensing agent, in the presence or absence of an activating agent, and in the presence or absence of a base. As a solvent, a condensing agent, an activator, and a base, the solvent, condensing agent, activator, and base which were illustrated by said A method can be used suitably.

  In the above reaction, the amount of compound [V] to be used can be 0.5 to 3 equivalents, preferably 1 to 2 equivalents, relative to compound [VI]. The amount of the condensing agent to be used can be 1 to 10 equivalents, preferably 1.5 to 4 equivalents, relative to compound [V] or [VI]. The amount of the base to be used can be 1 to 10 equivalents, preferably 2 to 4 equivalents, relative to compound [V] or [VI]. The amount of the activator to be used can be 1 to 10 equivalents, preferably 1.5 to 4 equivalents, relative to compound [V] or [VI]. This reaction can be carried out at -20 to 80 ° C, preferably 0 to 30 ° C.

(Method D)
Among the compounds [I] which are the active ingredients of the present invention, the general formula [ID]:

(Wherein R ¹² represents an optionally substituted nitrogen-containing aliphatic heterocyclic monocyclic group or an optionally substituted amino group, and other symbols have the same meaning as described above)
For example, the compound represented by the general formula [VII]:

(Wherein W ¹ represents a reactive residue, and other symbols have the same meaning as described above)
And a compound of the general formula [VIII]:

(In the formula, the symbols have the same meaning as described above.)
Or a compound [II] and a general formula [IX]:

(In the formula, the symbols have the same meaning as described above.)
It can manufacture by making the compound shown by react.

  Any reaction for obtaining compound [ID] from compounds [VII] and [VIII] or from compounds [II] and [IX] can be carried out in a solvent in the presence of a base. Any solvent may be used as long as it does not affect the reaction. For example, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl Examples thereof include sulfoxide and toluene, and examples of the base include triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine and the like. The amount of compound [VIII] or [II] to be used is 0.8 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound [VII] or [IX]. The amount of the base used may be 1 to 4 equivalents, preferably 2 to 3 equivalents, relative to compound [VII] or [VIII] or compound [II] or [IX]. This reaction can be carried out at 25 to 150 ° C, preferably 60 to 120 ° C.

  Compound [VII] includes compound [II] and general formula [X]:

(Wherein, ^{W 2} is a reactive residue, ^{W 1} has the same meaning as defined)
The compound [IX] can be produced by reacting a compound [IX] with the compound [X]. Can be manufactured. In the compound [X], examples of the reactive residue represented by W ¹ and W ² include a halogen atom, a phenoxy group, a p-nitrophenoxy group, a lower alkoxy group, or a nitrogen-containing aromatic heteromonocyclic group. Can be mentioned.

  The reaction for obtaining the compound [VII] or [IX] can be carried out in a solvent in the presence of a base. Any solvent may be used as long as it does not affect the reaction. For example, chloroform, methylene chloride, 1,2-dichloroethane, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl Examples thereof include sulfoxide and toluene, and examples of the base include triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine and the like. Examples of the phosgene precursor include triphosgene and diphosgene (phosgene dimer). Examples of the phosgene equivalent include p-nitrophenyl chloroformate, 1,1′-carbonyldiimidazole, diphenyl chlorocarbonate, and diethyl carbonate. N, N′-disuccinimidyl carbonate, dipyridin-2-yl carbonate and the like. The amount of compound [X] to be used may be 0.2 to 4 equivalents, preferably 0.4 to 2 equivalents, relative to compound [II] or [VIII]. The amount of the base used may be 3 to 6 equivalents, preferably 3 to 4 equivalents, relative to compound [II] or [VIII]. This reaction can be carried out at -4 to 60 ° C, preferably 0 to 30 ° C.

  In this method, it is also possible to obtain compound [ID] continuously without isolating compound [VII] or [IX].

Compound [I], which is an active ingredient of the present invention, can also be produced by converting the substituent on R ^{1 of the} compound obtained as described above into another desired substituent. Such a substituent conversion method may be appropriately selected according to the kind of the target substituent, and can be carried out, for example, as in (Method a) to (Method e).

(Method a)
The compound which is the active ingredient of the present invention having a group containing a substituted lower alkoxy group as a substituent on R ¹ [I], the active ingredient compound of the present invention having a group containing a hydroxyl group as a substituent on R ¹ And a halogenated lower alkyl having a corresponding substituent in the presence of a base (for example, sodium hydride, potassium carbonate).

Alternatively, the active ingredient compound of the present invention having a group containing a hydroxyl group as a substituent on R ¹ and the lower alkanol having the corresponding substituent are mixed in a suitable solvent in the presence of triphenylphosphine and diisopropyl azodicarboxylate. It can also be obtained by reacting with

(Method b)
Compound [I], which is an active ingredient of the present invention having a group containing a lower alkylamino group as a substituent on R ¹ , has a group containing a primary or secondary amino group as a substituent on R ^1. Can be obtained by reacting the active ingredient compound and the corresponding alkyl halide in a suitable solvent in the presence of a base.

(Method c)
The compound [I] which is an active ingredient of the present invention having a group containing an acylamino group such as a lower alkanoylamino group as a substituent on R ¹ is a group containing a primary or secondary amino group as a substituent on R ¹ It is obtained by reacting the active ingredient compound of the present invention having the above and the corresponding carboxylic acid or thiocarboxylic acid compound in the same manner as in Method A above.

(Method d)
As a substituent on R ¹ :

(In the formula, R ¹³ is a hydrogen atom or a lower alkyl group, R ¹⁴ and R ¹⁵ are bonded to each other to form a ring, and n represents an integer of 1 or 2)
Compound [I] which is an active ingredient of the present invention having a group containing a group represented by formula (I) is an active ingredient compound of the present invention having a group containing a primary or secondary amino group as a substituent on R ¹ , Formula [XI]:

(Wherein, X ¹ and X ² represent a halogen atom, and other symbols have the same meaning as described above)
And a product obtained by reacting the compound represented by general formula [XII]:
(R ¹⁴ ) (R ¹⁵ ) NH [XII]
(Wherein the symbols have the same meaning as above)
It can also manufacture by making the amine compound shown by react. This reaction can also be carried out in the same reaction vessel without isolating the intermediate product.

(Method e)
As a substituent on R ¹ :

(Where m represents an integer of 5 or 6)
Compound [I], which is an active ingredient of the present invention having a group containing a nitrogen-containing aliphatic heteromonocyclic group represented by formula (I), is an active ingredient compound of the present invention having a group containing an amino group as a substituent on R ¹ And general formula [XIII]:
_{^{X 3 - (CH 2) m}} -X 4 [XIII]
(Wherein X ³ and X ⁴ are halogen atoms, and other symbols have the same meanings as described above.)
It can obtain by making it react with the compound shown by presence of a base in a suitable solvent.

  In carrying out the above-described methods A to C and a to e, when the raw material compound or each intermediate has a functional group such as an amino group, an appropriate protecting group is introduced into the functional group by a conventional method of synthetic chemistry. If they disappear, those protecting groups may be removed as appropriate.

  Compound [II], which is a synthetic intermediate of compound [I], which is an active ingredient of the present invention, is obtained by, for example, converting compound [XIV] and compound [XV] as follows according to the method described in WO02 / 79189. Compound [II-A] is produced by reaction, and further compound [XVI] is reacted to produce compound [II-B], and then the amino-protecting group is removed from the compound by a conventional method. Can be made.

(In the formula, G represents an amino-protecting group, and other symbols have the same meaning as described above.)
The reaction for producing the above compound [II-A] can be carried out in the presence or absence of a solvent, in the presence or absence of an activator, and in the presence or absence of an additive. Any solvent may be used as long as it does not affect the reaction. Examples thereof include xylene and chloroform. Examples of the activator include hexamethyldisilazane, N, O-bistrimethylsilylacetamide, chlorotrimethylsilane, and the like. Examples of the additive include ammonium sulfate, chlorotrimethylsilane, triethylamine hydrochloride, pyridine hydrochloride, triethylamine and the like.

Compound [II-B] is compound [II-A] and general formula [XVI]:
R ² -QX ⁵ [XVI]
(Wherein X ⁵ represents a hydroxyl group or a leaving group, and other symbols have the same meaning as described above.)
And a lower alkyl having a leaving group in a suitable solvent in the presence of a dehydrating agent or a base. Any solvent may be used as long as it does not affect the reaction. For example, methylene chloride, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, N, N-dimethylacetamide, 1-methylpyrrolidinone, tetrahydrofuran, Examples include 1,2-dimethoxyethane, 1,4-dioxane, toluene, benzene and the like. When X ⁵ is a hydroxyl group, examples of the dehydrating agent include a combination of an azodicarboxylic acid diester and a trisubstituted phosphine or phosphorane, and X ⁵ is a leaving group such as a halogen group, a lower alkylsulfonyloxy group or an arylsulfonyl. In the case of an oxy group or the like, examples of the base include an alkali metal hydroxide such as lithium hydroxide, an alkali metal hydride, an alkali metal carbonate, an alkali metal lower alkoxide, or lithium diisopropylamide (LDA).

  Further, in the compound [II-B], examples of the protecting group G for the amino group include a benzyl group and a lower alkoxycarbonyl group, and these protecting groups can be removed by a conventional method.

Intermediate compound [V] is, for example, compound [II] and general formula [XVII]:
R ¹⁶ -COOH [XVII]
(R ¹⁶ represents a phenyl group substituted with a protected or esterified carboxyl group.)
Or a reactive derivative thereof (for example, a corresponding acid halide such as acid chloride), and a protective group or an ester residue is removed from the product according to a conventional method.

Compound [I], which is an active ingredient of the present invention, and synthetic intermediate [III] or [IV] thereof are a substituent on R ¹ and / or a substituent on R ^{2 of the} compound obtained as described above. Can also be produced by converting to other desired substituents. Such a substituent conversion method may be appropriately selected according to the type of the target substituent, and can be produced by applying, for example, an O-alkylation reaction, a reductive amination reaction, or the like. .

  Compound [I], which is an active ingredient of the present invention obtained by the above-mentioned methods [A] to [C] and [a] to [e], is optionally a pharmacologically acceptable salt. Can also be converted. Conversion to a pharmacologically acceptable salt may be performed according to methods known to those skilled in the art.

  In the present invention, examples of lower alkyl or lower alkoxy include linear or branched ones having 1 to 6 carbon atoms, and particularly those having 1 to 4 carbon atoms. Further, examples of the lower alkanoyl include linear or branched ones having 2 to 7 carbon atoms, particularly 2 to 5 carbon atoms, and examples of the cyclo lower alkyl include 3 to 8 carbon atoms, particularly 3 to 3 carbon atoms. 6 are listed. Lower alkenyl includes those having 2 to 8 carbon atoms, especially 2 to 4 carbon atoms. Lower alkynyl includes those having 2 to 8 carbon atoms, especially 2 to 4 carbon atoms. Examples of the lower alkylene include linear or branched ones having 1 to 6 carbon atoms, particularly 1 to 5 carbon atoms. Examples of the lower alkenylene include linear or branched ones having 2 to 8 carbon atoms, particularly 2 to 4 carbon atoms. Furthermore, as a halogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom is mentioned. Examples of the lower alkenoyl include a linear or branched alkenoyl group having 2 to 8 carbon atoms, particularly a linear or branched alkenoyl group having 3 to 6 carbon atoms. Examples of heteroaryl include 5- to 14-membered heteroaryl containing at least one hetero atom selected from a nitrogen atom, a sulfur atom and an oxygen atom, and in particular, at least one nitrogen atom as a hetero atom. Examples thereof include 5 to 10-membered monocyclic or bicyclic aryl.

  Compound [I] or a pharmacologically acceptable salt thereof, which is an active ingredient of the present invention, exhibits a superior antagonistic action against apamin in a competitive binding test with apamin known as an SK channel blocker. It is useful as a SK channel blocker. Therefore, the compound [I] or a pharmacologically acceptable salt thereof, which is an active ingredient of the present invention, prevents or treats diseases related to the SK channel, for example, gastrointestinal motility functions such as constipation and irritable bowel syndrome Application to the prevention and treatment of insufficiency, learning and memory disorders, emotional disorders, central diseases such as Alzheimer-type dementia, bladder dysfunction such as dysuria, myotonic dystrophy, and sleep apnea.

  In addition, compound [I], which is an active ingredient of the present invention, has a feature of low toxicity and high safety as a medicine.

  Compound [I], which is an active ingredient of the present invention, can be used for pharmaceutical use either in a free form or in the form of a pharmaceutically acceptable salt thereof. Examples of pharmacologically acceptable salts include inorganic acid salts such as hydrochloride, sulfate, phosphate or hydrobromide, acetate, fumarate, oxalate, citrate, methanesulfone. And organic acid salts such as acid salts, benzenesulfonate, tosylate and maleate. In addition, when it has a substituent such as a carboxyl group, a salt with a base (for example, an alkali metal salt such as sodium salt or potassium salt or an alkaline earth metal salt such as calcium salt) can be used.

  The compound [I] or a salt thereof, or the synthetic intermediate [II] or a salt thereof, which is an active ingredient of the present invention, includes any of its internal salts and adducts, solvates or hydrates thereof. .

  Compound [I] or a pharmacologically acceptable salt thereof, which is an active ingredient of the present invention, can be administered orally or parenterally, and can also be used as tablets, granules, capsules, powders, injections. It can be used as a conventional pharmaceutical preparation such as an inhalant.

  The dose of compound [I], which is an active ingredient of the present invention, or a pharmacologically acceptable salt thereof varies depending on the administration method, patient age, body weight, and condition. About 0.0001 to 1 mg / kg per day, especially about 0.001 to 0.1 mg / kg, orally, usually about 0.001 to 100 mg / kg per day, especially about 0.01 to 10 mg / kg It is preferably about kg.

  Specific examples (manufacturing examples) of the active ingredient compounds of the present invention synthesized by the above exemplified methods are shown below, but the active ingredients of the present invention are not limited thereby.

Production example

Production Example 1
4- [N- (cyclopropylcarbonyl) -N- [2- (dimethylamino) ethyl] amino] ethyl benzoate (compound obtained in Reference Example 11) 106 mg in 3 mL of ethanol was added 2N aqueous sodium hydroxide solution 21 μL. And stirred at room temperature overnight. After adding 42 μL of 2N hydrochloric acid to the reaction solution, it is concentrated to obtain a crude product carboxylic acid compound. To this compound was added 2 mL of methylene chloride, 105 mg of 1- (3-ethoxybenzyl) -4-piperazin-1-yl-1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (compound described in WO02 / 79189), 1- Hydroxybenzotriazole 51.7 mg, triethylamine 124.5 μL, and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride 73.4 mg are sequentially added, and the mixture is stirred at room temperature for 19 hours. The reaction mixture is diluted with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated and concentrated. The resulting crude product is purified by NH silica gel flash column chromatography (Chromatorex NH silica gel; manufactured by Fuji Silysia Chemical, solvent; ethyl acetate / chloroform = 1: 0 to 0: 1) to give 1- (3-ethoxybenzyl ) -4- [4- [4- [N- (cyclopropylcarbonyl) -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d Pyrimidine (127 mg, 84% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 597 [M + H] ^< +>.

Production Example 2
Trans-4- (1-pyrrolidinyl) cyclohexanecarboxylic acid / hydrochloride (compound obtained in Reference Example 87 (2)) 26 mg, methylene chloride 3.5 mL, 1- (3-ethoxybenzyl) -4-piperazine-1- Ile-1H-pyrazolo [3,4-d] pyrimidine dihydrochloride 30 mg, 0.5 M N, N-dimethylformamide solution 219 μL in 1-hydroxybenzotriazole, 35.6 μL triethylamine, N-cyclohexylcarbodiimide-N′-propyl 310.4 mg of oxymethylpolystyrene (PS-Carbodiimide 0.94 mmol / g; manufactured by Argonaut Technology) is sequentially added, and the mixture is stirred at room temperature for 24 hours using a parallel reaction apparatus (Quest 210; manufactured by Argonaut Technology). To the reaction solution, 120 mg of macroporous triethylammonium methylpolystyrene carbonate (MP-Carbonate 3.04 mmol / g; manufactured by Argonaute Technology) is added and stirred at room temperature for 3 hours. After separating the liquid layer from the reaction solution, the resin residue is washed successively with chloroform and methanol, and the washing solution is combined with the previous reaction solution and the solvent is distilled off with a centrifugal concentrator. The resulting crude product was purified by high performance liquid chromatography (XTerra PrepMS C18 column; manufactured by Waters, solvent; 10 mM ammonium carbonate / methanol = 1: 1 to 5:95) to give 1- (3-ethoxybenzyl)- 4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (27 mg, 71% yield) as an amorphous solid obtain.
MS (APCI) m / z; 518 [M + H] ⁺
IR (Nujol) cm ⁻¹ ; 1634, 1596, 1555, 1459.

Production Example 3
66 mg of 4- [2- (dimethylamino) ethoxy] benzoic acid hydrochloride (compound obtained in Reference Example 78 (2)), 2 mL of methylene chloride, 1- (3-ethoxybenzyl) -4-piperazin-1-yl -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride 100 mg, 1-hydroxybenzotriazole 49.3 mg, triethylamine 118.6 μL, 1-ethyl-3- [3- (dimethylamino) propyl] carbodiimide hydrochloride 70 mg Are sequentially added and stirred at room temperature for 17 hours. The reaction mixture is diluted with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated and concentrated. The obtained crude product was purified by NH silica gel flash column chromatography (solvent; ethyl acetate / chloroform = 1: 0 to 0: 1) to give 1- (3-ethoxybenzyl) -4- [4- [4 -[2- (Dimethylamino) ethoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (103 mg, 69% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 530 [M + H] ^< +>.

Production Example 4
(1) 1- (3-Ethoxybenzyl) -4-piperazin-1-yl-1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (2 g), triethylamine (2.18 mL) in methylene chloride (20 mL) suspension in ice Under cooling, a solution of 970 mg of terephthalic acid monomethyl chloride in 10 mL of methylene chloride is added dropwise and stirred at room temperature for 1 day. Water was added to the reaction mixture, and the mixture was stirred for 30 minutes and allowed to stand. The methylene chloride layer was separated, the aqueous layer was extracted with chloroform, combined with the previous methylene chloride layer, washed with saturated brine, and dried over anhydrous sodium sulfate. And concentrate. The resulting crude product was purified by silica gel flash column chromatography (Biotage Flash 40M, ethyl acetate / hexane = 1: 1) to give 1- (3-ethoxybenzyl) -4- [4- [4- (methoxy Carbonyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (2.4 g, 98% yield) is obtained as an amorphous solid. MS (APCI) m / z; 501 (M + H) ^<+> .
(2) To a suspension of 2.4 g of the compound obtained in (1) above in ethanol / tetrahydrofuran (1: 1, 25 mL), 10 mL of 10% aqueous sodium hydroxide solution is added dropwise and stirred at room temperature for 19 hours. The reaction mixture is diluted with chloroform, neutralized with 10% aqueous citric acid solution, and extracted twice with chloroform. The extract is washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained crude product carboxylic acid compound 50 mg, N, N-diethylethylenediamine 35.8 mg, 0.5 M N, N-dimethylformamide solution 308 μL in 1-hydroxybenzotriazole, N-cyclohexylcarbodiimide-N′-propyloxymethylpolystyrene ( 328 mg of PS-Carbodiimide (0.94 mmol / g) is sequentially added, and the mixture is stirred at room temperature for 24 hours using a parallel reactor (Quest 210). To the reaction solution, 120 mg of macroporous triethylammonium methylpolystyrene carbonate (MP-Carbonate 3.04 mmol / g) was added and stirred at room temperature for 1 hour. The liquid layer was separated, and the resin residue was washed successively with chloroform and methanol. Concentrate with the above reaction mixture. The obtained crude product was purified by high performance liquid chromatography (XTerra PrepMS C18 column, solvent; 10 mM ammonium carbonate / methanol = 80: 20 to 5:95) to give 1- (3-ethoxybenzyl) -4- [4. -[4- [2- (Diethylamino) ethylcarbamoyl] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (15.6 mg, 19% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 585 [M + H] ^< +>.
(3) The compound obtained in (1) above is dissolved in 1 mL of ethanol, 16 μL of 2N hydrochloric acid is added, the solvent is distilled off, the residue is dissolved in water, and lyophilized to give 1- (3- Ethoxybenzyl) -4- [4- [4- [4- [2- (diethylamino) ethylcarbamoyl] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride is obtained as an amorphous powder.
MS (APCI) m / z; 585 [M + H] ^< +>.

Production Example 5
(1) By treating the compound obtained in Reference Example 1 (3) in the same manner as in Production Example 1, 1- (3-ethoxybenzyl) -4- [4- [4- [N- [3- (dimethyl) Amino) propionyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine is obtained as an amorphous solid.
(2) A mixture of 131 mg of the compound obtained in the above (1) and 24.2 mg of fumaric acid was dissolved in water, and then freeze-dried to give 1- (3-ethoxybenzyl) -4- [4- [4 -[N- [3- (dimethylamino) propionyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine fumaric acid The salt is obtained as a powder.
MS (APCI) m / z; 628 [M + H] ^< +>.

Production Example 6
To 90 mg of 4- [N-[(2-methoxyethoxy) carbonyl] -N- [2- (dimethylamino) ethyl] amino] benzaldehyde (the compound obtained in Reference Example 97), 1.5 mL of tetrahydrofuran, 1- (3- 1. Ethoxybenzyl) -4- (1-piperazinyl) -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride 100 mg, triethylamine 90 μL, acetic acid 73 μL, macroporous triethylammonium methylpolystyrene cyanoborohydride (MP-Cyanoborohydride) 04 mmol / g (manufactured by Argonaute Technology) are sequentially added, and shaken at room temperature for 18 hours using a parallel reactor (MiniBlock; manufactured by METTLER TOLEDO). The reaction solution is separated, the resin residue is washed three times with tetrahydrofuran, and the washing solution and the reaction solution are combined and concentrated. The obtained crude product was purified by NH silica gel flash column chromatography (solvent; ethyl acetate / chloroform = 1: 0 to 0: 1) to give 1- (3-ethoxybenzyl) -4- [4- [4 -[N-[(2-methoxyethoxy) carbonyl] -N- [2- (dimethylamino) ethyl] amino] benzyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (159 mg, Yield 38%) is obtained as an amorphous solid.
MS (APCI) m / z; 617 [M + H] ^< +>.

Production Examples 7 to 83
The corresponding raw material compounds are treated in the same manner as in Production Example 1 or Production Example 1 and Production Example 4 (2) to obtain the compounds described in Table 1 below.

Production Examples 84-92
By treating the corresponding starting material compound in the same manner as in Production Example 2, the compounds shown in Table 2 below are obtained.

Production Examples 93 to 129
The corresponding raw material compounds are treated in the same manner as in Production Example 3 or Production Example 3 and Production Example 5 (2) to obtain the compounds shown in Table 3 below.

Production Examples 130-133
The corresponding raw material compounds are treated in the same manner as in Production Example 4 and Production Example 5 (2) to obtain the compounds described in Table 4 below.

Production Examples 134 to 139
The corresponding starting material compounds are treated in the same manner as in Production Example 6 to obtain the compounds shown in Table 5 below.

Production Examples 140-181
The corresponding raw material compounds are treated in the same manner as in any one of Production Examples 1 to 6 to obtain the compounds shown in Table 6 below.

Production Examples 182 to 341
The corresponding raw material compounds are treated in the same manner as in Production Example 1 or Production Example 1 and Production Example 4 (3) to obtain the compounds shown in Table 7 below.

Production Example 342
The corresponding starting material compounds are treated in the same manner as in Production Example 2 to obtain the compounds shown in Table 8 below.

Production Examples 343 to 365
The corresponding raw material compounds are treated in the same manner as in Production Example 3 or Production Example 3 and Production Example 4 (3) to obtain the compounds shown in Table 9 below.

Production Example 366
To a solution of tert-butyl 4- [N-acetyl-N- [2- (1-pyrrolidinyl) ethyl] amino] benzoate (compound obtained in Reference Example 107) in 37 mg of methylene chloride in 0.2 mL of trifluoroacetic acid was added. Add 2 mL and shake at room temperature for 1 day. The reaction mixture is concentrated, and the residue is sequentially azeotroped with chloroform, 4N dioxane hydrochloride solution and chloroform to obtain 4- [N-acetyl-N- [2- (1-pyrrolidinyl) ethyl] amino] benzoic acid hydrochloride. . The compound and 1- (3-ethoxybenzyl) -4-piperazin-1-yl-1H-pyrazolo [3,4-d] pyrimidine dihydrochloride were subjected to a condensation reaction in the same manner as in Production Example 3, The hydrochloride was prepared in the same manner as in Production Example 4 (3), and 1- (3-ethoxybenzyl) -4- [4- [4- [N-acetyl-N- [2- (1-pyrrolidinyl) ethyl] amino was prepared. ] Benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride (15 mg, 21% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 597 [M + H] ^< +>.

Production Examples 367 to 380
The corresponding starting material compound is treated in the same manner as in Production Example 366 to give the compound described in Table 9.1 below.

Production Example 381
(1) 30 mL of methylene chloride, 1.06 g of 4-hydroxybenzoic acid, 3.02 g of 1- (3-ethoxybenzyl) -4-piperazin-1-yl-1H-pyrazolo [3,4-d] pyrimidine dihydrochloride , 1-hydroxybenzotriazole (1.25 g), triethylamine (3.7 mL), and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (1.78 g) are sequentially added, and the mixture is stirred at room temperature for 17 hours. The reaction mixture is diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated. The solvent was distilled off from the organic layer, and the resulting residue was purified by silica gel flash column chromatography (chloroform / methanol = 50: 1) to give 1- (3-ethoxybenzyl) -4- [4- (4 -Hydroxybenzoyl) piperazin-1-yl] 1H-pyrazolo [3,4-d] pyrimidine (2.70 g, 80% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 459 [M + H] ^< +>.
(2) To a solution of 250 mg of the compound obtained in the above (1), 215 mg of 3-dimethylamino-2,2-dimethyl-1-propanol and 429 mg of triphenylphosphine in a 4.0 mL tetrahydrofuran solution under ice cooling, 330 mg of diisopropyl azodicarboxylate Is stirred at room temperature overnight. The reaction solution is diluted with 4 ml of methylene chloride and then treated with a cation exchange resin (ISOLUTE SCX, manufactured by IST, methanol / methylene chloride = 1: 1 to 1N aqueous ammonia / methanol). The obtained crude product was purified by silica gel flash column chromatography (chloroform / methanol = 10: 1), and further treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxybenzyl) -4- [4- [4- [3- (Dimethylamino) -2,2-dimethylpropoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride (257 mg, yield 78 %) As an amorphous solid.
MS (APCI) m / z; 572 [M + H] ^< +>.

Production Examples 382 to 403
The corresponding starting material compounds are treated in the same manner as in Production Example 381 to give the compounds shown in Table 10 below.

Production Example 404
(1) The corresponding starting material compound was treated in the same manner as in Production Example 381 to give 1- (3-ethoxybenzyl) -4- [4- [4-[[1- (tert-butoxycarbonyl) piperidin-4-yl]. ] Oxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (34 mg, 61% yield) is obtained.
MS (ESI) m / z; 642 [M + H] ^< +>.
(2) To a solution of 34 mg of the compound obtained in (1) above in 0.5 mL of methanol is added 4 N hydrochloric acid / dioxane (0.1 mL), and the mixture is stirred overnight at room temperature. The solvent was distilled off, and the resulting residue was dissolved in water and lyophilized to give 1- (3-ethoxybenzyl) -4- [4- [4- (4-piperidyloxy) benzoyl] piperazine-1- IL] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (27 mg, 79% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 542 [M + H] ^< +>.

Production Examples 405 to 406
The corresponding starting material compounds are treated in the same manner as in Production Example 404 to give the compounds shown in Table 11 below.

Production Example 407
(1) By treating 230 mg of 4-[[N-ethyl-N- (tert-butoxycarbonyl)] aminomethyl] benzoic acid methyl ester (the compound obtained in Reference Example 81) in the same manner as in Production Example 1, -(3-Ethoxybenzyl) -4- [4- [4-[[N-ethyl-N- (tert-butoxycarbonyl)] aminomethyl] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] Pyrimidine (330 mg, 2-step yield 70%) is obtained as an amorphous solid.
MS (APCI) m / z; 600 (M + H) ^<+> .
(2) Dissolve 330 mg of the compound obtained in (1) above in 2 mL of 1,4-dioxane, add 4 mL of 4N hydrochloric acid-dioxane solution, and stir at room temperature for 6 hours. Add 6 mL of diisopropyl ether and stir to remove the supernatant (repeat the washing operation twice). Dissolve the precipitate in 2 mL of water, add 3 mL of saturated aqueous sodium bicarbonate and 3 mL of chloroform, and stir. After standing, the organic layer is separated and concentrated. The obtained crude product was purified by NH silica gel flash column chromatography (Purif8Hi-Flash / L, solvent; hexane / ethyl acetate = 65: 35-0: 100) to give 1- (3-ethoxybenzyl) -4 -[4- [4- (Ethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (121 mg, 44% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 500 [M + H] ^< +>.
(3) 110 mg of the compound obtained in the above (2) is suspended in 500 μL of water, 220 μL of 2N hydrochloric acid is added, and then lyophilized to give 1- (3-ethoxybenzyl) -4- [4- [4 -(Ethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride is obtained as an amorphous solid.
MS (APCI) m / z; 500 [M + H] ^< +>.

Production Examples 408 to 415
The corresponding starting material compounds are treated in the same manner as in Production Example 407 to obtain the compounds described in Table 12 below.

Production Example 416
To a methylene chloride solution of 50 mg of the compound described in Production Example 415 and 50 mg of triethylamine, 10 mg of acetyl chloride is added and stirred at room temperature for 18 hours. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, and the mixture is extracted with chloroform. The obtained crude product was purified by high performance liquid chromatography (10 mM ammonium carbonate / methanol = 80: 20 to 5:95) and further treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxy Benzyl) -4- [4-[[trans-4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] Pyrimidine dihydrochloride (20 mg, 40% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 577 [M + H] ^< +>.

Production Examples 417 to 421
The corresponding starting material compounds are treated in the same manner as in Production Example 416 to obtain the compounds shown in Table 13 below.

Production Example 422
To a suspension of 40 mg of the compound described in Production Example 410 in 1 mL of tetrahydrofuran, 35 mg of potassium carbonate and 9 μL of ethyl iodide are sequentially added, and the mixture is stirred overnight at room temperature. The reaction solution is diluted with 5 mL of chloroform, 5 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and then the organic layer is separated and concentrated. The obtained crude product was purified by high performance liquid chromatography (10 mM ammonium carbonate / methanol = 80: 20 to 5:95), and the resulting product was treated in the same manner as in Production Example 4 (3) to give 1- (3-Ethoxybenzyl) -4- [4-[[trans-4- (N-ethyl-N-methylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine Obtain dihydrochloride (13 mg, 31% yield) as an amorphous solid.
MS (APCI) m / z; 506 [M + H] ^< +>.

Production Examples 423 to 424
The corresponding starting material compounds are treated in the same manner as in Production Example 422 to give the compounds shown in Table 14 below.

Production Example 425
(1) To a suspension of 50 mg of the compound described in Production Example 411 in dichloromethane (1 mL), triethylamine (44 μL) and chloroacetyl chloride (9 μL) are successively added under ice cooling, and the mixture is stirred under ice cooling for 2 hours. Under ice-cooling, 0.3 mL of a 2M dimethylamine-tetrahydrofuran solution is added and stirred overnight at room temperature. The reaction solution is diluted with 3 mL of chloroform, 5 mL of a saturated aqueous sodium hydrogen carbonate solution is added and stirred, and then the organic layer is separated and concentrated. The obtained crude product was purified by high performance liquid chromatography (10 mM ammonium carbonate / methanol = 80: 20 to 5:95) to give 1- (3-ethoxybenzyl) -4- [4-[[trans-4- [(N, N-dimethylglycyl) amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (20.4 mg, 40% yield) is obtained as an amorphous solid.
MS (ESI) m / z; 549 [M + H] ^< +>.
(2) The compound obtained in (1) above is treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxybenzyl) -4- [4-[[trans-4-[(N, N -Dimethylglycyl) amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (21.5 mg, 93% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 549 [M + H] ^< +>.

Production Examples 426 to 433
The corresponding starting material compounds are treated in the same manner as in Production Example 425 to give the compounds shown in Table 15 below.

Production Example 434
(1) To a suspension of 40 mg of the compound described in Production Example 411 in 1 mL of tetrahydrofuran, 0.2 mL of dimethylacetamide, 16.6 μL of 1,5-diiodopentane and 28 mg of sodium carbonate are sequentially added, followed by stirring at 70 ° C. for 23 hours. After allowing to cool, the reaction solution is diluted with 3 mL of chloroform, 5 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and then the organic layer is separated and concentrated. The resulting crude product was purified by high performance liquid chromatography (10 mM ammonium carbonate / methanol = 80: 20 to 5:95), and 1- (3-ethoxybenzyl) -4- [4-[[trans-4- ( 1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (12.9 mg, 34% yield) is obtained as an amorphous solid.
MS (ESI) m / z; 532 [M + H] ^< +>.
(2) 1- (3-Ethoxybenzyl) -4- [4-[[trans-4- (1-piperidyl)] is obtained by treating the compound obtained in (1) above in the same manner as in Production Example 4 (3). [Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (15.4 mg, quantitative) is obtained as an amorphous solid.
MS (APCI) m / z; 532 [M + H] ^< +>.

Production Example 435
The corresponding starting material compounds are treated in the same manner as in Production Example 434 to obtain the compounds described in Table 16 below.

Production Examples 436 to 442
The corresponding starting material compounds are treated in the same manner as in Production Example 407 to obtain the compounds described in Table 17 below.

Production Examples 443 to 500
The corresponding starting material compounds are treated in the same manner as in Production Example 3 to obtain the compounds shown in Table 18 below.

Production Examples 501 to 567
The corresponding starting material compounds are treated in the same manner as in Production Example 1 to give the compounds shown in Table 19 below.

Production Examples 568 to 577
The corresponding starting material compound is treated in the same manner as in Production Example 381 to give the compound shown in Table 20 below.

Production Examples 578 to 616
The corresponding starting material compound is treated in the same manner as in Production Example 366 to give the compound shown in Table 21 below.

Production Example 617
(1) By treating trans-4- [N-methyl-N- (tert-butoxycarbonyl) aminomethyl] cyclohexanecarboxylic acid (the compound obtained in Reference Example 239) in the same manner as in Production Example 3, 1- ( 3-Ethoxybenzyl) -4- [4-[[trans-4- [N-methyl-N- (tert-butoxycarbonyl) aminomethyl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine is obtained as an amorphous powder.
MS (APCI) m / z; 592 [M + H] ^< +>.
(2) The compound obtained in (1) above is treated in the same manner as in Production Example 404 (2) to give 1- (3-ethoxybenzyl) -4- [4-[[trans-4- (methylaminomethyl). ) Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride is obtained as an amorphous powder.
MS (APCI) m / z; 492 [M + H] ^< +>.

Production Example 618
(1) By treating 4-[[2- (dimethylamino) ethyl] amino] -3-methylbenzoic acid dihydrochloride (compound obtained in Reference Example 251) in the same manner as in Production Example 3, 1- ( 3-ethoxybenzyl) -4- [4- [3-methyl-4- [2- (dimethylamino) ethylamino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine Obtain as a solid.
MS (APCI) m / z; 543 [M + H] ^< +>.
(2) To a solution of 50 mg of the compound obtained in (1) above in 1 mL of 1,2-dichloroethane, 10 μL of acetaldehyde, 10 μL of acetic acid, and 29 mg of sodium triacetoxyborohydride are sequentially added under ice-cooling and stirred overnight at room temperature. Further, 10 μL of acetaldehyde, 10 μL of acetic acid, and 29 mg of sodium triacetoxyborohydride are sequentially added and stirred overnight at room temperature. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, and the mixture is extracted with chloroform. The obtained crude product was purified by high performance liquid chromatography (10 mM ammonium carbonate / methanol = 80: 20 to 5:95) and further treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxy Benzyl) -4- [4- [3-methyl-4- [N-ethyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4 d] Pyrimidine dihydrochloride (22 mg, 37% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 571 [M + H] ^< +>.

Production Examples 619 to 629
The corresponding starting material compounds are treated in the same manner as in Production Example 618 to give the compounds shown in Table 22 below.

Production Example 630
(1) 1- (3-Ethoxybenzyl) -4-piperazin-1-yl-1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (60 mg) is dissolved in 1.2 mL of methylene chloride, and N is added at 0 ° C. , N-diisopropylethylamine 85 μL and p-nitrophenyl chloroformate 49 mg are added and stirred at room temperature for 2 hours 30 minutes. After diluting the reaction solution with 1 mL of chloroform, 1.5 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated. Extract with chloroform again, dry the separated organic layer over anhydrous sodium sulfate, filter and concentrate. The obtained residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 9: 1 to 0:10) to give 1- (3-ethoxybenzyl) -4- [4-[(4-nitrophenoxy). Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (72 mg, 100% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 504 (M + H) ^<+> .
(2) 25 mg of the compound obtained in the above (1) is dissolved in 1.5 mL of N, N-dimethylformamide, and 51 μL of N, N-diisopropylethylamine and 65 mg of 4- (1-pyrrolidinyl) -piperidine are added at room temperature. Stir at 4 ° C. for 4 hours. The reaction solution is returned to room temperature, diluted with 1 mL of chloroform, 1.5 mL of a saturated aqueous sodium bicarbonate solution is added and stirred, and the organic layer is separated. The mixture is extracted again with chloroform, and the separated organic layer is dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform / methanol = 10: 0 to 85:15), and 1- (3-ethoxybenzyl) -4- [4-[[4- (1-pyrrolidinyl) piperidine. -1-yl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (19 mg, 73% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 519 (M + H) ^<+> .
(3) By treating 19 mg of the compound obtained in the above (2) in the same manner as in Production Example 4 (3), 1- (3-ethoxybenzyl) -4- [4-[[4- (1-pyrrolidinyl)] Piperidin-1-yl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride is obtained as an amorphous powder.
MS (APCI) m / z; 519 [M + H] ^< +>.

Production Examples 631 to 632
The corresponding starting material compounds are treated in the same manner as in Production Example 630 to obtain the compounds shown in Table 23 below.

Production Example 633
(1) By treating 245 mg of methyl 4-[[1- (tert-butoxycarbonylaminomethyl) cyclopropyl] methoxy] benzoate (compound obtained in Reference Example 235) in the same manner as in Production Example 1, 1- (3-Ethoxybenzyl) -4- [4- [4-[[1- (tert-butoxycarbonylaminomethyl) cyclopropyl] methoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d Pyrimidine (380 mg, 98% yield) is obtained as a colorless liquid.
MS (APCI) m / z; 642.5 [M + H] ^< +>.
(2) 1- (3-ethoxybenzyl) -4- [4- [4-[[1- (amino) obtained by treating in the same manner as in Production Example 404 (2) from 100 mg of the compound obtained in (1) above. The crude product of (methyl) cyclopropyl] methoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride is further treated in the same manner as in Preparation Example 618 (2). 1- (3-ethoxybenzyl) -4- [4- [4-[[1- (dimethylaminomethyl) cyclopropyl] methoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4 d] Pyrimidine hydrochloride (33 mg, 34% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 570 [M + H] ^< +>.

Production Examples 634 to 636
The corresponding starting material compounds are treated in the same manner as in Production Example 633 to give the compounds shown in Table 24 below.

Production Example 637
1- (3-Ethoxybenzyl) -4- [4- [3-methyl-4- [2- (dimethylamino) ethylamino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] The pyrimidine (compound obtained in Production Example 618 (1)) is treated in the same manner as in Production Example 416 to give 1- (3-ethoxybenzyl) -4- [4- [3-methyl-4- [N-acetyl- N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (26 mg, 42%) is obtained as an amorphous solid.
MS (APCI) m / z; 585 [M + H] ^< +>.

Production Examples 638 to 650
The corresponding starting material compound is treated in the same manner as in Production Example 637 to give the compound shown in Table 25 below.

Production Example 651
(1) By treating 2.0 g of ethyl trans-4- (methoxymethoxy) cyclohexanecarboxylate (compound obtained in Reference Example 237) in the same manner as in Production Example 1, 1- (3-ethoxybenzyl) -4 -[4-[[trans-4- (methoxymethoxy) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (2.88 g, 78% yield) as an amorphous solid obtain.
MS (APCI) m / z; 509 [M + H] ^< +>.
(2) To a suspension of 2.8 g of the compound obtained in (1) above in 20 mL of ethanol, 2.0 mL of concentrated hydrochloric acid and 2.0 mL of water are added and stirred at 80 ° C. for 1 hour. The reaction solution is diluted with ether, and the precipitated crystals are collected by filtration to give 1- (3-ethoxybenzyl) -4- [4-[(trans-4-hydroxycyclohexyl) carbonyl] piperazin-1-yl]- 1H-pyrazolo [3,4-d] pyrimidine hydrochloride (2.81 g, 99% yield) is obtained as colorless crystals.
MS (APCI) m / z; 465 [M + H] ^< +>.
(3) To a suspension of 50 mg of the compound obtained in (2) above in 0.5 mL of toluene was added 80 mg of 2- (dimethylamino) ethyl chloride hydrochloride and 50 mg of 60% oily sodium hydride, and the mixture was heated at 100 ° C. for 2 days. Stir. Water is added to the reaction solution, extracted with chloroform, and the solvent is distilled off under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate) and further treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxybenzyl) -4- [4-[[trans -4- [2- (Dimethylamino) ethoxy] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride (14 mg, 24% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 536 [M + H] ^< +>.

Production Example 652
(1) Treating 256 mg of methyl 4-[(2S) -2- (tert-butoxycarbonylamino) -4-methylpentyloxy] benzoate (compound obtained in Reference Example 285) in the same manner as in Production Example 1. 1- (3-ethoxybenzyl) -4- [4- [4-[(2S) -2- (tert-butoxycarbonylamino) -4-methylpentyloxy] benzoyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine (400 mg, 99% yield) is obtained as a colorless liquid.
MS (APCI) m / z; 659 [M + H] ^< +>.
(2) To a solution of 50 mg of the compound obtained in (1) above in 3 ml of tetrahydrofuran was added 10 mg of 60% oily sodium hydride under ice cooling and stirred for 0.5 hours, and then 55 mg of iodomethane was added dropwise, and the mixture was stirred at room temperature for 3 hours. Stir. Water is added to the reaction mixture, and the mixture is extracted with ethyl acetate. The obtained crude product was purified by NH silica gel flash column chromatography (hexane / ethyl acetate = 9: 1 to 1: 9) to give 1- (3-ethoxybenzyl) -4- [4- [4- [ (2S) -2- [N-Methyl-N- (tert-butoxycarbonyl) amino] -4-methylpentyloxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (35 mg Yield 67%) as a colorless oil.
MS (APCI) m / z; 672 [M + H] ^< +>.
(3) By treating the compound obtained in (2) in the same manner as in Production Example 404 (2), 1- (3-ethoxybenzyl) -4- [4- [4-[(2S) -2 -(Methylamino) -4-methylpentyloxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (15 mg, 46% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 572 [M + H] ^< +>.

Production Example 653
The corresponding starting material compound is treated in the same manner as in Production Example 652 to give the compound shown in Table 26 below.

製造例６５４
（１）アルゴン雰囲気下、塩化オキザリル４．４８ｍＬの塩化メチレン５０ｍＬ溶液に、−６０℃でジメチルスルホキシド４．５５ｇの塩化メチレン５ｍＬ溶液を１５分間かけて滴下する。この溶液に、トランス−４−（ヒドロキシメチル）シクロヘキサンカルボン酸メチル（参考例２３８で得られる化合物）５．９ｇの塩化メチレン３０ｍＬ溶液を３０分かけて滴下し、さらに同温で１時間撹拌する。−６０℃で反応液にトリエチルアミン１６．７ｍＬを滴下し、同温で３０分撹拌後、０℃に昇温してさらに１時間撹拌する。反応液をクロロホルムで希釈し、水、５％クエン酸水溶液、水、飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥し、減圧濃縮することによって粗生成トランス−４−ホルミルシクロヘキサンカルボン酸メチル（５．３２ｇ、収率９１％）を油状物として得る。
（２）上記（１）で得られる化合物５００ｍｇ、３−ジメチルアミノプロピルアミン６００ｍｇの塩化メチレン１０ｍＬ混合液に、氷冷下、水素化トリアセトキシホウ素ナトリウム９８３ｍｇ、酢酸３５３ｍｇを順次加え、室温で５日間撹拌する。反応液に注意深く飽和重曹水を加えて中和し、クロロホルムで２回抽出した後、減圧濃縮する。得られる組成生物はシリカゲルカラムフラッシュクロマトグラフィー（クロロホルム／メタノール／アンモニア水＝９：１：０．１）で精製することにより、トランス−４−［３−（ジメチルアミノ）プロピルアミノメチル］シクロヘキサンカルボン酸メチル（２３９ｍｇ、収率３２％）を油状物として得る。
ＭＳ（ＡＰＣＩ）ｍ／ｚ；２５７［Ｍ＋Ｈ］^＋。
（３）上記（２）で得られる化合物９２ｍｇのクロロホルム０．５ｍＬ溶液に、氷冷下、塩化２−フロイル６８μＬのクロロホルム０．５ｍＬ溶液、ピリジン６７μＬを順次加え、室温で１日間撹拌する。反応液に飽和重曹水を加え、クロロホルムで３回抽出し、合した有機層を遠心濃縮機で減圧下濃縮する。得られる粗生成物をＮＨシリカゲルカラムフラッシュクロマトグラフィー（ヘキサン／酢酸エチル＝９：１〜１：１）で精製することにより、トランス−４−［［Ｎ−（２−フロイル）−Ｎ−［３−（ジメチルアミノ）プロピル］アミノ］メチル］シクロヘキサンカルボン酸メチル（１０２ｍｇ、収率７５％）を油状物として得る。
ＭＳ（ＡＰＣＩ）ｍ／ｚ；３７３［Ｍ＋Ｈ］^＋。
（４）上記（３）で得られる化合物を製造例１と同様に処理することにより、１−（３−エトキシベンジル）−４−［４−［［トランス−４−［Ｎ−（２−フロイル）−Ｎ−［３−（ジメチルアミノ）プロピル］アミノメチル］シクロヘキシル］カルボニル］ピペラジン−１−イル］−１Ｈ−ピラゾロ［３，４−ｄ］ピリミジン・塩酸塩をアモルファス粉末として得る。
ＭＳ（ＡＰＣＩ）ｍ／ｚ；６５７［Ｍ＋Ｈ］^＋。

Production Example 654
(1) A dimethyl sulfoxide 4.55g methylene chloride 5mL solution is dripped over 15 minutes at -60 degreeC to a 50 mL methylene chloride solution of 4.48mL oxalyl chloride under argon atmosphere. To this solution, a solution of 5.9 g of methyl trans-4- (hydroxymethyl) cyclohexanecarboxylate (compound obtained in Reference Example 238) in 30 mL of methylene chloride is added dropwise over 30 minutes and further stirred at the same temperature for 1 hour. 16.7 mL of triethylamine is added dropwise to the reaction solution at −60 ° C., and the mixture is stirred for 30 minutes at the same temperature. The reaction solution was diluted with chloroform, washed successively with water, 5% aqueous citric acid solution, water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude methyl trans-4-formylcyclohexanecarboxylate ( 5.32 g, 91% yield) are obtained as an oil.
(2) To a mixed solution of 500 mg of the compound obtained in (1) above and 600 mg of 3-dimethylaminopropylamine in 10 mL of methylene chloride, 983 mg of sodium triacetoxyborohydride and 353 mg of acetic acid were sequentially added under ice cooling, and the mixture was stirred at room temperature for 5 days. Stir. The reaction solution is carefully neutralized with saturated aqueous sodium hydrogen carbonate, extracted twice with chloroform, and concentrated under reduced pressure. The resulting product is purified by silica gel column flash chromatography (chloroform / methanol / aqueous ammonia = 9: 1: 0.1) to give trans-4- [3- (dimethylamino) propylaminomethyl] cyclohexanecarboxylic acid. Methyl (239 mg, 32% yield) is obtained as an oil.
MS (APCI) m / z; 257 [M + H] ^< +>.
(3) To a solution of 92 mg of the compound obtained in (2) above in 0.5 mL of chloroform, under ice-cooling, add 0.5 mL of 2-furoyl chloride in 0.5 mL of chloroform and 67 μL of pyridine, and stir at room temperature for 1 day. Saturated aqueous sodium hydrogen carbonate is added to the reaction mixture, and the mixture is extracted three times with chloroform. The combined organic layers are concentrated under reduced pressure using a centrifugal concentrator. The resulting crude product was purified by NH silica gel column flash chromatography (hexane / ethyl acetate = 9: 1 to 1: 1) to obtain trans-4-[[N- (2-furoyl) -N- [3. Obtain methyl-(dimethylamino) propyl] amino] methyl] cyclohexanecarboxylate (102 mg, 75% yield) as an oil.
MS (APCI) m / z; 373 [M + H] ^< +>.
(4) The compound obtained in (3) above is treated in the same manner as in Production Example 1 to give 1- (3-ethoxybenzyl) -4- [4-[[trans-4- [N- (2-furoyl). ) -N- [3- (Dimethylamino) propyl] aminomethyl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride is obtained as an amorphous powder.
MS (APCI) m / z; 657 [M + H] ^< +>.

Production Examples 655 to 670
The corresponding starting material compound is treated in the same manner as in Production Example 654 to give the compound shown in Table 27 below.

Production examples 671 to 703
The corresponding starting material compound is treated in the same manner as in any of Production Examples 404, 407, 617, and 652, to give the compounds described in Table 27.1 below.

Production Examples 704 to 712
The corresponding starting material compound is treated in the same manner as in Production Example 1 to give the compounds described in Table 27.2 below.

Production Example 713
(1) By treating 720 mg of the compound obtained in Production Example 630 (1) and 1.05 g of 4-piperidone hydrochloride monohydrate in the same manner as in Production Example 630 (2), 1- (3-ethoxybenzyl) -4- [4-[[4-Oxopiperidin-1-yl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (654 mg, 97% yield) is obtained as an amorphous solid. .
MS (APCI) m / z; 464 [M + H] ^< +>.
(2) By treating 50 mg of the compound obtained in (1) above in the same manner as in Production Example 6, 1- (3-ethoxybenzyl) -4- [4-[[4- (dimethylamino) piperidine-1- [Il] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (15.6 mg, 30% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 493 [M + H] ^< +>.
(3) By treating 13.8 mg of the compound obtained in (2) above in the same manner as in Production Example 4 (3), 1- (3-ethoxybenzyl) -4- [4-[[4- (dimethylamino) ) Piperidin-1-yl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (15.9 mg, 99.6% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 493 [M + H] ^< +>.

Production Example 714
By treating 50 mg of the compound obtained in Production Example 441 in the same manner as in Production Example 6, 1- (3-ethoxybenzyl) -4- [4-[[trans-4- (N-ethyl-Nn-propyl) was obtained. Amino) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (59.3 mg, 64%) is obtained as an amorphous solid.
MS (APCI) m / z; 534 [M + H] ^< +>.

Production Example 715
(1) In 20 mL of methylene chloride in 2.1 g of 4-fluorobenzenesulfonyl chloride, 6 mL of pyridine and 1- (3-ethoxybenzyl) -4-piperazin-1-yl-1H-pyrazolo [3,4-d] pyrimidine・ After adding 3 g of dihydrochloride under ice cooling, warm to room temperature and stir for 16 hours. The reaction solution is diluted with 20 mL of chloroform, 20 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated. The aqueous layer is extracted with chloroform, and the organic layers are combined, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 1: 1 to 1: 3) to give 1- (3-ethoxybenzyl) -4- [4- (4-fluorobenzene). (Sulfonyl) piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (3.2 g, 88% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 497 [M + H] ^< +>.
(2) By treating 100 mg of the compound obtained in (1) above in the same manner as in Reference Example 1- (1), 1- (3-ethoxybenzyl) -4- [4- [4-[[2- ( Dimethylamino) ethyl] amino] benzenesulfonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (91 mg, 80% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 565 [M + H] ^< +>.

Production Example 716
By treating 57 mg of the compound obtained in Production Example 715 in the same manner as in Production Example 416, and then treating the resulting compound in the same manner as in Production Example 4 (3), 1- (3-ethoxybenzyl) -4- [4- [4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] benzenesulfonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride ( 51 mg, 75% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 607 [M + H] ^< +>.

Production Example 717
By treating 50 mg of the compound obtained in Production Example 441 in the same manner as in Production Example 422 (2), and then treating the resulting product in the same manner as in Production Example 4 (3), 1- (3-ethoxybenzyl) -4- [4-[[trans-4- [N-propyl-N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d Pyrimidine dihydrochloride (3.4 mg, 6.5% yield) is obtained as an amorphous solid.
MS (ESI) m / z; 577 [M + H] ^< +>.

Production Example 718
The corresponding starting material compound was treated in the same manner as in Production Example 713 to give 1- (3-ethoxybenzyl) -4- [4-[[4-[[2- (dimethylamino) ethyl] amino] piperidin-1-yl. ] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine is obtained. The product was then treated in the same manner as in Preparation Example 416 to give 1- (3-ethoxybenzyl) -4- [4-[[4- [N- (cyclopropylcarbonyl) -N- [2- ( Dimethylamino) ethyl] amino] piperidin-1-yl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (23 mg, 34% yield) is obtained as an amorphous solid. .
MS (APCI) m / z; 604 [M + H] ^< +>.

Production Example 719
(1) Add 1.56 g of diphenylcyanocarbonimide to a solution of 1.0 g of 4-piperidinopiperidine in 5 mL of methylene chloride and 15 mL of isopropanol, and stir at room temperature for 24 hours. The reaction solution is diluted with 20 mL of ethyl acetate, and then 30 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated. The aqueous layer is extracted with chloroform, and the organic layers are combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform / methanol = 9: 1 to 5: 1) to thereby obtain phenyl N-cyano-1,4′-bipiperidine-1′-carboxymidate (2.5 g Yield quant) as an amorphous solid.
MS (APCI) m / z; 313 [M + H] ^< +>.
(2) To a solution of 70 mg of the compound obtained in (1) above in 3 mL of tetrahydrofuran, 14.4 mg of sodium hydride and 1- (2-fluoro-3-methylbenzyl) -4-piperazin-1-yl-1H-pyrazolo [ 3,4-d] pyrimidine (60 mg) is added and the mixture is stirred at 100 ° C. for 24 hours. After diluting the reaction solution with 3 mL of chloroform, 5 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated. The aqueous layer is extracted with chloroform, and the organic layers are combined, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue is purified by silica gel column chromatography (Purif8, Hi-flash / M, chloroform / methanol = 100: 0 to 85:15) to give 1- (2-fluoro-3-methylbenzyl) -4 -[4- [1- [1,4′-bipiperidin-1′-yl (cyanoimino) methyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (77.4 mg, yield 95) %) As an amorphous solid.
MS (APCI) m / z; 545 [M + H] ^< +>.

Production Example 720
(1) By treating 282 mg of the compound obtained in Production Example 407 in the same manner as in Production Example 31 (1), 1- (3-ethoxybenzyl) -4- [4- [4-[[N-[( Cyanoimino) (phenoxy) methyl] -N-ethylamino] methyl] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (221 mg, 69% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 644 [M + H] ^< +>.
(2) 241 μL of a dimethylamine aqueous solution is added to an acetonitrile solution of 64 mg of the compound obtained in (1) above, and the mixture is stirred at 100 ° C. for 16 hours. The reaction is brought to room temperature and concentrated. The obtained residue is purified by silica gel column chromatography (Purif8, Hi-flash / M, chloroform / methanol = 100: 0 to 90:10) to give 1- (3-ethoxybenzyl) -4- [4- [4-[[N-[(Cyanoimino) (dimethylamino) methyl] -N-ethylamino] methyl] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (51 mg, yield) 86%) as an amorphous solid.
MS (APCI) m / z; 595 [M + H] ^< +>.
(3) By treating 51 mg of the compound obtained in (2) above in the same manner as in Production Example 4 (3), 1- (3-ethoxybenzyl) -4- [4- [4-[[N-[( Cyanoimino) (dimethylamino) methyl] -N-ethylamino] methyl] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride (45.8 mg, 80% yield) Is obtained as an amorphous solid.
MS (APCI) m / z; 595 [M + H] ^< +>.

Production Example 721
The corresponding starting compound was treated in the same manner as in Production Example 366 to give 1- (3-ethoxybenzyl) -4- [4- [4- [2- (dimethylamino) ethylamino] benzoyl] piperazin-1-yl]- 1H-pyrazolo [3,4-d] pyrimidine is obtained. 50 mg of the product is dissolved in 1 mL of a mixed solution of methylene chloride / isopropanol = 1: 1, 25 mg of diphenyl cyanocarbonimidate is added, and the mixture is stirred at 50 ° C. for 6 hours. After diluting the reaction solution with 2 mL of chloroform, 2 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated. The aqueous layer is extracted with chloroform, and the organic layers are combined, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (Purif8Hi-Flash / M, chloroform / methanol = 100: 0 to 90:10) to give 1- (3-ethoxybenzyl) -4- [4- [4 -[N- [2- (dimethylamino) ethyl] -N-[(2-propyloxy) (cyanoimino) methyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (44.3 mg, 69% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 639 [M + H] ^< +>.

Production Example 722
(1) By treating 1.0 g of monomethyl 1,4-cyclohexanedicarboxylate in the same manner as in Production Example 3, 1- (3-ethoxybenzyl) -4- [4-[[trans-4- (methoxycarbonyl) Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrozolo [3,4-d] pyrimidine (1.83 g, 81% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 507 [M + H] ^< +>.
(2) The compound obtained in (1) above and N, N, N′-triethyl-1,2-ethylenediamine are treated in the same manner as in Production Example 4 (2), and then the product is produced in Production Example 4 (3). By treating in the same manner, 1- (3-ethoxybenzyl) -4- [4-[[trans-4- [N-ethyl-N- [2- (diethylamino) ethyl] carbamoyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine dihydrochloride is obtained as an amorphous powder.
MS (ESI) m / z; 619 [M + H] ^< +>.

Production Example 723
By treating ethyl 4-[[2- (dimethylamino) ethyl] amino] cyclohexanecarboxylate in the same manner as in Production Example 654 (3) and (4), 1- (6-propyl-2-pyridylmethyl)- 4- [4-[[4- [N-naphthoyl-N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine Obtained as an amorphous solid.
MS (ESI) m / z; 688 [M + H] ^< +>.

Production Example 724
(1) To a solution of 37 mg of ethyl 6-chloro-3-pyridazinecarboxylate in 1.5 mL of tetrahydrofuran is added 46 mg of N, N, N′-trimethylpropane-1,3-diamine and stirred overnight at room temperature. After 1.5 ml of tetrahydrofuran is added to the reaction solution for dilution, 400 mg of MP-ISOCYANATE (polystyrene methyl isocyanate, 1.43 mmol / g) is added and shaken overnight at room temperature. The resin was separated by filtration and extracted with a chloroform / methanol mixture, and the combined solution layer was concentrated with a centrifugal concentrator to give crude 6- [N- [3- (dimethylamino) propyl] -N-methylamino]-. Ethyl 3-pyridazinecarboxylate is obtained.
MS (ESI) m / z; 267 [M + H] ^< +>.
(2) By treating the compound obtained in (1) above in the same manner as in Production Example 1 and Production Example 4 (3), 1- (3-ethoxybenzyl) -4- [4-[[6- [N -Methyl-N- [3- (dimethylamino) propyl] amino] pyridazin-3-yl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride is obtained as an amorphous solid. .
MS (APCI) m / z; 559 [M + H] ^< +>.

Production Example 725
(1) To a solution of 500 mg of the compound obtained in Production Example 22 and 291 mg of N-benzyloxycarbonyl-β-methylalanine in 5 mL of methylene chloride is added 230 μL of diethyl cyanophosphonate, and the mixture is stirred overnight at room temperature. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, and the mixture is extracted with chloroform. The solvent is distilled off under reduced pressure. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 10: 1) to give 1- (3-ethoxybenzyl) -4- [4- [4- [N- [3- [N '-Methyl-N'-(benzyloxycarbonyl) amino] propionyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (431 mg, 61% yield) is obtained as a yellow liquid.
MS (APCI) m / z; 748 [M + H] ^< +>.
(2) A suspension of 480 mg of the compound obtained in (1) above, 81 mg of ammonium formate, and 100 mg of 10% palladium carbon catalyst in 5 mL of methanol is heated to reflux for 2 hours. After filtering the reaction solution, the filtrate is concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform / methanol = 5: 1), and then treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxybenzyl) -4- [4- [4 -[N- [3- (methylamino) propionyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride (390 mg, 99% yield) is obtained as a yellow liquid.
MS (APCI) m / z; 614 [M + H] ^< +>.

Production Example 726
(1) By treating the compound 1.29 g obtained in Reference Example 310 in the same manner as in Production Example 1, 1- (3-ethoxybenzyl) -4- [4-[[trans-4- [4-[( 2-Nitrophenyl) sulfonyl] piperazin-1-yl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (1.91 g, 85% yield) is obtained as a yellow liquid. .
MS (APCI) m / z; 718 [M + H] ^< +>.
(2) A suspension of 1.71 g of the compound obtained in (1) above, 658 mg of potassium carbonate, and 270 μL of thiophenol in 10 mL of N, N-dimethylformamide is stirred at room temperature for 4 hours. The reaction solution is diluted with water / ethyl acetate, and then treated with a cation exchange resin (SCX-2 manufactured by IST, methanol / water (1: 1) to 1N ammonia-methanol) to give 1- (3-ethoxybenzyl). ) -4- [trans-4-[[4- (1-piperazinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (1.09 g, 86% yield) Is obtained as a colorless solid.
MS (APCI) m / z; 533 [M + H] ^< +>.
(3) To a solution of 50 mg of the compound obtained in the above (2) in 1 mL of 1,2-dichloroethane, 15 μL of formaldehyde solution, 11 μL of acetic acid, and 30 mg of sodium triacetoxyborohydride are sequentially added under ice-cooling and stirred overnight at room temperature. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, and the mixture is extracted with chloroform. The solvent is distilled off under reduced pressure. The resulting crude product was purified by high performance liquid chromatography (10 mM ammonium carbonate / methanol) to give 1- (3-ethoxybenzyl) -4- [4-[[trans-4- (4-methylpiperazine-1 -Yl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine (47 mg, 92% yield) is obtained as a colorless solid.
MS (APCI) m / z; 547 [M + H] ^< +>.

Production Example 727
To a solution of 50 mg of the compound obtained in Production Example 725 in 3 mL of methylene chloride are added 10 μL of ethyl chlorocarbonate and 22 μL of triethylamine, and the mixture is stirred overnight at room temperature. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, and the mixture is extracted with chloroform. The solvent is distilled off under reduced pressure. The resulting crude product is purified by silica gel column chromatography (chloroform / methanol = 10: 1) and then treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxybenzyl) -4- [ 4- [4- [N- [3- [N′-methyl-N ′-(ethoxycarbonyl) amino] propionyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride (17 mg, 30% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 686 [M + H] ^< +>.

Production Examples 728-738
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 416, 714, 715, 716, and 717 to obtain the compounds described in Table 27.3 below.

Production Examples 739 to 745
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 1, 366, and 407 to obtain the compound described in Table 27.4 below.

Production Examples 746-749
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 3, 407, and 434 to obtain the compounds described in Table 27.5 below.

Production Examples 750-770
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 713 and 718 to obtain the compound described in Table 27.6 below.

Production Examples 771-798
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 720 and 724 to give the compounds described in Table 27.7 below.

Production Examples 799 to 874
The corresponding starting material compounds are treated in the same manner as in Production Example 1 to give the compounds described in Table 27.8 below.

Production Example 875
The corresponding starting material compound is treated in the same manner as in Production Example 3 to give the compound shown in Table 27.9 below.

Production Examples 876-891
The corresponding starting material compound is treated in the same manner as in Production Example 723 to give the compound described in Table 27.10 below.

Production Examples 892-900
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 633 and 726 to obtain the compound described in Table 27.11 below.

Production Examples 901-908
The corresponding starting material compound is treated in the same manner as in Production Example 366 to give the compound described in Table 27.12 below.

Production examples 909 to 915
The corresponding starting material compound is treated in the same manner as in Production Example 719 to give the compound described in Table 27.13 below.

Production Example 916
The corresponding starting material compound is treated in the same manner as in Production Example 720 to give the compound described in Table 27.14 below.

Production Examples 917 to 927
The corresponding starting material compound is treated in the same manner as in Production Example 722 to give the compound described in Table 27.15 below.

Production Examples 928 to 939
The corresponding starting material compound is treated in the same manner as in Production Example 723 to give the compound described in Table 27.16 below.

Production Examples 940 to 941
The corresponding starting material compound is treated in the same manner as in Production Example 727 to give the compound described in Table 27.17 below.

Production Examples 942-947
The corresponding starting material compound is treated in the same manner as in Production Example 630 to give the compound described in Table 27.18 below.

Production Examples 948 to 967
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 723 and 725 to obtain the compound described in Table 27.19 below.

Production Examples 968 to 969
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 720 and 727 to obtain the compound described in Table 27.20 below.

Production Examples 970-989
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 723 and 724 to give the compounds described in Table 27.21 below.

Production Examples 990-994
The corresponding starting material compound is treated in the same manner as in Production Example 713 to give the compound described in Table 27.22 below.

Production Examples 995-1018
The corresponding starting material compound is treated in the same manner as in Production Example 713 to give the compound described in Table 27.23 below.

Production Examples 1019 to 1040
The corresponding starting material compound is treated in the same manner as in Production Example 718 to give the compound described in Table 27.24 below.

Production Examples 1041 to 1048
The corresponding starting material compounds are treated in the same manner as in Production Example 1 to give the compounds described in Table 27.25 below.

Production Examples 1049-1071
The corresponding starting material compound is treated in the same manner as in Production Example 654 to give the compound described in Table 27.26 below.

Production Examples 1072 to 1074
The corresponding starting material compound is treated in the same manner as in Production Example 416 to obtain the compound described in Table 27.27 below.

Production Example 1075
45 mg of the compound obtained in Production Example 726 (2) was treated in the same manner as in Production Example 416 to give 1- (3-ethoxybenzyl) -4- [trans-4-[[4- (4-acetylpiperazine-1 -Yl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine is obtained as a yellow liquid. The compound was then treated in the same manner as in Production Example 4 (3) to give 1- (3-ethoxybenzyl) -4- [trans-4-[[4- (4-acetylpiperazin-1-yl) cyclohexyl]. Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine hydrochloride (39.8 mg; yield: 78%) is obtained as an amorphous solid.
MS (APCI) m / z; 575 [M + H] ^< +>.

Production Example 1076
The corresponding starting material compound is treated in the same manner as in Production Example 1075 to give the compound described in Table 27.28 below.

Production Examples 1077 to 1078
The corresponding starting material compound is treated in the same manner as in Production Example 637 to give the compound described in Table 27.29 below.

Production Examples 1079-1081
The corresponding starting material compound is treated in the same manner as in Production Example 407 to obtain the compound described in Table 27.30 below.

Production Examples 1082 to 1087
The corresponding starting material compound is treated in the same manner as in any one of Production Examples 1 and 3, to give the compounds described in Table 27.31 below.

Production Examples 1088 to 1092
The corresponding starting material compound is treated in the same manner as in Production Example 637 to give the compound described in Table 27.32.

Production Examples 1093 to 1094
The corresponding starting material compound is treated in the same manner as in Production Example 1 to give the compound described in Table 27.33 below.

Production Examples 1095 to 1102
The corresponding starting material compound is treated in the same manner as in Production Example 1 to give the compounds described in Table 27.34 below.

Production Examples 1103 to 1123
The corresponding starting material compound is treated in the same manner as in Production Example 1 or 637 to obtain the compound described in Table 27.35 below.

Production Examples 1124 to 1125
The corresponding starting material compound is treated in the same manner as in Production Example 723 to give the compound described in Table 27.36 below.

Reference example 1
(1) A mixture of 20 mL of ethyl 4-fluorobenzoate, 20 g of N, N-dimethylethylenediamine, and 32.9 g of potassium carbonate in 200 mL of dimethyl sulfoxide was stirred at 80 ° C. for 3 days and then allowed to cool to room temperature. Add ethyl and water and stir. The mixture is extracted twice with ethyl acetate, and then only the basic components are extracted from the organic layer into the aqueous layer with 10% hydrochloric acid. The aqueous layer is washed with ethyl acetate, the aqueous layer is neutralized with 10% sodium hydroxide, extracted three times with ethyl acetate, dried over sodium sulfate, and the solvent is distilled off under reduced pressure. The obtained crude product was purified by NH silica gel flash column chromatography (hexane / ethyl acetate = 8: 1 to 4: 1) to give ethyl 4-[[2- (dimethylamino) ethyl] amino] benzoate ( 12.45 g, 44% yield) is obtained as an oil.
MS (APCI) m / z; 237 [M + H] ^< +>.
(2) To a solution of ethyl 4-[[2- (dimethylamino) ethyl] amino] benzoate and 10 mL of pyridine in 20 mL of methylene chloride is added dropwise 2.55 mL of acryloyl chloride under ice-cooling, and the mixture is stirred at room temperature for 3 hours. . Water and saturated aqueous sodium hydrogen carbonate solution are sequentially added to the reaction mixture, and the mixture is stirred and extracted with chloroform. The extract is washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel flash column chromatography (Flash 40M; manufactured by Biotage, chloroform / methanol = 1: 0 to 50: 1) to give 4- [N-acryloyl-N- [2- (dimethyl Amino) ethyl] amino] ethyl benzoate (1.62 g, 26% yield) is obtained as a red oil.
(3) A mixture of 1.62 g of ethyl 4- [N-acryloyl-N- [2- (dimethylamino) ethyl] amino] benzoate and 5 mL of 50% dimethylamine aqueous solution obtained in the above (2) at room temperature was used. After stirring for 1.5 hours, the solvent is distilled off under reduced pressure. The obtained crude product was purified by silica gel flash column chromatography (Flash 40M, chloroform / methanol = 1: 0 to 50: 1 to chloroform / methanol / aqueous ammonia = 25: 1: 0.1) to give 4- [ Ethyl N- [3- (dimethylamino) propionyl] -N- [2- (dimethylamino) ethyl] amino] benzoate (1.78 g, 95% yield) is obtained as a red oil.
MS (APCI) m / z; 336 [M + H] ^< +>.

Reference Examples 2-10
The corresponding starting material compounds are treated in the same manner as in Reference Example 1 to give the compounds shown in Table 28 below.

Reference Example 11
To a solution of 200 mg of ethyl 4-[[2- (dimethylamino) ethyl] amino] benzoate (compound obtained in Reference Example 1 (1)) and 115 μL of cyclopropanecarbonyl chloride in 4 mL of methylene chloride was added 137 μL of pyridine under ice cooling. Add dropwise and stir at room temperature for 23 hours. Water and saturated aqueous sodium hydrogen carbonate solution are sequentially added to the reaction mixture, and the mixture is stirred, extracted with chloroform, and concentrated. The obtained crude product was purified by silica gel flash column chromatography (Hi-FLASH column; manufactured by Yamazen, solvent; chloroform / methanol = 1: 0 to 89:11) to give 4- [N- (cyclopropylcarbonyl) Ethyl -N- [2- (dimethylamino) ethyl] amino] benzoate (209 mg, 81% yield) is obtained as a yellow oil.
MS (APCI) m / z; 305 [M + H] ^< +>.

Reference Examples 12-26
The corresponding starting material compounds are treated in the same manner as in Reference Example 11 to give the compounds shown in Table 29 below.

Reference Example 27
200 mg of ethyl 4-[[2- (dimethylamino) ethyl] amino] benzoate (compound obtained in Reference Example 1 (1)) and 143 μL of n-butyl isocyanate in 4 mL of methylene chloride were stirred at room temperature for 23 hours, Add 143 μL of n-butyl isocyanate and heat and stir at 50 ° C. for 17 hours. After concentrating the reaction solution, the resulting crude product is purified by gel permeation chromatography (JAI GEL-H column, chloroform) to give 4- [N- (butylcarbamoyl) -N- [2- ( Dimethylamino) ethyl] amino] ethyl] benzoate (179 mg, 63% yield) is obtained as a yellow resin.
MS (APCI) m / z; 336 [M + H] ^< +>.

Reference Examples 28-30
The corresponding starting material compounds are treated in the same manner as in Reference Example 27 to give the compounds listed in Table 30 below.

Reference Example 31
To a solution of 1.5 g of ethyl 4-benzylaminobenzoate in 15 mL of methylene chloride, 0.56 mL of chloroacetyl chloride and 1.54 mL of N, N-diisopropylethylamine are successively added dropwise under ice cooling, and the mixture is stirred for 1 hour. 3 mL of diethylamine is added at the same temperature, and the temperature is naturally raised to room temperature, followed by stirring for 12 hours. 10 mL of water is added to the reaction solution to separate the organic layer, and then the aqueous layer is extracted with 5 mL of chloroform and concentrated together with the previous organic layer. The obtained crude product was purified by NH silica gel flash column chromatography (hexane / ethyl acetate = 6: 1 to 3: 1) to give 4- [N- (N ′, N′-diethylglycyl) -N -Benzylamino] ethyl benzoate (2.0 g, 92% yield) is obtained as a brown liquid.
MS (APCI) m / z; 369 [M + H] ^< +>.

Reference Examples 32-35
The corresponding starting material compounds are treated in the same manner as in Reference Example 31 to give the compounds listed in Table 31 below.

Reference Example 36
(1) To a solution of 25 g of methyl 4-formylbenzoate in 250 mL of methylene chloride, 67 g of N, N-dimethylethylenediamine, 87 mL of acetic acid, and 50.6 g of sodium triacetoxyborohydride are sequentially added and stirred overnight at room temperature. The solvent is distilled off under reduced pressure, saturated aqueous potassium carbonate solution is added to the residue, and the mixture is extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give methyl 4-[[[2- (dimethylamino) ethyl] amino] methyl] benzoate (31.9 g, yield 89%). Is obtained as a colorless oil.
MS (APCI) m / z; 237 [M + H] ^< +>.
(2) To a solution of 18.1 g of p-nitrophenyl chloroformate in 300 mL of methylene chloride, 14.2 mL of 3- (dimethylamino) propanol was added dropwise and stirred at room temperature for 4 hours, followed by 4-[[[2- (dimethylamino ) 13.7 g of ethyl] amino] methyl] benzoate and 25 mL of triethylamine are sequentially added and stirred at room temperature for 1 day. The reaction solution is washed with a saturated aqueous potassium carbonate solution and dried over sodium sulfate, and the solvent is distilled off under reduced pressure. The resulting crude product was purified by NH silica gel flash column chromatography (Chromatorex NH silica gel, solvent; ethyl acetate / hexane = 1: 1) to give 4-[[N- [2- (dimethylamino) ethyl]- Methyl N-[[3- (dimethylamino) propoxy] carbonyl] amino] methyl] benzoate (7.97 g, 38% yield) is obtained as a colorless oil.
MS (APCI) m / z; 366 [M + H] ^< +>.

Reference Example 37
4-[[[2- (Dimethylamino) ethyl] amino] methyl] benzoate (compound obtained in Reference Example 36 (1)) To a solution of 200 mg of 4 mL of methylene chloride was added 110 μL of propionic acid chloride, and the mixture was cooled with ice. Add 137 μL of pyridine and stir at room temperature for 4 hours. After diluting the reaction solution with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and then the organic layer is separated, and the solvent is distilled off with a centrifugal concentrator. The resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to give 4-[[N-propionyl-N- [2- (dimethylamino) ethyl] amino]. Methyl] methyl benzoate (191 mg, 78% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 293 [M + H] ^< +>.

Reference Examples 38-42
The corresponding starting material compounds are treated in the same manner as in Reference Example 37 to give the compounds described in Table 32 below.

Reference Example 43
4-[[[2- (Dimethylamino) ethyl] amino] methyl] benzoate (compound obtained in Reference Example 36 (1)) To a solution of 200 mg of 4 mL of methylene chloride was added 143 μL of n-butyl isocyanate and room temperature. For 4 hours. After diluting the reaction solution with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and then the organic layer is separated, and the solvent is distilled off with a centrifugal concentrator. The resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to give 4-[[N- (butylcarbamoyl) -N- [2- (dimethylamino) ethyl. ] Methyl] methyl] benzoate (261 mg, 92% yield) is obtained as a pale yellow oil.
MS (APCI) m / z; 336 [M + H] ^< +>.

Reference Example 44
To a solution of 300 mg of methyl 4-formylbenzoate in 6 mL of 1,2-dichloroethane is added 113 μL of diethylamine, 581 mg of sodium triacetoxyborohydride and 261 μL of acetic acid are added under ice cooling, and the mixture is stirred at room temperature for 18 hours. After diluting the reaction solution with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and then the organic layer is separated, and the solvent is distilled off with a centrifugal concentrator. The resulting crude product was purified by NH silica gel column chromatography (hexane / ethyl acetate = 70: 30 to 40:60) to give methyl 4- (diethylaminomethyl) benzoate (144 mg, yield 60%) as an oil. Get as a thing.
MS (APCI) m / z; 222 [M + H] ^< +>.

Reference Examples 45-59
The corresponding starting material compound is treated in the same manner as in Reference Example 44 to give the compound shown in Table 33 below.

Reference Example 60
4-[[2- (Dimethylamino) ethyl] amino] ethyl benzoate (compound obtained in Reference Example 1 (1)) To a solution of 200 mg of 1,2-dichloroethane in 4 mL was added 384 μL of isobutyraldehyde, and the resulting mixture was cooled with ice. 448 mg of sodium acetoxyborohydride and 145 μL of acetic acid are added and stirred at room temperature for 24 hours. The reaction mixture is diluted with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated and concentrated. The resulting crude product was purified by NH silica gel column chromatography (hexane / ethyl acetate = 80: 20 to 50:50) to give 4- [N- [2- (dimethylamino) ethyl] -N-isobutylamino. ] Ethyl benzoate (239 mg, 97% yield) is obtained as a pale yellow oil.
MS (APCI) m / z; 293 [M + H] ^< +>.

Reference Examples 61-66
The corresponding starting material compounds are treated in the same manner as in Reference Example 60 to give the compounds shown in Table 34 below.

Reference Example 67
N- (tert-butoxycarbonyl) glycine in a solution of 3.0 g of ethyl 4-[[2- (dimethylamino) ethyl] amino] benzoate (compound obtained in Reference Example 1 (1)) (3.0 g) in 30 mL of methylene chloride; Add 89 g, add 2.89 mL of diethyl cyanophosphonate under ice cooling, and stir at room temperature for 24 hours. The reaction mixture is diluted with 20 mL of chloroform, 50 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated, washed with saturated brine, dried over sodium sulfate, and the solvent is distilled off under reduced pressure. The resulting crude product was fractionated by silica gel column chromatography (chloroform / methanol / 28% aqueous ammonia = 100: 10: 1), and then gel permeation chromatography (manufactured by Nippon Analytical Industries, solvent; chloroform). Purify and methyl 4- [N- [N ′-(tert-butoxycarbonyl) glycyl] -N- [2- (dimethylamino) ethyl] amino] benzoate (4.2 g, 84% yield) pale yellow Obtain as crystals.
MS (APCI) m / z; 394 [M + H] ^< +>.

Reference Example 68
(1) 27 mL of 50% dimethylamine aqueous solution is added dropwise to a solution of 22.8 g of methyl 4-bromomethylbenzoate in 450 mL of N, N-dimethylformamide and stirred at room temperature for 3 hours. The reaction mixture is poured into ice water and extracted with ethyl acetate. The combined organic layers are washed successively with water and saturated brine, and dried over sodium sulfate. The crude product obtained by distilling off the solvent under reduced pressure was purified by silica gel flash chromatography (chloroform / methanol = 10: 1) to give methyl 4-[(dimethylamino) methyl] benzoate (27.5 g). 99% yield) as a brown oil.
MS (APCI) m / z; 194 [M + H] ^< +>.
(2) 66 mL of concentrated hydrochloric acid and 167 mL of water are added to 19.2 g of methyl 4-[(dimethylamino) methyl] benzoate obtained in (1) above, and the mixture is refluxed overnight. The solvent is distilled off under reduced pressure and the resulting crude crystals are washed with ether to give 4-[(dimethylamino) methyl] benzoic acid hydrochloride (19.0 g, yield 88%) as a colorless powder.
MS (APCI) m / z; 179 [M + H] ^< +>.

Reference Example 69
(1) 8.9 g of N-bromosuccinimide and 342 mg of 2,2′-azobisisobutyronitrile are sequentially added to a solution of 6.3 g of methyl 6-methylnicotinate in 100 mL of carbon tetrachloride, and heated to reflux for 6 hours. After cooling to room temperature, 300 mL of hexane is added, insolubles are removed by filtration, and the filtrate is distilled off under reduced pressure. The resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate = 10: 1) and then stirred in hexane to give methyl 6- (bromomethyl) nicotinate (3.4 g, yield 35%). Is obtained as colorless crystals.
(2) 3 mL of 50% dimethylamine aqueous solution is added to 5 mL of tetrahydrofuran of 350 mg of the compound obtained in the above (1), and stirred at room temperature for 10 minutes. Ethyl acetate is added, washed successively with water and saturated brine, and dried over sodium sulfate. The resulting crude product is purified by silica gel column chromatography (chloroform / methanol = 100: 1) to give methyl 6- (dimethylaminomethyl) nicotinate (276 mg, yield 93%) as a colorless oil.
MS (APCI) m / z; 195 [M + H] ^< +>.

Reference examples 70-77
The corresponding starting material compound is treated in the same manner as in Reference Example 69 to give the compound shown in Table 35 below.

Reference Example 78
(1) To a solution of 15.3 g of ethyl 4-hydroxybenzoate in 150 mL of N, N-dimethylformamide, 15.9 g of 2-dimethylaminoethyl chloride hydrochloride and 43.2 g of potassium carbonate are sequentially added and stirred at 110 ° C. overnight. . Add water to the reaction mixture and extract with ethyl acetate. The combined organic layers are washed with a saturated aqueous sodium bicarbonate solution and water, and then dried over sodium sulfate. After the solvent was distilled off under reduced pressure, the resulting crude product was purified by silica gel flash column chromatography (chloroform / methanol = 10: 1) to give ethyl 4- [2- (dimethylamino) ethoxy] benzoate (14 0.1 g, 65% yield) as a brown oil.
MS (APCI) m / z; 238 [M + H] ^< +>.
(2) Concentrated hydrochloric acid (40 mL) and water (100 mL) are added to the compound (14.1 g) obtained in (1) above and refluxed overnight. The crude crystals obtained by distilling off the solvent under reduced pressure are washed with methanol / ether to give 4- [2- (dimethylamino) ethoxy] benzoic acid hydrochloride (14.1 g, yield 56%) as a brown powder.
MS (APCI) m / z; 210 [M + H] ^< +>.

Reference Example 79
The corresponding starting material compounds are treated in the same manner as in Reference Example 78 to give the compounds shown in Table 36 below.

Reference Example 80
(1) To 30 mL of methanol, 1.33 mL of thionyl chloride is added dropwise under ice cooling and stirred for 10 minutes. Add 3.0 g of 4-hydroxycinnamic acid and stir at room temperature for 4 days. The reaction mixture is concentrated, diluted with 50 mL of ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over sodium sulfate. After distilling off the solvent under reduced pressure, recrystallization from ethyl acetate / hexane gave methyl 4-hydroxycinnamate (2.86 g, yield 88%) as pale yellow crystals.
Melting point 136.5-137 [deg.] C.
(2) To a solution of 1.53 g of the compound obtained in (1) above in 25 mL of N, N-dimethylformamide, add 1.69 g of 3-chloropropyldimethylamine hydrochloride, 3.12 g of potassium carbonate, and 105 mg of tetrabutylammonium iodide. After sequential addition, the mixture is stirred at 80 ° C. for 17 hours. After allowing to cool, 100 mL of water is added and extracted twice with 150 mL of ethyl acetate. The separated organic layer is washed with 150 mL of water twice and saturated brine successively and dried over sodium sulfate. The solvent was distilled off under reduced pressure to obtain methyl trans-3- [4- [3- (dimethylamino) propoxy] phenyl] acrylate (2.07 g, yield 92%) as a pale yellow oil.
MS (APCI) m / z; 264 [M + H] ⁺
(3) To a solution of 2.07 g of the compound obtained in (2) above in 15 mL of methanol, add 15 mL of 1N aqueous sodium hydroxide and stir at room temperature for 15 hours. The reaction mixture is concentrated and neutralized with 1N hydrochloric acid to adjust to pH 7. Trans-3- [4- [3- (dimethylamino) propyloxy] phenyl] acrylic acid (1.93 g, yield 98%) is obtained as colorless crystals by adding methanol and stirring crystallization.
Melting point 191-193 [deg.] C.

Reference Example 81
(1) Dissolve 5.08 g of methyl 4- (aminomethyl) benzoate in 30 mL of methylene chloride, add 6.4 g of di-tert-butyl dicarbonate under ice cooling, warm to room temperature, and stir for 24 hours. Dilute with 20 mL of methylene chloride, add 40 mL of water and stir. After standing, the organic layer is separated and concentrated to obtain 4- [N- (tert-butoxycarbonyl) aminomethyl] benzoic acid methyl ester as a crude product.
(2) Dissolve 1.5 g of the compound obtained in (1) above in 15 mL of tetrahydrofuran, add 407 mg of 60% oily sodium hydride under ice cooling, warm to room temperature, and stir for 30 minutes. Under ice cooling, 2.26 mL of ethyl iodide is added dropwise, and the mixture is stirred at 60 degrees for 1 hour. The temperature is lowered to room temperature, diluted with 10 mL of ethyl acetate, and 20 mL of water is added and stirred. After standing, the organic layer is separated and concentrated. 4-[[N-ethyl-N- (tert-butoxycarbonyl)] aminomethyl] was obtained by producing the resulting crude product by NH silica gel flash column chromatography (solvent; hexane / ethyl acetate = 20: 1). Benzoic acid methyl ester (929 mg, 56% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 294 [M + H] ^< +>.

Reference Example 82
(1) To a solution of 610 mg of 4-hydroxybenzaldehyde in 20 mL of N, N-dimethylformamide, 1.08 g of 2-dimethylaminoethyl chloride and 2.0 g of potassium carbonate are sequentially added, followed by stirring at room temperature for 18 hours. Add 100 mL of ethyl acetate, wash with water and saturated brine, and dry over sodium sulfate. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 20: 1 to 10: 1) to give 4- [2- (dimethylamino) ethoxy] benzaldehyde (640 mg, yield 66%). Obtained as a pale yellow oil.
MS (APCI) m / z; 194 [M + H] ^< +>.
(2) To a solution of 807 mg of tert-butyl dimethylphosphonoacetate in 20 mL of tetrahydrofuran is added 144 mg of 60% oily sodium hydride under ice cooling, and the mixture is stirred for 30 minutes. A solution of 580 mg of the compound obtained in (1) above in 10 mL of tetrahydrofuran is added and stirred at room temperature for 1 hour. After adding ice water and extracting with ethyl acetate, the organic layer is washed with saturated brine and dried over sodium sulfate. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 20: 1), whereby trans-3- [4- [2- (dimethylamino) ethoxy] phenyl] acrylic acid tert-butyl ester ( 920 mg, 100% yield) is obtained as colorless crystals.
MS (APCI) m / z; 292 [M + H] ^< +>.
(3) 10 mL of a 4N hydrochloric acid dioxane solution of 880 mg of the compound obtained in (2) above is stirred at room temperature for 6 hours. Diluted with diethyl ether, the precipitated crystals were collected by filtration and washed with diethyl ether to obtain trans-3- [4- [2- (dimethylamino) ethoxy] phenyl] acrylic acid hydrochloride (750 mg, 91% yield). ) As colorless crystals.
MS (APCI) m / z; 236 [M + H] ^< +>.

Reference Example 83
(1) In an argon atmosphere, 8.7 mL of thionyl chloride is added dropwise to 90 mL of methanol at −30 ° C. over 15 minutes. After completion, the mixture is stirred at −20 ° C. for 0.5 hour, 5.0 g of 3-amino-4-methoxybenzoic acid is added and stirred at the same temperature for 15 minutes, and then stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the residual crystals were washed with methanol / ether to give methyl 3-amino-4-methoxybenzoate hydrochloride (6.25 g, yield 96%) as colorless crystals (melting point 213-215 ° C.). obtain.
MS (APCI) m / z; 182 [M + H] ^< +>.
(2) 2.4 mL of pyridine and 0.56 mL of methanesulfonyl chloride are sequentially added to a suspension of 1.08 g of methyl 3-amino-4-methoxybenzoate hydrochloride obtained above in 10 mL of tetrahydrofuran and stirred at room temperature for 30 minutes. To do. Water is added to the reaction mixture, and the mixture is stirred and extracted with ethyl acetate. The extract is treated with a diatomaceous earth column and then concentrated under reduced pressure. The resulting residue is recrystallized from ether / hexane to give methyl 3-methanesulfonylamino-4-methoxybenzoate (1.08 g, 69% yield) as crystals.
MS (APCI) m / z; 258 [M-H] ^- .
(3) A mixed solution of 260 mg of methyl 3-methanesulfonylamino-4-methoxybenzoate (compound obtained in the above (2)), 222 mg of potassium carbonate, 414 mg of 2-chloroethyldiethylamine hydrochloride and 2 mL of dimethyl sulfoxide Stir vigorously for hours. Water is added to the reaction mixture, and the mixture is stirred and extracted with ethyl acetate. The extract is washed with saturated brine, filtered through a NH silica gel short column, and concentrated under reduced pressure. The obtained residue was purified by silica gel flash column chromatography (HI-FLASH column; manufactured by Yamazen, solvent; chloroform / methanol = 1: 0 to 95: 5), converted into hydrochloride with an hydrochloric acid ethyl acetate solution, and 3- [N- [2- (Diethylamino) ethyl] -N- (methanesulfonyl) amino] -4-methoxybenzoic acid hydrochloride (228 mg, 93% yield) is obtained as a colorless resin.
MS (APCI) m / z; 359 [M + H] ^< +>.

Reference Example 84
(1) To a solution of 76.1 g of vanillin in 500 mL of N, N-dimethylformamide, 130 g of 4- (2-chloroethyl) morpholine hydrochloride, 7.5 g of sodium iodide, and 207 g of potassium carbonate were sequentially added, and then at 80 ° C. for 15 hours. Stir. The solvent is distilled off under reduced pressure, and the residue is diluted with ethyl acetate, washed with saturated brine, and dried over sodium sulfate. After distilling off the solvent under reduced pressure, diisopropyl ether is added to the residue and filtered to give 3-methoxy-4- (2-morpholinoethoxy) benzaldehyde (112.6 g, yield 85%) as yellow-orange crystals.
MS (APCI) m / z; 266 [M + H] ^< +>.
(2) 6.4 g of 60% oily sodium hydride is added to a solution of 37.0 g of triethyl phosphonoacetate in 150 mL of tethydrofuran under ice cooling, and the mixture is stirred for 0.5 hours. A solution of 40.0 g of the compound obtained in (1) above in 140 mL of tetrahydrofuran is added dropwise thereto and stirred at the same temperature for 2 hours. The reaction solution is diluted with 500 mL of ethyl acetate, washed with saturated brine, and dried over magnesium sulfate. After distilling off the solvent under reduced pressure, diisopropyl ether was added to the resulting crude product and filtered to obtain ethyl trans-3- [3-methoxy-4- (2-morpholinoethoxy) phenyl] acrylate (46.2 g). Yield 91%) as yellow-orange crystals.
MS (APCI) m / z; 336 [M + H] ^< +>.
(3) To a solution of 43.3 g of the compound obtained in (2) above in 250 mL of methanol is added 100 mL of 2N aqueous sodium hydroxide solution, and the mixture is stirred overnight at room temperature. After distilling off the solvent under reduced pressure, the reaction solution is neutralized and the precipitated crystals are collected by filtration. The crude crystals were dissolved in ethanol, insolubles were filtered off, and recrystallized to obtain trans-3- [3-methoxy-4- (2-morpholinoethoxy) phenyl] acrylic acid (34.8 g, yield 88%). Is obtained as yellow crystals.
MS (APCI) m / z; 308 [M + H] ^< +>.

Reference Example 85
(1) While cooling at −30 ° C., 254 mL of thionyl chloride is added dropwise to 1500 mL of methanol over about 1 hour. After completion, the mixture is stirred at room temperature for 0.5 hour, and then added with 500.0 g of trans-cyclohexane-1,4-dicarboxylic acid and stirred at room temperature for 17 hours. The reaction mixture is concentrated under reduced pressure, and the residue is diluted with chloroform and washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer is dried over sodium sulfate and the solvent is removed under reduced pressure. The resulting residue is crystallized from hexane, filtered and dried to obtain 545.0 g of dimethyl trans-cyclohexane-1,4-dicarboxylate.
MS (APCI) m / z: 201 [M + H] ^< +>.
(2) 150.0 g of dimethyl trans-cyclohexane-1,4-dicarboxylate obtained in (1) above was dissolved in 1500 mL of tetrahydrofuran, and 149 g of 28% sodium methoxide-methanol solution and 13.2 g of water were added under ice cooling. The mixed solution is added dropwise. The reaction solution is returned to room temperature and stirred for 3.5 hours, and then 1500 mL of hexane is poured and the precipitate is collected by filtration. Subsequently, the resulting precipitate is added to a mixed solution of 50 mL of concentrated hydrochloric acid, 450 mL of water, and 1000 mL of chloroform under ice-cooling. After stirring for 20 minutes at room temperature, the chloroform layer is separated and the aqueous layer is extracted with chloroform. . The organic layers are combined, dried over sodium sulfate, and the solvent is distilled off under reduced pressure. The obtained residue is crystallized from hexane, filtered and dried to obtain 106.0 g of monomethyl trans-cyclohexane-1,4-dicarboxylate.
MS (ESI) m / z: 185 [M-H] -.
(3) 100.0 g of monomethyl trans-cyclohexane-1,4-dicarboxylate obtained in (2) above is dissolved in 1000 mL of tert-butanol, and after adding 155 g of diphenyl phosphate azide and 78.6 mL of triethylamine, about 60 Heat at 0 ° C. for 1 hour and heat at reflux for an additional 17 hours. After allowing to cool, ice water is poured into the reaction mixture, and the mixture is extracted with ethyl acetate. The organic layer is washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained residue is dissolved in 250 mL of methanol, 750 mL of water is added, and the mixture is stirred under ice-cooling. After 0.5 hour, the precipitate was collected by filtration, washed successively with water-methanol (3: 1) 1000 mL and hexane, dried, and methyl trans-4- (tert-butoxycarbonylamino) cyclohexanecarboxylate 117. 0.0 g is obtained.
MS (APCI) m / z: 275 [M + NH 4] +.

Reference Example 86
(1) Dissolve 234.0 g of the compound obtained in Reference Example 85 in 500 mL of dioxane, add 500 mL of 4N hydrochloric acid in dioxane, and stir at room temperature for 19 hours. The reaction mixture is concentrated under reduced pressure, and the resulting residue is suspended in diethyl ether. The precipitate is collected by filtration to obtain 121.9 g of trans-4-aminocyclohexanecarboxylic acid methyl hydrochloride.
MS (APCI) m / z: 158 [M + H] ^< +>.
(2) 93.0 g of trans-4-aminocyclohexanecarboxylic acid methyl hydrochloride obtained in (1) above is dissolved in 1000 mL of methanol, 95.4 mL of 35% aqueous formaldehyde solution, 39.4 g of sodium acetate and 10% palladium-carbon. Add 10 g and stir at room temperature under atmospheric hydrogen atmosphere for 3.5 hours. Insoluble matter is removed by filtration through Celite, and the filtrate is concentrated under reduced pressure. To the resulting residue is poured 500 mL of 20% aqueous potassium carbonate solution, and the mixture is extracted with chloroform. The organic layer is dried over sodium sulfate and potassium carbonate, and the solvent is distilled off under reduced pressure. The resulting residue is purified by NH silica gel column chromatography (elution solvent: hexane / ethyl acetate = 2/1) to obtain 87.3 g of methyl trans-4- (dimethylamino) cyclohexanecarboxylate.
MS (APCI) m / z: 186 [M + H] ^< +>.
(3) Dissolve 27.6 g of the compound obtained in (2) above in 300 mL of dioxane and 100 mL of water, add 50 mL of 6N hydrochloric acid, and heat to reflux for 4 hours. Add 50 mL of 6N hydrochloric acid and heat to reflux for an additional hour. The reaction solution is concentrated under reduced pressure, azeotroped with toluene, and the resulting residue is suspended in diisopropyl ether. The precipitate is collected by filtration, washed with diisopropyl ether and dried to obtain 27.5 g of trans-4- (dimethylamino) cyclohexanecarboxylic acid / hydrochloride.
MS (APCI) m / z: 172 [M + H] ^< +>.

Reference Example 87
(1) 10 g of the compound obtained in Reference Example 86 (1), 19.2 g of 1,4-diiodobutane, and 16.4 g of sodium carbonate are suspended in 60 mL of tetrahydrofuran 300 mL-N, N-dimethylacetamide and stirred at 70 ° C. for 20 hours. To do. After the reaction solution is concentrated under reduced pressure, the residue is dissolved in ethyl acetate-water, and the organic layer is separated. The organic layer is washed successively with water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The resulting residue is purified by NH silica gel column chromatography (elution solvent: ethyl acetate / hexane = 1/5) to obtain 10.9 g of methyl trans-4- (1-pyrrolidinyl) cyclohexanecarboxylate.
MS (APCI) m / z: 212 [M + H] ^< +>.
(2) 2N hydrochloric acid (80 mL) is added to a dioxane (150 mL) solution of the compound (10.9 g) obtained in (1) above, and stirred at 110 ° C. for 3 hours while distilling off methanol. The reaction mixture is concentrated under reduced pressure, and the resulting residue is suspended in diethyl ether and collected by filtration to obtain 11.1 g of trans-4- (1-pyrrolidinyl) cyclohexanecarboxylic acid / hydrochloride.
MS (APCI) m / z: 198 [M + H] ^< +>.

Reference Example 88
(1) 47.5 g of the compound obtained in Reference Example 86 (1), 34.5 mL of bis (2-chloroethyl) ether, 77.9 g of sodium carbonate, and 88 g of sodium iodide were added to 1400 mL of tetrahydrofuran and 280 mL of N, N-dimethylacetamide. And reflux for 18 hours. Add bis (2-chloroethyl) ether (23 mL) and sodium iodide (22 g) to the reaction mixture, and further reflux for 6 hours. After the reaction solution is concentrated under reduced pressure, the residue is dissolved in ethyl acetate-water, and the organic layer is separated. The organic layer is washed with water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The resulting residue was purified by NH-silica gel column chromatography (elution solvent: ethyl acetate / hexane = 1/30, followed by ethyl acetate / hexane = 1/5, further 1/3), and trans-4- 53.9 g of methyl morpholinocyclohexanecarboxylate are obtained.
MS (APCI) m / z: 228 [M + H] ^< +>.
(2) 400 mL of 2N hydrochloric acid is added to a solution of 53.8 g of the compound obtained in (1) above in 750 mL of dioxane, and the mixture is stirred at 110 ° C. for 4 hours while distilling off methanol. The reaction mixture is concentrated, and the resulting residue is suspended in diethyl ether and collected by filtration to obtain 54.8 g of trans-4-morpholinocyclohexanecarboxylic acid / hydrochloride.
MS (APCI) m / z: 214 [M + H] ^< +>.

Reference Example 89
(1) 6.29 g of trans-4- (aminomethyl) cyclohexanecarboxylic acid is suspended in 32 mL of methanol, and 6 mL of thionyl chloride is added dropwise under ice cooling. The reaction solution is returned to room temperature and stirred overnight, and then the reaction solution is concentrated under reduced pressure to obtain 8.69 g of methyl trans-4- (aminomethyl) cyclohexanecarboxylate / hydrochloride.
MS (APCI) m / z: 172 [M + H] ^< +>.
(2) Suspend 8.69 g of the compound obtained in (1) above in 400 mL of dichloromethane, add 11.2 mL of triethylamine, and stir for several minutes at room temperature. Then, under ice-cooling, 15.9 mL of 35% aqueous formaldehyde solution and triacetoxy Add 25.43 g of sodium borohydride. The reaction solution is returned to room temperature, stirred for 2 hours, poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with chloroform. The organic layer is washed successively with water and saturated brine, dried over sodium sulfate, and the solvent is distilled off under reduced pressure to obtain 7.42 g of methyl trans-4- (dimethylaminomethyl) cyclohexanecarboxylate.
MS (APCI) m / z: 200 [M + H] ^< +>.
(3) 7.41 g of the compound obtained in (2) above is dissolved in 140 mL of dioxane, 70 mL of 2N hydrochloric acid is added, and the mixture is refluxed with heating for 3 hours. After allowing to cool, the reaction solution is concentrated under reduced pressure, and the resulting residue is azeotroped with toluene and dried to obtain 8.45 g of trans-4- (dimethylaminomethyl) cyclohexanecarboxylic acid / hydrochloride as an amorphous solid.
MS (APCI) m / z: 186 [M + H] ^< +>.

Reference Example 90
(1) Suspend 33.6 g of 60% oily sodium hydride in 600 mL of tetrahydrofuran, and dropwise add a solution of 188.4 g of triethyl phosphonoacetate in 100 mL of tetrahydrofuran under ice cooling. After stirring for 0.5 hour under the same cooling, 100 mL of tetrahydrofuran of 75.00 g of pyridine-4-carbaldehyde is added dropwise and stirred for 1 hour. Under the same cooling, 1000 mL of ice water is poured into the reaction solution and extracted with ethyl acetate. The organic layer is washed successively with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The resulting residue is suspended in a small amount of diisopropyl ether under ice cooling, and the precipitate is collected by filtration. After washing sequentially with diisopropyl ether and hexane, drying is performed to obtain 77.53 g of ethyl 3- (4-pyridyl) acrylate.
MS (APCI) m / z: 178 [M + H] ^< +>.
(2) 28.00 g of the compound obtained in the above (1) is dissolved in 280 mL of acetic acid, 1.80 g of platinum oxide is added, and the mixture is shaken at room temperature for 24 hours in a hydrogen atmosphere. The insoluble material is removed by filtration, and the filtrate is concentrated under reduced pressure. The resulting residue is dissolved in 200 mL of dioxane, 200 mL of 4N hydrogen chloride-dioxane is added, and then the solvent is distilled off under reduced pressure. The resulting residue is suspended in diethyl ether-diisopropyl ether, and the precipitate is collected by filtration. After washing with diisopropyl ether and drying, 33.50 g of ethyl 3- (4-piperidyl) propionate · hydrochloride is obtained.
MS (APCI) m / z: 186 [M + H] ^< +>.

Reference Example 91
Dissolve 50.00 g of ethyl (4-pyridyl) acetate in 500 mL of acetic acid, add 3.44 g of platinum oxide, and shake for 20 hours at room temperature in a hydrogen atmosphere. The insoluble material is removed by filtration, and the filtrate is concentrated under reduced pressure. The resulting residue is dissolved in dioxane (200 mL), 4N hydrogen chloride-dioxane (400 mL) is added, and the solvent is evaporated under reduced pressure. The resulting residue is suspended in diethyl ether-diisopropyl ether, and the precipitate is collected by filtration. After washing with diisopropyl ether and drying, 61.80 g of ethyl (4-piperidyl) acetate / hydrochloride is obtained.
MS (APCI) m / z: 172 [M + H] ^< +>.

Reference Example 92
(1) 70.83 g of ethyl 3- (4-piperidyl) propionate / hydrochloride (compound obtained in Reference Example 90) is dissolved in 700 mL of ethanol, and 38.2 mL of 2-iodopropane and 132.3 g of potassium carbonate are added. Reflux for 6 hours. The insoluble material is removed by filtration, and the filtrate is concentrated under reduced pressure. The resulting residue is diluted with 800 mL of ethyl acetate, washed successively with water and saturated brine, and dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained residue was purified by NH silica gel column chromatography (eluent: n-hexane / ethyl acetate = 20 / 1-9 / 1) to give ethyl 3- (1-isopropylpiperidin-4-yl) propionate 13 g are obtained.
MS (APCI) m / z: 228 [M + H] ^< +>.
(2) Dissolve 57.12 g of the compound obtained in (1) above in 1200 mL of dioxane, add 600 mL of 2N hydrochloric acid, and reflux with heating for 3 hours. The reaction solution is concentrated under reduced pressure and azeotroped with dioxane, and the resulting residue is suspended in 500 mL of diethyl ether and diisopropyl ether (1: 1). The precipitate is collected by filtration, washed with diisopropyl ether and dried to obtain 55.36 g of 3- (1-isopropylpiperidin-4-yl) propionic acid / hydrochloride.
MS (APCI) m / z: 200 [M + H] ^< +>.

Reference Examples 93-94
The corresponding starting material compounds are treated in the same manner as in Reference Examples 92 (1) and (2) to give the compounds described in Table 37 below.

Reference Example 95
(1) 5.00 g of the compound obtained in Reference Example 91, 3.62 g of 4-chloropyridine · hydrochloride, and 10.1 mL of triethylamine are suspended in 130 mL of xylene and heated to reflux for 20 hours. The reaction mixture is cooled with water, and insolubles are removed by filtration. The filtrate is concentrated under reduced pressure, and the resulting residue is diluted with chloroform and washed with water. After drying with magnesium sulfate, the solvent is distilled off under reduced pressure. The resulting residue is purified by NH silica gel column chromatography (elution solvent: chloroform / ethyl acetate = 4/1) to obtain 4.15 g of [1- (4-pyridyl) piperidin-4-yl] ethyl acetate.
MS (APCI) m / z: 249 [M + H] ^< +>.
(2) Dissolve 4.15 g of the compound obtained in (1) above in 200 mL of dioxane, add 70 mL of 1N hydrochloric acid, and heat to reflux for 4 hours. The reaction mixture is concentrated under reduced pressure, and the resulting residue is lyophilized to obtain 3.90 g of [1- (4-pyridyl) piperidin-4-yl] acetic acid / hydrochloride.
MS (APCI) m / z: 221 [M + H] ^< +>.

Reference Example 96
(1) A mixed solution of ethyl isonipecotate 1.57 g, propionaldehyde 1.0 g, 10% palladium carbon 500 mg in 20 mL of methanol is vigorously stirred in a hydrogen atmosphere at room temperature for 2 hours. After substituting hydrogen with argon, palladium carbon in the reaction solution is filtered off and washed with 100 mL of methanol, and then the washing solution and the filtrate are combined and the solvent is distilled off. The obtained residue was dissolved in ethanol (20 mL), 4N hydrochloric acid dioxane solution (20 mL) was added, the solvent was distilled off under reduced pressure, and the residue was crystallized from ethanol / ether to give 1-propylpiperidine-4-carboxylate The hydrochloride (1.81 g, 77% yield) is obtained as colorless crystals.
Melting point 114-117 ° C
(2) A mixture of 1.79 g of the compound obtained in (1) above and 20 mL of concentrated hydrochloric acid is heated to reflux for 2 hours. The reaction mixture is allowed to cool to room temperature and concentrated under reduced pressure. After adding ether to the residue and stirring, the separated supernatant ether layer was removed, and the residue was crystallized from ethanol / ether to give 1-propylpiperidine-4-carboxylic acid hydrochloride (1.11 g, yield 70%). Obtained as colorless crystals.
Melting point 222-224 [deg.] C.

Reference Example 97
To a solution of 300 mg of 4-[[2- (dimethylamino) ethyl] amino] benzaldehyde in 4 mL of methylene chloride is added 234 μL of 2-methoxyethyl chloroformate, 252 μL of pyridine is added dropwise under ice cooling, and the mixture is stirred at 50 ° C. for 2 days. The reaction mixture is diluted with 5 mL of chloroform, 10 mL of saturated aqueous sodium hydrogen carbonate solution is added and stirred, and the organic layer is separated and concentrated. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to give 4- [N-[(2-methoxyethoxy) carbonyl] -N- [2- ( Dimethylamino) ethyl] amino] benzaldehyde (290 mg, 63% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 294 [M + H] ^< +>.

Reference Example 98
A solution of 500 mg terephthalic acid monomethyl chloride, 178 mg N, N-dimethylethylenediamine and 650 mg diisopropylethylamine in 5.0 mL methylene chloride is stirred overnight at room temperature. The reaction solution is diluted with ethyl acetate, saturated aqueous sodium hydrogen carbonate is added and stirred, the organic layer is separated, and the solvent is distilled off. The resulting crude product was purified by NH-silica gel flash column chromatography (hexane / ethyl acetate = 9: 1) to give methyl 4-[[[2- (dimethylamino) ethyl] amino] carbonyl] benzoate. (355 mg, 70% yield) is obtained as yellow crystals.
MS (APCI) m / z; 251 [M + H] ^< +>.

Reference Example 99
Under an argon atmosphere, 1.19 g of lithium aluminum hydride was suspended in 50 mL of tetrahydrofuran, and under ice-cooling, ethyl (1-isopropylpiperidin-4-yl) acetate (compound obtained in Reference Example 93- (1)) 6.43 g Is added dropwise over 15 minutes, the temperature is raised to room temperature, and the mixture is stirred for 1.5 hours. Under ice-cooling, 1.2 mL of water, 2.4 mL of 2N aqueous sodium hydroxide solution and 2.4 mL of water are sequentially added, and the mixture is warmed to room temperature and stirred for 2 hours. Add magnesium sulfate and stir for 10 minutes, then filter and concentrate the solution. The resulting crude product was purified by NH silica gel flash column chromatography (solvent; hexane / ethyl acetate = 1: 1) to give 2- (1-isopropylpiperidin-4-yl) ethanol (5.09 g, yield). 99%) as a colorless oil.
MS (APCI) m / z; 172 [M + H] ^< +>.

Reference Example 100
Under an argon atmosphere, 3.29 g of lithium aluminum hydride was suspended in 160 mL of tetrahydrofuran, and under ice cooling, 5.00 g of ethyl 1-isopropylpiperidine-4-carboxylate (the compound obtained in Reference Example 94 (1)) was added. The mixture is warmed to room temperature and stirred for 14 hours. Under ice cooling, 3.3 mL of water, 6.6 mL of 2N aqueous sodium hydroxide solution and 6.6 mL of water are sequentially added, and the mixture is warmed to room temperature and stirred for 1 hour. Add magnesium sulfate and stir for 10 minutes, then filter and concentrate the solution. The resulting crude product was produced by NH silica gel flash column chromatography (solvent; hexane / ethyl acetate = 1: 1) to give (1-isopropylpiperidin-4-yl) methanol (3.75 g, yield 99%). ) As a colorless oil.
MS (APCI) m / z; 158 [M + H] ^< +>.

Reference Example 101
To a mixed solution of 10 g of 1-methyl-2-imidazolecarbaldehyde in 80 mL of ethanol and 80 mL of tetrahydrofuran is added 4.2 g of sodium borohydride under ice cooling, and the mixture is stirred at room temperature for 2 hours. After distilling off the solvent, the residue is dissolved in chloroform, washed with saturated aqueous sodium hydrogen carbonate, and dried over anhydrous sodium sulfate. Diisopropyl ether was added to the crude product obtained by distilling off the solvent under reduced pressure, and the precipitated crystals were collected by filtration to give (1-methyl-1H-imidazol-2-yl) methanol (9.9 g, yield 98%). ) As colorless crystals.
MS (APCI) m / z; 113 [M + H] ^< +>.

Reference Example 102
(1) 2.0 g of methyl 4-[[(tert-butoxycarbonyl) amino] methyl] benzoate (compound obtained in Reference Example 81 (1)) was dissolved in 20 mL of tetrahydrofuran, and 60% oily hydrogenated under ice cooling. Add 0.9 g of sodium and stir at room temperature for 30 minutes. Under ice cooling, 2.3 mL of methyl iodide is added dropwise, and the mixture is stirred at room temperature for 3 hours. After dilution with ethyl acetate and washing with water, the solvent was concentrated under reduced pressure to give methyl 4-[[N-methyl-N- (tert-butoxycarbonyl) amino] methyl] benzoate (1.9 g, yield 94%). Obtained as a yellow oil.
MS (APCI) m / z; 280 [M + H] ^< +>.
(2) Add 10.0 mL of 4N hydrochloric acid / dioxane to 5.0 mL of methanol of 1.5 g of the compound obtained in (1) above, and stir at room temperature for 1 hour. After dilution with ether, the precipitated crystals are collected by filtration to give methyl 4-[(methylamino) methyl] benzoate (0.89 g, yield 78%) as colorless crystals.
MS (APCI) m / z; 180 [M + H] ^< +>.
(3) A suspension of 100 mg of the compound obtained in (2) above, 160 mg of 2- (diethylamino) ethyl chloride hydrochloride and 260 mg of potassium carbonate in 3.0 mL of N, N-dimethylformamide is stirred at 80 ° C. for 3 hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 10: 1) to give 4-[[N-methyl-N-[[2- (diethylamino) ethoxy] carbonyl] amino] methyl]. Methyl benzoate (94 mg, 64% yield) is obtained as a yellow oil.
MS (APCI) m / z; 323 [M + H] ^< +>.

Reference Example 103
(1) To a solution of methyl 5-aminofuran-2-carboxylate (1.0 g) and pyridine (1.2 mL) in methylene chloride (6.0 mL) was added dropwise cyclopropanecarbonyl chloride (0.78 mL) under ice cooling, and the mixture was stirred at room temperature for 2 hours. To do. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, the mixture is extracted with chloroform and dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate = 3: 1) to give methyl 5-[(cyclopropylcarbonyl) amino] furan-2-carboxylate (0.82 g, yield). 56%) is obtained as colorless crystals.
MS (APCI) m / z; 210 [M + H] ^< +>.
(2) A suspension of 200 mL of the compound obtained in (1) above, 275 mg of 2- (dimethylamino) ethyl chloride hydrochloride and 530 mg of potassium carbonate, and 3.0 mL of N, N-dimethylformamide is stirred at 80 ° C. for 3 hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the solvent is evaporated under reduced pressure. The resulting crude product is purified by silica gel column chromatography (chloroform / methanol = 10: 1) to give 5- [N- (cyclopropylcarbonyl) -N- [2- (dimethylamino) ethyl] amino] furan. Methyl-2-carboxylate (196 mg, 73% yield) is obtained as a colorless oil.
MS (APCI) m / z; 281 [M + H] ^< +>.

Reference Example 104
(1) Thionyl chloride (5.0 mL) is added dropwise to a solution of 10 g of 2-nitrothiophene-4-carboxylic acid in 50 mL of ethanol under ice cooling, and the mixture is stirred overnight at room temperature. The solvent is distilled off under reduced pressure, a saturated aqueous sodium hydrogen carbonate solution is added to the residue, the mixture is extracted with ethyl acetate, and dried over anhydrous magnesium sulfate. Without purifying the crude product obtained by distilling off the solvent under reduced pressure, 16 g of iron powder, 16 g of ammonium chloride, 100 mL of ethanol and 100 mL of water are added, and the mixture is heated to reflux for 2 hours. The reaction mixture is diluted with ethyl acetate, insoluble material is filtered off, washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain ethyl 5-aminothiophene-3-carboxylate (6.34 g, yield 65%) as a brown oil.
MS (APCI) m / z; 172 [M + H] ^< +>.
(2) A solution of 5.62 g of the compound obtained in (1) above, 15.8 g of di-t-butyl dicarbonate, 6.4 mL of pyridine, 0.4 g of 4- (dimethylamino) pyridine, and 50 mL of methylene chloride at room temperature. Stir for 3 hours. The reaction solution is washed with water and dried over anhydrous magnesium sulfate. To the residue obtained by distilling off the solvent under reduced pressure, 22 g of cesium carbonate and 50 mL of ethanol are added and stirred at 80 ° C. overnight. The insoluble material was removed by filtration, and the resulting crystals diluted with water were collected by filtration to obtain ethyl 5-[(tert-butoxycarbonyl) amino] thiophene-3-carboxylate (6.07 g, yield 68%) as brown. Obtain as crystals.
MS (APCI) m / z; 272 [M + H] ^< +>.
(3) A 15 mL suspension of N, N-dimethylformamide in 1.5 g of the compound obtained in (2) above, 1.5 g of 2- (dimethylamino) ethyl chloride hydrochloride and 3.0 g of potassium carbonate at 80 ° C. Stir for hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 50: 1) to give 5- [N- (tert-butoxycarbonyl) -N- [2- (dimethylamino) ethyl] amino] thiophene. Ethyl-3-carboxylate (1.53 g, 81%) is obtained as a brown oil.
MS (APCI) m / z; 343 [M + H] ^< +>.
(4) To the compound obtained in (3) above, 5.0 mL of methanol and 10.0 mL of 4N hydrochloric acid / dioxane are added and stirred at room temperature for 3 hours. The solvent is distilled off under reduced pressure, neutralized with a saturated aqueous sodium hydrogen carbonate solution, extracted with chloroform, and dried over anhydrous magnesium sulfate. The crude product obtained by distilling off the solvent under reduced pressure was purified by silica gel column chromatography (chloroform / methanol = 10: 1) to give 5-[[2- (dimethylamino) ethyl] amino] thiophene-3-carboxylic acid. Ethyl acid (0.75 g, 56% yield) is obtained as a brown oil.
MS (APCI) m / z; 243 [M + H] ^< +>.
(5) To a solution of 50 mg of the compound obtained in (4) above and 33 mg of pyridine in 3 mL of methylene chloride, 24 mg of acetyl chloride is added dropwise under ice cooling, and the mixture is stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, the mixture is extracted with chloroform and dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The resulting crude product is purified by silica gel column chromatography (hexane / ethyl acetate = 1: 1) to give 5- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] thiophene-3- Ethyl carboxylate (46 mg, 79% yield) is obtained as a yellow oil.
MS (APCI) m / z; 285 [M + H] ^< +>.

Reference Example 105
A solution of ethyl 5-[[2- (dimethylamino) ethyl] amino] thiophene-3-carboxylate (compound obtained in Reference Example 104 (4)) (50 mg) and n-butyl isocyanate (31 mg) in chloroform (3 mL) at 60 ° C. Stir overnight. Saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture, the mixture is extracted with chloroform and dried over anhydrous magnesium sulfate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane / ethyl acetate = 1: 1) to give 5- [N- (butylcarbamoyl) -N- [2- (dimethylamino) ethyl] amino] thiophene. Ethyl-3-carboxylate (58 mg, 82% yield) is obtained as a yellow oil.
MS (APCI) m / z; 342 [M + H] ^< +>.

Reference Example 106
250 mg of 5- (ethoxycarbonyl) thiophene-2-carboxylic acid, 3.0 mL of methylene chloride, 100 mg of N, N-dimethylethylenediamine, 205 mg of 1-hydroxybenzotriazole, 610 mg of triethylamine, 1-ethyl-3- (3-dimethylaminopropyl) ) 290 mg of carbodiimide hydrochloride is added sequentially and stirred at room temperature overnight. The reaction mixture is diluted with chloroform, saturated aqueous sodium hydrogen carbonate is added and stirred, the organic layer is separated, and the solvent is evaporated. The resulting crude product was purified by NH-silica gel flash column chromatography (ethyl acetate) to give ethyl 5-[[[2- (dimethylamino) ethyl] amino] carbonyl] thiophene-2-carboxylate (160 mg Yield 53%) as brown crystals.
MS (APCI) m / z; 271 [M + H] ^< +>.

Reference Example 107
(1) A mixed solution of 2.14 g of tert-butyl 4-fluorobenzoate and 1 mL of 1- (2-aminoethyl) pyrrolidine is stirred at 120 ° C. for 1 day under an argon atmosphere. After allowing to cool to room temperature, ethyl acetate and water are added, the mixture is extracted twice with ethyl acetate, and the organic layer is concentrated under reduced pressure using a centrifugal concentrator. The resulting crude product was purified by NH silica gel column flash chromatography (hexane / ethyl acetate = 8: 1 to 4: 1) to give 4-[[2- (1-pyrrolidinyl) ethyl] amino] benzoic acid tert. -Butyl (1.62 g, 51% yield) is obtained as an oil.
MS (APCI) m / z; 291 [M + H] ^< +>.
(2) To a solution of 96 mg of tert-butyl 4-[[2- (1-pyrrolidinyl) ethyl] amino] benzoate and 67 μL of pyridine obtained above in 1 mL of chloroform under ice-cooling, 47 μL of acetyl chloride was added at room temperature. Stir for days. Chloroform is added to the reaction solution, diluted, and then washed with saturated aqueous sodium hydrogen carbonate. The washing solution is re-extracted twice with chloroform, and all organic layers are combined. The resulting crude product was purified by NH silica gel column flash chromatography (hexane / ethyl acetate = 4: 1 to 2: 3) to give 4- [N-acetyl-N- [2- (1-pyrrolidinyl) ethyl. Amino] tert-butyl benzoate (37 mg, 33% yield) is obtained as a colorless oil.
MS (APCI) m / z; 333 [M + H] ^< +>.

Reference Example 108
(1) Dissolve 2.0 mL of oxalyl chloride in 120 mL of dichloromethane, and dropwise add a solution of 3.3 mL of dimethyl sulfoxide in 15 mL of dichloromethane under cooling with dry ice-acetone. After stirring for 10 minutes under the same cooling, a solution of 3.00 g of (1-isopropylpiperidin-4-yl) methanol obtained in Reference Example 100 in 30 mL of dichloromethane is added dropwise over about 15 minutes. After completion, the reaction solution is stirred for 2 hours under the same cooling, and 13.3 mL of triethylamine is added dropwise over 10 minutes. The reaction solution is stirred for 1 hour while returning to room temperature, and then poured into a saturated aqueous solution of sodium bicarbonate. Extract with dichloromethane and evaporate the solvent under reduced pressure. The aqueous layer is extracted with ethyl acetate, and the dichloromethane extraction residues are combined, washed with water and saturated brine, and dried over sodium sulfate. The solvent is distilled off under reduced pressure to obtain 1.96 g of 1-isopropylpiperidine-4-carbaldehyde as a crude product.
MS (APCI) m / z; 156 [M + H] ^< +>.
(2) Dissolve 7.96 g of triethyl phosphonoacetate in 50 mL of tetrahydrofuran, and add 1.45 g of 60% oily sodium hydride little by little under ice cooling. After stirring for 20 minutes under the same cooling, a solution of 5.03 g of 1-isopropylpiperidine-4-carbaldehyde obtained in (1) above in 25 mL of tetrahydrofuran is added. The reaction mixture is stirred for 3 hours under the same cooling, then diluted with diethyl ether, poured into water and extracted with ethyl acetate. The organic layer is washed with water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The resulting residue is purified by NH-silica gel column chromatography (elution solvent: n-hexane / ethyl acetate = 9/1) to obtain 6.87 g of ethyl 3- (1-isopropylpiperidin-4-yl) acrylate. .
MS (APCI) m / z; 226 [M + H] ^< +>.
(3) Dissolve 1.01 g of ethyl 3- (1-isopropylpiperidin-4-yl) acrylate obtained in (2) above in 20 mL of ethanol, add 4.5 mL of 2N aqueous sodium hydroxide solution at room temperature. Stir for 24 hours. After adding 9 mL of 2N hydrochloric acid to the reaction solution and concentrating under reduced pressure, the resulting residue is freeze-dried to obtain 1.43 g of 3- (1-isopropylpiperidin-4-yl) acrylic acid / hydrochloride.
MS (APCI) m / z; 198 [M + H] ^< +>.

Reference Example 109
In an argon atmosphere, a mixture of ethyl p-aminobenzoate (25.2 g), triethyl orthoformate (80 g) and trifluoroacetic acid (0.2 mL) was heated to reflux for 3 hours, allowed to cool to room temperature, concentrated under reduced pressure, and further azeotroped with ethanol. . The residue is suspended in 400 mL of ethanol, 23 g of sodium borohydride is added under ice cooling, and the mixture is heated to reflux for 3 hours. The reaction mixture is allowed to cool to room temperature, ethyl acetate and water are added, and the mixture is stirred at room temperature for 1 day. The organic layer is separated and dried over anhydrous sodium sulfate, and the solvent is distilled off under reduced pressure. The resulting crude product was purified by silica gel column flash chromatography (Flash 75M manufactured by Biotage, hexane / ethyl acetate = 4: 1) to give ethyl 4- (methylamino) benzoate (12.7 g, yield 46). %) As a pale yellow amorphous solid.
MS (APCI) m / z; 180 [M + H] ^< +>.

Reference Example 110
8.35 g of trans-4- (aminomethyl) cyclohexanecarboxylic acid was suspended in 100 mL of dioxane, 50 mL of water and 50 mL of 1N aqueous sodium hydroxide solution were added, and then 12.7 g of di-tert-butyl dicarbonate under ice-cooling. Is dripped. The reaction solution is returned to room temperature and stirred for 4 hours, and then the reaction solution is concentrated under reduced pressure. The obtained residue is diluted with ethyl acetate, and an aqueous citric acid solution is added to adjust the pH to about 3 to 4, followed by extraction with ethyl acetate. The organic layer is washed with water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained residue is suspended in n-hexane, collected by filtration and dried to obtain trans-4- (tert-butoxycarbonylaminomethyl) cyclohexanecarboxylic acid (13.30 g, yield 97%) as crystals.
MS (ESI) m / z: 256 [M-H] -.

Reference Example 111
(1) 30.0 g of methyl trans-4- (tert-butoxycarbonylamino) cyclohexanecarboxylate obtained in Reference Example 85 was dissolved in 150 mL of N, N-dimethylformamide, and 60% oily sodium hydride 5 under ice-cooling. Add 60 g. After stirring for 0.5 hour under the same cooling, 14.5 mL of methyl iodide and 0.15 mL of methanol are sequentially added, and the reaction solution is returned to room temperature and stirred for 4 hours. Under ice-cooling, a saturated aqueous ammonium chloride solution and ice water are poured into the reaction mixture, and the mixture is extracted with ethyl acetate. The organic layer is washed successively with water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 10: 1 to 7: 1), and trans-4- [N-methyl-N- (tert-butoxycarbonyl) amino] cyclohexanecarboxyl. Methyl acid (26.3 g, 83% yield) is obtained as an amorphous solid.
MS (APCI) m / z: 272 [M + H] ^< +>.
(2) Dissolve 44.78 g of methyl trans-4- [N-methyl-N- (tert-butoxycarbonyl) amino] cyclohexanecarboxylate obtained in (1) above in 300 mL of methanol, and add 100 mL of 2N aqueous sodium hydroxide solution. And stirred at room temperature for 6 hours. The reaction mixture is concentrated under reduced pressure, and ice water, ethyl acetate and 10% hydrochloric acid are added to the residue under ice cooling, followed by extraction with ethyl acetate. The organic layer is washed successively with water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The resulting residue is suspended in a small amount of ethyl acetate, and then n-hexane is poured and the crystals are collected by filtration. After washing several times with n-hexane-diisopropyl ether and drying, trans-4- [N-methyl-N- (tert-butoxycarbonyl) amino] cyclohexanecarboxylic acid (39.20 g, 92%) is obtained as crystals.
MS (ESI) m / z: 256 [M−H] ⁻
Reference Example 112
(1) By treating 1 g of 3-methoxy-4-methylbenzoic acid in the same manner as in Reference Example 69, methyl 3-methoxy-4-[(dimethylamino) methyl] benzoate (792 mg, 64% yield) was obtained as an oil. Get as a thing.
MS (APCI) m / z; 224 [M + H] ^< +>.
(2) To a solution of 792 mg of the compound obtained in (1) above in 10 mL of ethanol is added 2.1 mL of 2N aqueous sodium hydroxide solution, and the mixture is stirred at 60 ° C. for 2 hours. After cooling to room temperature, 4.3 mL of 2N hydrochloric acid is added, and the solvent is distilled off under reduced pressure. Methanol was added to the residue, insolubles were removed by filtration, and the solvent was distilled off under reduced pressure to give 3-methoxy-4-[(dimethylamino) methyl] benzoic acid / hydrochloride (890 mg, yield 100%) as an amorphous solid. obtain.
MS (APCI) m / z; 210 [M + H] ^< +>.

Reference Example 113
Methyl 3-bromo-4-[(dimethylamino) methyl] benzoate (compound obtained in Reference Example 156) In a solution of 200 mg of dimethylformamide in 2 mL of methyl boric acid 132 mg, [1,1′-bis (diphenylphosphino) ferrocene ] 60 mg of palladium dichloride-dichloromethane complex and 305 mg of potassium carbonate are sequentially added, and the mixture is stirred at 115 ° C. for 3 hours under an argon atmosphere. The reaction mixture is diluted with 10 mL of ethyl acetate, 10 mL of saturated aqueous sodium hydrogen carbonate is added and stirred, the organic layer is separated, and the solvent is distilled off with a centrifugal concentrator. The resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to give methyl 3-methyl-4-[(dimethylamino) methyl] benzoate (65 mg, yield). 43%) is obtained as an amorphous solid.
MS (APCI) m / z; 208 [M + H] ^< +>.

Reference Example 114
44.5 g of powder molecular sieve 4A and then 7.7 g of the compound obtained in Reference Example 86 (1) were added to a suspension of 24.5 g of cesium hydroxide monohydrate in 500 mL of dimethylformamide, and then stirred at room temperature for 30 minutes. . Add 11 g of dimethylaminoethyl chloride hydrochloride and stir for 22 hours. The insoluble material was filtered off through celite and washed with ethyl acetate. The back solution was concentrated under reduced pressure. To a solution of the obtained crude product in chloroform (100 mL) is added ice-cooled di-tert-butyl dicarbonate (16 g) in chloroform (10 mL), and the mixture is stirred at room temperature for 1.5 hours. The reaction solution is washed with 100 mL of saturated aqueous sodium hydrogen carbonate solution and then dried over sodium sulfate, and the solvent is distilled off under reduced pressure. The resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 50: 1) to give trans-4- [N- (tert-butoxycarbonyl) -N- [2- (dimethyl Methyl amino) ethyl] amino] cyclohexanecarboxylate (1.7 g, 11% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 329 [M + H] ^< +>.

Reference Example 115
To a suspension of 500 mg of the compound obtained in Reference Example 90 in 10 mL of dichloromethane are added 388 μL of diethyl ketone, 471 μL of triethylamine, and 956 mg of sodium triacetoxyborohydride under ice cooling, and the mixture is stirred overnight at room temperature. The reaction mixture is diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution is added, and the mixture is stirred. Separate the organic layer and concentrate. The resulting crude product was purified by silica gel column chromatography (elution solvent: chloroform / methanol = 100: 0 to 90:10) and ethyl 3- [1- (3-pentyl) piperidin-4-yl] propionate. 130 mg are obtained.
MS (APCI) m / z: 256 [M + H] ^< +>.

Reference Examples 116-234
The corresponding starting material compounds are treated in the same manner as in any one of the above Reference Examples 1-115 to obtain the compounds described in Table 38 below.

Reference Example 235
(1) 7.5 mL of a 2M borane / dimethyl sulfide complex-tetrahydrofuran solution is added dropwise to 2.0 mL of tetrahydrofuran of 500 mg of 1- (carbamoyl) -1-cyclopropanecarboxylic acid, and the mixture is heated to reflux for 4 hours. 10% hydrochloric acid is added to the reaction solution, and the mixture is further heated to reflux for 30 minutes. The reaction solution is cooled to room temperature, neutralized with saturated aqueous sodium hydrogen carbonate solution, 10 mL of dioxane and 1.3 g of di-tert-butyl dicarbonate are added, and the mixture is stirred at room temperature for 3 hours. The reaction solution is extracted with ethyl acetate, and the solvent is distilled off under reduced pressure. The resulting crude product was purified by silica gel flash column chromatography (hexane / ethyl acetate = 3: 1) to give 1-hydroxymethyl-1- (tert-butoxycarbonylaminomethyl) cyclopropane (337 mg, yield 45). %) As a yellow oil.
MS (APCI) m / z; 202 [M + H] ^< +>.
(2) To a solution of 337 mg of the compound obtained in (1) above, 280 mg of methyl 4-hydroxybenzoate and 650 mg of triphenylphosphine in 3.0 mL of tetrahydrofuran was added dropwise 510 mg of diisopropyl azodicarboxylate under ice cooling, and then overnight at room temperature. Stir. The solvent was distilled off from the reaction solution under reduced pressure, and the resulting crude product was purified by NH-silica gel flash column chromatography (hexane / ethyl acetate = 3: 2) to give 4-[[1- (tert-butoxycarbonyl Aminomethyl) cyclopropyl] methoxy] methyl benzoate (515 mg, 92% yield) is obtained as colorless crystals.
MS (APCI) m / z; 353 [M + H] ^< +>.

Reference Example 236
A suspension of tert-butyl 4-fluorobenzoate (300 mg), 2- (dimethylamino) ethanethiol hydrochloride (420 mg) and potassium carbonate (620 mg) in dimethylsulfoxide (3.0 mL) is stirred at 80 ° C. for 4 hours. The reaction mixture is diluted with water and extracted with ethyl acetate, and the solvent is evaporated under reduced pressure. 4N Hydrochloric acid-dioxane (1.5 mL) is added to the obtained crude product, and the mixture is stirred overnight at room temperature. The reaction mixture is diluted with ether, and the precipitated crystals are collected by filtration to give 4- [2- (dimethylamino) ethylthio] benzoic acid (380 mg, yield 99%) as colorless crystals.
MS (APCI) m / z; 226 [M + H] ^< +>.

Reference Example 237
2.67 g of sodium borohydride is added to a solution of 24 g of ethyl 4-cyclohexanonecarboxylate in 200 mL of methanol at −78 ° C., and the mixture is stirred at the same temperature for 1 hour. Water is added and methanol is distilled off under reduced pressure, followed by extraction with ethyl acetate. The organic layer is washed with saturated brine, dried over magnesium sulfate, and the solvent is distilled off under reduced pressure. To a 200 mL methylene chloride solution of 20 g of the resulting crude product (ethyl 4-hydroxycyclopropanecarboxylate), 50 mL of diisopropylethylamine and 16 mL of chloromethyl methyl ether are added dropwise under ice cooling, and the mixture is stirred overnight at room temperature. Water is added to the reaction solution, extracted with ethyl acetate, and the solvent is distilled off under reduced pressure. The resulting crude product was purified by silica gel flash column chromatography (hexane / ethyl acetate = 15: 1) to give ethyl trans-4- (methoxymethoxy) cyclohexanecarboxylate (12.3 g, yield 40%). Is obtained as a colorless oil.
MS (APCI) m / z; 234 [M + NH 4] +.

Reference Example 238
14.3 g of monomethyl trans-cyclohexane-1,4-dicarboxylate (compound obtained in Reference Example 85 (2)) was dissolved in 78 mL of tetrahydrofuran, and 1.0 M borane / tetrahydrofuran complex tetrahydrofuran solution at −50 ° C. in an argon atmosphere. 100 mL is added dropwise over 1 hour, the temperature is raised to −10 ° C., and the mixture is further stirred for 1 hour. Under ice-cooling, 160 mL of water and 160 mL of saturated aqueous sodium hydrogen carbonate solution are added to the reaction mixture, and the mixture is extracted 4 times with 160 mL of ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate, and the solvent is distilled off under reduced pressure. The residue is purified by silica gel column flash chromatography (chloroform / methanol = 20: 1) to give methyl trans-4- (hydroxymethyl) cyclohexanecarboxylate (13.25 g, yield 100%) as an oil.
MS (APCI) m / z; 173 [M + H] ^< +>.

Reference Example 239
(1) To a solution of 5.86 g of trans-4- (aminomethyl) cyclohexanecarboxylic acid methyl hydrochloride and 12 mL of triethylamine in 100 mL of chloroform is added dropwise 2.69 g of acetyl chloride under ice cooling, and the mixture is stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted twice with chloroform. The combined extracts were washed successively with 10% hydrochloric acid, saturated brine, saturated aqueous sodium hydrogen carbonate solution and saturated brine, then dried over anhydrous sodium sulfate and reduced pressure. Concentrate. The resulting assembled product is purified by silica gel column flash chromatography (hexane / ethyl acetate = 1: 1 to ethyl acetate) to give methyl trans-4- (acetylaminomethyl) cyclohexanecarboxylate (5.92 g, yield). 98%) is obtained as an amorphous solid.
MS (APCI) m / z; 214 [M + H] ^< +>.
(2) To a solution of 4.32 g of the compound obtained in (1) above in 50 mL of dimethylformamide, under ice-cooling, 1.0 g of 60% oily sodium hydride, 5.91 g of methyl iodide and 5 drops of methanol were sequentially added at room temperature. Stir for 8 hours, add 430 mg of 60% oily sodium hydride, 1.5 mL of methyl iodide and 2 drops of methanol, and stir for 2 hours. The reaction mixture is poured into water, extracted three times with ethyl acetate, washed twice with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting crude product was purified by silica gel column flash chromatography (hexane / ethyl acetate = 1: 2-ethyl acetate) to give methyl trans-4- (N-methyl-N-acetylaminomethyl) cyclohexanecarboxylate ( 3.04 g, 66% yield) is obtained as an oil.
MS (APCI) m / z; 228 [M + H] ^< +>.
(3) The compound (3.03 g) obtained in (2) above is hydrolyzed with 14 mL of 2N sodium hydroxide in a methanol / tetrahydrofuran mixed solvent. After evaporating the solvent from the reaction solution under reduced pressure, the residue is neutralized with dilute hydrochloric acid and extracted with chloroform. The extract is dried over anhydrous sodium sulfate and concentrated under reduced pressure. 500 mg of the crude product is heated under reflux in 5 mL of 5N hydrochloric acid for 2 days, and the reaction solution is concentrated under reduced pressure. A mixed solvent of 6 mL of 1N aqueous sodium hydroxide and 4 mL of dioxane and 1.0 g of di-tert-butyl dicarbonate are added to the resulting residue, and the mixture is stirred at room temperature for 12 hours. The reaction mixture is diluted with water, washed with ether, the aqueous layer is neutralized with 10% aqueous citric acid solution, and extracted with ethyl acetate. The extract was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give trans-4- [N-methyl-N- (tert-butoxycarbonyl) aminomethyl] cyclohexanecarboxylic acid ( 608 mg, 90% yield) is obtained as an oil.
MS (ESI) m / z; 270 [M-H] -.

Reference Example 240
By treating 500 mg of the compound obtained in Reference Example 238 with 689 mg of isopropyl- (2-methoxyethyl) amine in the same manner as in Production Example 654 (1), (2), trans-4- [N-isopropyl-N- ( Methyl 2-methoxyethyl) aminomethyl] cyclohexanecarboxylate (445 mg, 56% yield) is obtained as an oil.
MS (APCI) m / z; 272 [M + H] ^< +>.

Reference Example 241
(1) To a solution of 6.0 g of ethyl 4- (benzylamino) benzoate in 60 mL of methylene chloride, 3.95 mL of chlorobutyryl chloride and 6.14 mL of N, N-diisopropylethylamine are successively added dropwise under ice cooling, and the mixture is stirred for 12 hours. The reaction solution is diluted with chloroform, and 10% hydrochloric acid is added to separate the organic layer. The organic layer is washed successively with water, saturated aqueous sodium hydrogen carbonate solution, water and saturated brine, and dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel flash chromatography (Biotage Flash75S, hexane / ethyl acetate = 4: 1) to give ethyl 4- [N-benzyl-N- (4-chlorobutyryl) amino] benzoate. (8.27 g, 100% yield) is obtained as an oil.
MS (APCI) m / z; 360/362 [M + H] ^< +>.
(2) A solution of 1.0 g of the compound obtained in (1) above, 287 μL of diethylamine and 417 mg of sodium iodide in 2.5 mL of dimethyl sulfoxide is stirred at 100 ° C. for 1 day in an argon atmosphere. The reaction mixture is cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution is added, the mixture is extracted twice with chloroform, and concentrated under reduced pressure. The resulting crude product was purified by NH silica gel flash chromatography (hexane / ethyl acetate = 4: 1) to give ethyl 4- [N-benzyl-N- [4- (diethylamino) butyryl] amino] benzoate ( 280 mg, 25% yield) is obtained as an oil.
MS (APCI) m / z; 397 [M + H] ^< +>.

Reference Example 242
Under ice cooling and argon atmosphere, 1.37 mL of diisopropyl azodicarboxylate is added dropwise to a mixed solution of 500 mL of ethyl 3,4-dihydroxybenzoate, 565 μL of N, N-dimethylethanolamine, and 1.51 g of triphenylphosphine in 20 mL of methylene chloride. The reaction is warmed to room temperature and stirred for 1 day. The reaction solution is diluted with ethyl acetate and washed with water, and then the basic compound is extracted from the ethyl acetate layer into the aqueous layer with 10% hydrochloric acid. The aqueous layer is neutralized with sodium hydrogen carbonate, extracted twice with a mixed solvent of chloroform / methanol / tetrahydrofuran = 4: 1: 1, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting crude product was purified by NH silica gel flash chromatography (hexane / ethyl acetate = 1: 1 to chloroform / methanol = 19: 1) to give 4- [2- (dimethylamino) ethoxy] -3-hydroxy. Ethyl benzoate (240 mg, 35% yield) is obtained as an oil.
MS (APCI) m / z; 254 [M + H] ^< +>.

Reference Example 243
To a mixed solution of 10 g of ethyl 4-aminobenzoate and 9.0 g of 4- (dimethylamino) benzaldehyde in 200 mL of methylene chloride were sequentially added 18.9 g of sodium triacetoxyborohydride and 3.47 mL of acetic acid under ice cooling, and at room temperature. Stir for 2 days. The reaction solution is neutralized with a saturated aqueous sodium hydrogen carbonate solution, extracted twice with chloroform, and concentrated under reduced pressure. The resulting crude product is triturated in hexane / ethyl acetate to give ethyl 4- [4- (dimethylamino) benzylamino] benzoate (11.6 g, 64% yield) as a powdered solid.
MS (APCI) m / z; 299 [M + H] ^< +>.

Reference Example 244
(1) A mixed solution of 15.9 g of 4- (bromomethyl) benzaldehyde and 290 mL of chloroform of 29 g of (1-ethoxycarbonylethylidene) triphenylphosphorane was heated to reflux for 12 hours, allowed to cool to room temperature, concentrated, and chromatographed on silica gel (chloroform ) To give ethyl 3- [4- (bromomethyl) phenyl] -2-methylacrylate (18 mg, 79% yield) as an oil.
(2) To a solution of 0.89 g of pyrrolidine and 1.38 g of potassium carbonate in 10 mL of water, a solution of 2.83 g of the compound obtained in (1) above in 5 mL of tetrahydrofuran is added dropwise and stirred overnight at room temperature. The reaction mixture is diluted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained crude product was dissolved in ether and insoluble matter was removed by filtration, 0.9 g of oxalic acid was added, and the resulting precipitate was collected by filtration to give 2-methyl-3- [4-[(1-pyrrolidinyl) methyl. ] Ethyl hemioxalate (phenyl) acrylate (2.67 g, 84% yield) is obtained as a solid.
(3) After treating 2.2 g of the compound obtained in (2) above with ethyl acetate / 10% aqueous potassium carbonate solution, the ethyl acetate layer is concentrated under reduced pressure. Dissolve the residue in 10 mL of methanol, add 1.38 g of potassium hydroxide and stir at 50 ° C. for 5 hours. After allowing to cool to room temperature, 5 mL of ethanol was added, and the precipitated crystals were collected by filtration to give potassium 2-methyl-3- [4-[(1-pyrrolidinyl) methyl] phenyl] acrylate (1.65 g, 83% yield). ) As a solid.
M.M. p. 268 ° C. (decomposition).

Reference Example 245
(1) Dissolve 500 mg of methyl 4- (bromomethyl) benzoate in 5 mL of tetrahydrofuran, add 929 mg of cyclopentylamine, and stir at room temperature for 3 hours. Dilute with 5 mL of chloroform, add 5 mL of saturated aqueous sodium bicarbonate and stir to separate the organic layer. The mixture is extracted again with chloroform, and the separated organic layer is dried over anhydrous sodium sulfate, filtered and concentrated. The resulting residue was purified by silica gel column chromatography (n-hexane / ethyl acetate = 9: 1 to 5: 5), and methyl 4- (cyclopentylaminomethyl) benzoate (469 mg, 92% yield) was obtained as a colorless oil. Get as.
MS (APCI) m / z; 234 (M + H) ^<+> .
(2) By treating 480 mg of the compound obtained in the above (1) in the same manner as in Reference Example 89 (2), methyl 4-[(N-cyclopentyl-N-methylamino) methyl] benzoate (420 mg, yield) 83%) is obtained as a colorless oil.
MS (APCI) m / z; 248 (M + H) ^<+> .

Reference Example 246
(1) The corresponding compound is treated in the same manner as in Reference Example 107 (1) to give tert-butyl 4-[[3- (dimethylamino) -2,2-dimethylpropyl] amino] benzoate.
(2) 4- [N- [3- (dimethylamino) -2,2-dimethylpropyl] -N- is obtained by treating 500 mg of the compound obtained in (1) above in the same manner as in Reference Example 89 (2). Ethylamino] tert-butyl benzoate (468 mg, 85% yield) is obtained as a colorless oil.
MS (APCI) m / z; 335 (M + H) ^<+> .

Reference Example 247
(1) 1.00 g of methyl trans-4-aminocyclohexanecarboxylate (compound obtained in Reference Example 86 (1)) was treated in the same manner as in Reference Example 89 (2), and then the resulting product was treated as Reference Example 81. By treating in the same manner as in (1), methyl trans-4- [N- (tert-butoxycarbonyl) -N-ethylamino] cyclohexanecarboxylate (258.4 mg, yield 14%) is obtained as a colorless oil. .
MS (APCI) m / z; 303 (M + NH 4) +.

Reference Example 248
(1) To a solution of 28.2 g of malononitrile in 30 mL of methanol is added a suspension of 25 g of acetoin in 30 mL of methanol. The reaction mixture is poured into 300 mL of ice-cold water, and the precipitated crystals are collected by filtration to give 2-amino-4,5-dimethyl-3-furonitrile (28.91 g, 75%) as colorless crystals.
(2) 13.6 g of the compound obtained in (1) above was dissolved in 200 mL of methylene chloride, 18.9 g of piperidine was added, and then a solution of ethyl chlorooxoacetate (16.3 g) in 200 mL of methylene chloride was added dropwise. The mixture is stirred at 0 ° C. for 1 hour 30 minutes. After diluting the reaction solution with 100 mL of chloroform, 300 mL of water is added and stirred, and the organic layer is separated. The mixture is extracted again with chloroform, and the organic layer is washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (chloroform / ethyl acetate = 9: 1) to give ethyl [(3-cyano-4,5-dimethylfuran-2-yl) amino] oxoacetate (17 g, yield 72). %) As a colorless powder. Under an argon atmosphere, 30 mL of formic acid and 30 mL of acetic anhydride are mixed and stirred at 60 ° C. for 2 hours. To the mixed solution is added 7.07 g of [(3-cyano-4,5-dimethylfuran-2-yl) amino] oxoacetate obtained above, and the mixture is stirred at reflux for 14 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform / ethyl acetate = 9: 1 to chloroform / methanol = 19: 1) to give 5,6-dimethyl-4-oxo-3,4- Ethyl dihydrofuro [2,3-d] pyrimidine-2-carboxylate (4.30 g, 61% yield) is obtained as a colorless powder.
M.M. p. 180-182 ° C.
(3) Dissolve 2.36 g of the compound obtained in the above (2) in 60 mL of N, N-dimethylformamide, add 2.16 g of dimethylaminoethyl chloride / hydrochloride and 4.14 g of potassium carbonate, and then at 60 ° C. for 14 hours. Stir. The reaction solution is diluted with 50 mL of chloroform, 70 mL of water is added and stirred, and the organic layer is separated. The mixture is extracted again with chloroform, and the organic layer is washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The resulting residue is purified by silica gel column chromatography (chloroform / ethyl acetate / methanol = 6: 2: 1). The obtained product is treated in the same manner as in Production Example 5 (2) to give ethyl 4- [2- (dimethylamino) ethoxy] -5,6-dimethylfuro [2,3-d] pyrimidine-2-carboxylate. Obtain fumarate (780 mg, 18% yield) as a colorless powder.
M.M. p. 173-174 ° C.
(4) Dissolve 1.44 g of the compound obtained in (3) above in 20 mL of ethanol, add 2.34 mL of 2N aqueous sodium hydroxide solution, and stir at room temperature for 2 hours. The reaction mixture is concentrated, diethyl ether is added to the resulting residue, and the precipitated crystals are collected by filtration. The obtained crystals were purified by reverse phase column chromatography (HP-20, water / methanol = 1: 0 to 1: 1) to give 4- [2- (dimethylamino) ethoxy] -5,6- Dimethyl furo [2,3-d] pyrimidine-2-carboxylic acid (970 mg, 74% yield) is obtained as a colorless powder.
M.M. p. 179-180 ° C.

Reference Example 249
(1) Dissolve 1 g of 5-hydroxy-2- (hydroxymethyl) -4H-pyranone in 20 mL of N, N-dimethylformamide, add 1.95 g of potassium carbonate and 1.37 g of tert-butyl bromoacetate, and add 16 at room temperature. Stir for hours. The reaction mixture is diluted with 10 mL of tetrahydrofuran, water and saturated brine are added and stirred, and the organic layer is separated. The mixture is extracted again with tetrahydrofuran, and the organic layer is washed again with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The obtained residue was washed with diethyl ether and collected by filtration to give tert-butyl [[6- (hydroxymethyl) -4-oxo-4H-pyran-3-yl] oxy] acetate (1.49 g, yield). 88%) as a colorless powder.
MS (ESI) m / z; 257 (M + H) ⁺
M.M. p. 90-92 ° C.
(2) 50 g of the compound obtained in (1) above was dissolved in 600 mL of methylene chloride, and desmartin periodate [1,1,1-tris (acetyloxy) -1,1-dihydro-1,2-benziodo 91.04 g of xol-3 (1H) -one] is added and stirred at room temperature for 5 days. The reaction is filtered through celite and extracted with ethyl acetate. After filtration of the extract, the filtrate is concentrated. The resulting residue was washed with diethyl ether and collected by filtration to give tert-butyl [(6-formyl-4-oxo-4H-pyran-3-yl) oxy] acetate (17.1 g, yield 34.5). %) As a brown powder.
(3) By treating 2.0 g of the compound obtained in (2) above in the same manner as in Production Example 6, [[4-oxo-6-[(1-pyrrolidinyl) methyl] -4H-pyran-3-yl ] Tert-butyl acetate (1.06 g, 44% yield) is obtained as a yellow powder.
MS (ESI) m / z; 310 (M + H) ⁺
M.M. p. 93-94 ° C.
(4) Dissolve 700 mg of the compound obtained in (3) above in 5 mL of methylene chloride, add 2.5 mL of trifluoroacetic acid at 0 ° C., and stir at room temperature for 24 hours. The reaction mixture is concentrated, ethyl acetate and water are added and stirred, and the aqueous layer is separated. It was washed again with ethyl acetate, and the aqueous layer was lyophilized to give [[4-oxo-6-[(1-pyrrolidinyl) methyl] -4H-pyran-3-yl] oxy] acetic acid (820 mg, yield). 99%) as a colorless powder.
MS (ESI) m / z; 254 (M + H) ^<+> .

Reference Example 250
(1) Dissolve 12 g of the compound obtained in Reference Example 249 (2) in toluene, add 17.36 g of (1-methoxycarbonylmethylidene) triphenylphosphorane, and stir at 60 ° C. for 3 hours. The reaction mixture was concentrated, and the resulting crude product was purified by silica gel flash chromatography (hexane / ethyl acetate = 1: 1) to give [2-[(1E) -2- (methoxycarbonyl) vinyl] -4. -Oxo-4H-pyran-3-yl] tert-butyloxyacetate (10.99 g, 75% yield) is obtained as colorless crystals. MS (ESI) m / z; 311 (M + H) ⁺
M.M. p. 115-116 ° C.
(2) Dissolve 8.83 g of the compound obtained in (1) above in 100 mL of tetrahydrofuran, add 100 mL of water and 20.1 mL of 2N aqueous sodium hydroxide solution, and stir at room temperature for 4 hours. At 0 ° C., 23 mL of hydrochloric acid is gradually added to the reaction solution, followed by concentration. 1.0 g of the resulting crude product is dissolved in 7 mL of N, N-dimethylformamide, 3 mL of N-methylmorpholine and 3.9 mL of polyphosphoric acid are added, and the mixture is stirred at room temperature for 4 days. The reaction mixture is diluted with ethyl acetate, saturated aqueous sodium hydrogen carbonate solution and saturated brine are added and stirred, and the organic layer is separated. The mixture is extracted again with ethyl acetate, and the organic layer is washed with saturated brine. The organic layer is dried over magnesium sulfate, filtered, and the filtrate is concentrated. The obtained crude product was purified by silica gel flash chromatography (chloroform / methanol = 19: 1) to obtain [2-[(1E) -2-[(4-methylpiperazin-1-yl) carbonyl] vinyl]. -4-Oxo-4H-pyran-3-yl] tert-butyl oxyacetate (450 mg, 35% yield) is obtained as yellow crystals.
MS (ESI) m / z; 379 (M + H) ⁺
M.M. p. 124-125 ° C.
(3) Dissolve 390 mg of the compound obtained in (2) above in 5 mL of methylene chloride, add 2 mL of trifluoroacetic acid at 0 ° C., and stir at room temperature for 5 hours. The reaction mixture was concentrated, water was added and lyophilized to obtain [2-[(1E) -2-[(4-methylpiperazin-1-yl) carbonyl] vinyl] -4-oxo-4H-pyran- 3-yl] oxyacetic acid (330 mg, 73% yield) is obtained as a colorless powder.
MS (ESI) m / z; 323 (M + H) ^<+> .

Reference Example 251
(1) By treating 4 g of tert-butyl 4-fluoro-3-methylbenzoate in the same manner as in Reference Example 1 (1), 4-[[2- (dimethylamino) ethyl] amino] -3-methylbenzoate Tert-butyl acid (1.3 g, 24% yield) is obtained as an oil.
MS (APCI) m / z; 279 [M + H] ^< +>.
(2) To a solution of 1.3 g of the compound obtained in (1) above in 5 mL of dioxane, 5 mL of 4N hydrochloric acid-dioxane solution and 3 mL of 5N hydrochloric acid are added and stirred at 60 ° C. for 10 minutes. After cooling the reaction solution to room temperature, the solvent was distilled off under reduced pressure, and the residue was dissolved in water and freeze-dried to give 4-[[2- (dimethylamino) ethyl] amino] -3-methylbenzoic acid-2. The hydrochloride (1.35 g, 98% yield) is obtained as an amorphous solid.
MS (APCI) m / z; 223 [M + H] ^< +>.

Reference Example 252
(1) A mixture of 23.1 g of ethyl 4,4,4-trifluoroacetoacetate, 7.54 g of urea and 18.6 g of ethyl orthoformate is stirred at 130 ° C. for 1.5 hours under an argon atmosphere. Add xylene (100 mL) to the reaction mixture and stir at 140 ° C. for 17 hours. The solvent was distilled off from the reaction solution under reduced pressure, and the residue was diluted with methanol. After the activated carbon powder treatment, the solvent was distilled off under reduced pressure and crystallized with diisopropyl ether to give 2-hydroxy-4-trifluoromethyl-5. Obtain ethyl pyrimidinecarboxylate (20.3 g, 69% yield).
MS (ESI) m / z: 235 [M-H] -.
(2) A solution of 5.0 g of the compound obtained in (1) above in 30 mL of phosphorus oxychloride is heated to reflux for 2 hours. The reaction mixture is concentrated, poured into ice water, and extracted with chloroform. The extract is washed with saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane / ethyl acetate = 5: 1) to give ethyl 2-chloro-4-trifluoromethyl-5-pyrimidinecarboxylate (4.3 g, yield 80). %) As an oil.
MS (GC-EI) m / z: 254 [M ^<+ >].
(3) To a solution of 500 mg of the compound obtained in (2) above in 3 mL of tetrahydrofuran is added a solution of 421 mg of N, N, N′-trimethylethylenediamine in 2 mL of tetrahydrofuran under an argon atmosphere, and the mixture is stirred at room temperature for 1 hour. The reaction mixture is diluted with ethyl acetate, washed successively with saturated aqueous sodium hydrogen carbonate solution, water and saturated brine, dried over sodium sulfate, and the solvent is evaporated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 50: 1) to give 2- [N-methyl-N- [2- (dimethylamino) ethyl] amino]- Ethyl 4-trifluoromethyl-5-pyrimidinecarboxylate (540 mg, 77% yield) is obtained as an oil.
MS (APCI) m / z; 321 [M + H] ^< +>.

Reference Example 253
To a solution of 500 mg of the compound obtained in Reference Example 86 (1) in 10 mL of 1,2-dichloroethane, 665 μL of triethylamine, 688 μL of propionaldehyde, 1.68 g of sodium triacetoxyborohydride and 546 μL of acetic acid were added under ice cooling, and 3 at room temperature. Stir for days. The reaction mixture is diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution is added, and the mixture is extracted with chloroform. The solvent was distilled off under reduced pressure, and a solution of di-t-butyl dicarbonate (690 mg) in chloroform (2 mL) was added to a chloroform solution (6 mL) of the residue, followed by stirring at room temperature for 2 hours. After the reaction solution was distilled off under reduced pressure, the resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to obtain methyl trans-4- (dipropylamino) cyclohexanecarboxylate. (600 mg, 78% yield) is obtained as an oil.
MS (APCI) m / z; 242 [M + H] ^< +>.

Reference Example 254
(1) Add 238 mg of Lindlar catalyst to a solution of 2 g of methyl 4- (3-hydroxy-1-propynyl) benzoate in 32 mL of methanol and stir at room temperature for 18 hours in a hydrogen atmosphere. 90 mg of Lindlar catalyst is added, and after stirring for 1 hour, the insoluble material is filtered through Celite, and the filtrate is concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate = 100: 0 to 50:50) to give methyl 4- (3-hydroxy-1-propenyl) benzoate (1.5 g). Yield 75%) as an amorphous solid.
MS (APCI) m / z; 175 [M + H-H 2 O] +.
(2) To a solution of 200 mg of the compound obtained in (1) above in 4 mL of tetrahydrofuran, add 218 μL of triethylamine and 105 μL of methanesulfonyl chloride under ice cooling, and stir for 30 minutes. The reaction mixture is diluted with ethyl acetate, 10% aqueous citric acid solution is added, and the mixture is extracted with ethyl acetate. The extract is washed successively with water and saturated brine, dried over sodium sulfate, and the solvent is distilled off under reduced pressure. 2 mL of 2M dimethylamine-tetrahydrofuran solution is added to 2 mL of dimethylformamide solution of the resulting crude product (methyl 4- (3-methylsulfonyloxy-1-propenyl) benzoate), and the mixture is stirred at room temperature for 2 days. The reaction mixture is diluted with ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution, and the solvent is evaporated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to give methyl 4- [3- (dimethylamino) -1-propenyl] benzoate (198 mg). Yield 87%) as an oil.
MS (APCI) m / z; 220 [M + H] ^< +>.

Reference Example 255
To a solution of 500 mg of methyl 4- (3-tosyloxypropyl) benzoate in 3 mL of dimethylformamide is added 2.2 mL of a 2M dimethylamine-tetrahydrofuran solution, and the mixture is stirred at 50 ° C. for 15 hours. The reaction mixture is diluted with ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution, and the solvent is evaporated under reduced pressure. The resulting crude product was purified by silica gel column chromatography (chloroform / methanol = 100: 0 to 90:10) to give methyl 4- [3- (dimethylamino) propyl] benzoate (357 mg, yield 100%). ) As an oil.
MS (APCI) m / z; 222 [M + H] ^< +>.

Reference Example 256
By treating methyl 4- (3-hydroxy-1-propynyl) benzoate in the same manner as in Reference Example 254 (2), methyl 4- [3- (1-pyrrolidinyl) -1-propynyl] benzoate (463 mg, yield) 91%) is obtained as an oil.
MS (APCI) m / z; 244 [M + H] ^< +>.

Reference Example 257
4- [2- (dimethylamino) ethyl] aminobenzoic acid dihydrochloride is obtained as an amorphous solid by treating tert-butyl 4-fluorobenzoate in the same manner as in Reference Example 251.
MS (APCI) m / z; 209 [M + H] ^< +>.

Reference examples 258 to 303
The corresponding compounds are treated in the same manner as described in any of the above Reference Examples, or by a combination thereof as appropriate, to give the compounds described in Table 39 below.

Reference Example 304
(1) After adding 200 mL of a 25% hydrobromic acid / acetic acid solution to a mixed solution of 20 g of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 50 mL of acetic acid, dimethyl sulfoxide 22 at room temperature Add 0.0 g dropwise and stir for 3 days. The resulting precipitate was collected by filtration, washed successively with acetic acid and water and then dried at 40 ° C. overnight to give 6-oxo-1,6-dihydropyridazine-3-carboxylic acid (10.55 g, yield 54%). ) As colorless crystals.
MS (ESI) m / z; 139 [M-H] -.
(2) Add 3 mL of thionyl chloride and 2 drops of dimethylformamide to a 5 mL toluene solution of 1.0 g of the compound obtained in (1) above, and stir at 80 ° C. for 3 hours. After allowing to cool, the reaction mixture was concentrated under reduced pressure, ether was added to the resulting residue, the precipitated crystals were collected by filtration, washed with ether and dried to give ethyl 6-chloro-1,6-dihydropyridazine-3-carboxylate. (813 mg, 61% yield) is obtained as a colorless powder.
MS (APCI) m / z; 187/189 [M + H] ^< +>.

Reference Example 305
To a solution of ethyl 4-cyclohexanecarboxylate (5 g), N, N-dimethylethylene-1,2-diamine (6.45 mL) and acetic acid (3.36 mL) in chloroform (50 mL) was added ice-cooled sodium triacetoxyborohydride (9.8 g) at room temperature. For 4 days. A saturated aqueous sodium hydrogen carbonate solution is added to the reaction mixture and stirred, and potassium carbonate is added to make the aqueous layer basic, followed by extraction twice with chloroform. The extract is dried and concentrated under reduced pressure. The resulting crude product was purified by silica gel column flash chromatography (Flash75M column, chloroform / methanol / aqueous ammonia = 19: 1: 0.3) to give ethyl 4- (2-dimethylaminoethylamino) cyclohexanecarboxylate. (Cis / trans mixture, 6.63 g, 94% yield) is obtained as an oil.
MS (APCI) m / z; 243 [M + H] ^< +>.

Reference Example 306
The corresponding starting material compound is treated in the same manner as in Reference Example 242 to give ethyl 4- (3-dimethylamino-2,2-dimethylpropoxy) -3-hydroxybenzoate (MS (APCI) m / z: 296 [M + H] ⁺ ). To a solution of 80 mg of the compound in 1.5 mL of dimethylformamide, 22.7 mg of 60% oily sodium hydride is added under ice cooling, and the mixture is stirred for 20 minutes. 4- (2-Chloroethyl) morpholine / hydrochloride (55.4 mg) was added to the resulting solution, and the mixture was stirred at room temperature for 1 day. Water was added to the reaction mixture, and the mixture was extracted 3 times with chloroform. The solvent was distilled off under reduced pressure. The resulting crude product is purified by NH silica gel column flash chromatography (ethyl acetate / hexane = 5: 95 to 25:75) to give 4- (3-dimethylamino-2,2-dimethylpropoxy) -3- Ethyl (2-morpholin-4-ylethoxy) benzoate (53 mg, 70% yield) is obtained as an oil.
MS (APCI) m / z; 409 [M + H] ^< +>.

Reference Example 307
10 mL of N, N-dimethylethylenediamine is added to a solution of 10 g of methyl 6-chloronicotinate in 15 mL of N, N-dimethylsulfoxide and stirred at 75 ° C. overnight. Water is added to the reaction mixture, and the mixture is extracted with ethyl acetate. The resulting crude product was purified by NH silica gel flash column chromatography (hexane / ethyl acetate = 1: 1) to give methyl 6-[(2-dimethylaminoethyl) amino] nicotinate (4.09 g, yield). 31%) is obtained as a yellow liquid.
MS (APCI) m / z; 224 [M + H] ^< +>.

Reference Example 308
(1) To a suspension of 75 mg of 1-amino-2-methyl-2-propanethiol hydrochloride in 2 mL of N, N-dimethylformamide was added 50 mg of 60% oily sodium hydride, and the mixture was stirred at room temperature for 30 minutes. Add 50 mg of tert-butyl fluorobenzoate and stir at 70 ° C. for 4 hours. Water is added to the reaction mixture, and the mixture is extracted with ethyl acetate. The resulting crude product was purified by NH silica gel flash column chromatography (ethyl acetate) to give tert-butyl 4-[(2-amino-1,1-dimethylethyl) thio] benzoate (54 mg, yield 75). %) As a colorless oil.
MS (APCI) m / z; 282 [M + H] ^< +>.
(2) By treating 59 mg of the compound obtained in (1) in the same manner as in Production Example 618 (2), tert-butyl 4-[(2-dimethylamino-1,1-dimethylethyl) thio] benzoate (40 mg, 62% yield) is obtained as a yellow oil.
MS (APCI) m / z; 310 [M + H] ^< +>.

Reference Example 309
(1) Add 0.5 mL of concentrated sulfuric acid to a 20 mL methanol solution of 1.5 g of 4-mercaptobenzoic acid, and heat to reflux overnight. The solvent is distilled off under reduced pressure, neutralized with a saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The solvent was distilled off under reduced pressure to obtain methyl 4-mercaptobenzoate (1.6 g, yield 99%) as a colorless oil.
MS (APCI) m / z; 167 [M-H] -.
(2) By treating 50 mg of the compound obtained in (1) in the same manner as in Production Example 381, methyl 4-[(3-dimethylamino-2,2-dimethylpropyl) thio] benzoate (58 mg, yield) 69%) is obtained as a brown oil.
MS (APCI) m / z; 282 [M + H] ^< +>.

Reference Example 310
(1) To 25 ml of an aqueous solution of 5.0 g of diethanolamine and 5.5 g of sodium carbonate, 10.5 g of 2-nitrobenzenesulfonyl chloride is added little by little at 65 ° C., followed by stirring at 90 ° C. for 3 hours. Water is added to the reaction mixture, and the mixture is extracted with ethyl acetate. Add 10 ml of thionyl chloride to the resulting residue and stir at 90 ° C. for 2 hours. The reaction solution is poured into water and extracted with chloroform, and the solvent is distilled off under reduced pressure. The resulting crude product was purified by silica gel flash column chromatography (hexane / ethyl acetate = 4: 1) to give N, N-di (chloroethyl) -2-nitrobenzenesulfonamide (7.1 g, yield 46%). ) As a yellow liquid.
MS (APCI) m / z; 327/329 [M + H] ^< +>.
(2) By treating 2.0 g of the compound obtained in the above (1) and 1.0 g of methyl trans-4-aminocyclohexanecarboxylate in the same manner as in Production Example 434 (1), trans-4- [4- Methyl (2-nitrobenzenesulfonyl) piperazin-1-yl] cyclohexanecarboxylate (1.29 g, 61% yield) is obtained as a yellow oil.
MS (APCI) m / z; 412 [M + H] ^< +>.

Reference Example 311
2.0 g of methyl trans-4- [N- (tert-butoxycarbonyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexanecarboxylate (the compound obtained in Reference Example 114) was prepared in the same manner as in Production Example 404 (2 ) To give methyl trans-4- [N- [2- (dimethylamino) ethyl] amino] cyclohexanecarboxylate (1.5 g, yield 82%) as colorless crystals.
MS (APCI) m / z; 229 [M + H] ^< +>.

Reference Example 312
The corresponding starting material compound is treated in the same manner as in Reference Example 256 to give methyl 4- [3- (methylamino) -1-propynyl] benzoate. Di-tert-butyl dicarbonate is added to a solution of 227 mg of the compound in 4 mL of chloroform under ice cooling, and the mixture is stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane / ethyl acetate = 8: 1) to give 4- [3- (N-methyl-N-tert-butoxycarbonylamino). ) -1-propynyl] methyl benzoate (225 mg, 86% yield) is obtained as colorless crystals.
MS (APCI) m / z; 321 [M + NH 4] +.

Reference Example 313
The same treatment as in Reference Example 254 gives methyl 4- [3- (methylamino) -cis-1-propenyl] benzoate. The compound was treated in the same manner as in Reference Example 312 to give methyl 4- [3- (N-methyl-N-tert-butoxycarbonylamino) -cis-1-propenyl] benzoate (135 mg, yield). 86%) is obtained as colorless crystals.
MS (APCI) m / z; 323 [M + NH 4] +.

Reference Example 314
The same treatment as in Reference Example 255 gives methyl 4- [3- (methylamino) propyl] benzoate. By treating 117 mg of this compound in the same manner as in Reference Example 312, methyl 4- [3- (N-methyl-N-tert-butoxycarbonylamino) propyl] benzoate (123 mg, yield 90%) was obtained as colorless crystals. obtain.
MS (APCI) m / z; 325 [M + NH 4] +.

Reference examples 315 to 355
By treating the corresponding compound in the same manner as described in any of the above Reference Examples, the compounds described in Table 40 below are obtained.

Reference examples 356 to 357
The corresponding compounds are treated in the same manner as described in any of the above Reference Examples to give the compounds listed in Table 41 below.

Experimental example

Experimental Example 1 ( ¹²⁵ I-apamine binding inhibitory action)
1. Experimental animal species; guinea pig, strain; Hartley, sex; male, age: 4 weeks of age or older Sample preparation The sample is dissolved in buffer (3) (5 mM Tris-HCl, 5.4 mM KCl, 0.1% BSA (bovine serum albumin); pH 7.4). However, a hardly soluble sample is dissolved in dimethyl sulfoxide (DMSO) and then diluted with a buffer solution (3).
3. Experimental procedures Hugues et al. (Life Sciences 31: 437-443, 1982) and Catterall et al. , 11379-11387, 1979).
A. Preparation of Membrane Specimens Removed mucosa from isolated colon of guinea pig, homogenized in buffer (1) (40 mM Tris-HCl, 8% sucrose; pH 7.4), and centrifuged (16000 × g, 20 min), and the supernatant is further centrifuged (130000 × g, 60 min). The obtained precipitate is suspended in buffer (1), layered on 33%, 40% sucrose, and then centrifuged (160000 × g, 90 min). The 8/33% layer is separated, suspended in buffer (2) (5 mM Tris-HCl; pH 7.4), and further centrifuged (160000 × g, 60 min). Suspend in buffer (3) (5 mM Tris-HCl, 5.4 mM KCl, 0.1% BSA; pH 7.4) so that the protein concentration of the resulting precipitate is 500 μg / ml, and store frozen in liquid nitrogen.
B. Binding experiment Membrane specimen (10 μg / ml or 20 μg / ml), ¹²⁵ I-apamine (10 pM) and specimen are added to buffer (3), and the mixture is bathed at 4 ° C. for 60 minutes. After filtration with a cell harvester, ¹²⁵ I on the filter paper is measured with a γ-counter, and the inhibition rate (IC50 value) of the specimen for specific binding of ¹²⁵ I-apamine is calculated. The binding amount of ¹²⁵ I-apamin in the presence of 100 nM apamin is defined as nonspecific binding.

  The results are as shown in Table 42 below.

Experimental example 2 (rat colon transport ability promoting effect)
1. Experimental animals Species: Rat, strain: SD (SD), gender: male, age: 6-7 weeks, group 1: 7-8 cases Sample Preparation Dissolve the sample in 2 equimolar amount of citric acid solution. However, the hardly soluble sample is suspended in 0.5% CMC (carboxymethylcellulose). The administration volume is 5 ml / kg.
3. Experimental procedure The following experiment is performed by modifying the method of Ueda et al. (Applied Pharmacology, Vol. 3, pp. 265-269, 1969). The animals fasted from the afternoon of the previous day are opened under anesthesia with pentobarbital (30 mg / kg, ip), a cannula is attached to the origin of the colon, and the abdomen is closed. After the 3-day recovery period, it is subjected to the experiment. Clonidine (50 μg / kg, sc) was administered to the above rats fasted from the afternoon the day before the experiment under ether light anesthesia, and the dye from the cannula (1.5% CMC + 0.5% Evans blue, 0.2 ml / rat) ) Inject and administer test compound orally (po). After 3 hours, the animal was killed by cervical dislocation, the large intestine was removed, the total length and the distance from the colon origin to the tip of the stool containing the pigment were measured, and the ratio (%) was determined as the ability to transport the large intestine. Measure as The minimum dose of the test drug that shows increased colonic transport ability compared to the control group (clonidine + test drug solvent) is the effective dose in this test system.

  The results are as shown in Table 43 below.

  From Experimental Example 1, it was shown that Compound [I], which is an active ingredient of the present invention, has an SK channel blocking action.

Experimental Example 2 showed that Compound [I], which is an active ingredient of the present invention, is useful for the treatment and prevention of constipation.

Claims (16)

Formula [I]:

(Wherein R ¹ is
(A) a substituted aryl group,
(B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group,
(C) a substituted cyclo-lower alkyl group,
(D) an optionally substituted amino group, or (E) a substituted heteroaryl group,
R ² is
(A) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group,
Y is a single bond, a lower alkylene group or a lower alkenylene group,
Z is —CO—, —CH ₂ —, —SO ₂ — or the following formula:

A group represented by
Q is a lower alkylene group,
q represents 0 or 1)
Or a pharmacologically acceptable salt thereof as an active ingredient. R ¹ is
(A) an aryl group substituted with 1 to 3 groups selected from the following (i) to (xv):
(I) hydroxyl group;
(Ii) a halogen atom;
(Iii) a lower alkyl group;
(Iv) a lower alkyl group optionally substituted with a hydroxyl group, a lower alkoxy lower alkyl group, an amino lower alkanoyl group (the amino part of the group is a lower alkyl group, a lower alkoxycarbonyl group or the following formula:

(Wherein R ³¹ represents a lower alkyl group)
A mono- or di-lower alkylamino lower alkyl group, a mono- or di-lower alkylcarbamoyl group, a lower alkanoyl group optionally substituted with a hydroxyl group, a cyclo-lower alkylcarbonyl group, a lower group An alkoxy lower alkanoyl group, a lower alkoxy lower alkoxycarbonyl group, a cyclo lower alkyl lower alkyl group, a lower alkyl sulfonyl group, an aryl lower alkyl group (the aryl portion of the group may be substituted with a mono- or di-lower alkylamino group) , A lower alkenoyl group, a thiocarbamoyl group optionally substituted with a lower alkyl group, a heteroarylcarbonyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower Alkanoyl group, arylsulfonyl group Aryl moiety of the group may be substituted with a mono- or di-lower alkylamino group), the following formula:

(Wherein R ³² represents a lower alkoxy group)
An amino group optionally substituted with one or two groups selected from a group represented by the above and a nitrogen-containing aliphatic heteromonocyclic group optionally substituted with a lower alkyl group;
(V) an amino group (the group may be substituted with a group selected from a lower alkyl group and an aryl lower alkyl group), a heteroaryl group optionally substituted with a lower alkyl group, and a lower alkyl group; A lower alkoxy group which may be substituted with a group selected from nitrogen-containing aliphatic heteromonocyclic groups which may be
(Vi) a lower alkyl group, lower alkanoyl group, mono- or di-lower alkylamino lower alkyl group, mono- or di-lower alkylamino lower alkoxycarbonyl group, lower alkoxy-lower alkanoyl group, mono- or di-lower optionally substituted with a hydroxyl group Alkylcarbamoyl group, lower alkoxy lower alkoxycarbonyl group, lower alkoxy lower alkyl group, cyclo lower alkylcarbonyl group, aryl lower alkyl group, cyclo lower alkyl group, cyclo lower alkyl lower alkyl group, nitrogen-containing aliphatic heteromonocyclic group substitution Lower alkoxycarbonyl group and the following formula:

(Wherein R ³³ represents an amino group, a mono- or di-lower alkylamino group, or a mono- or di-lower alkylamino lower alkylamino group)
An amino lower alkyl group optionally substituted with a group selected from the groups represented by:
(Vii) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group optionally substituted with a group selected from a hydroxyl group, a lower alkyl group optionally substituted with a hydroxyl group, a lower alkoxy lower alkyl group and a carbamoyl group;
(Viii) a carbamoyl optionally substituted by a group selected from a lower alkyl group, a mono- or di-lower alkylamino lower alkyl group, a heteroaryl group-substituted lower alkyl group and a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group Group;
(Ix) a nitrogen-containing aliphatic heteromonocyclic group which may be substituted with a lower alkyl group (the nitrogen-containing aliphatic heteromonocyclic group may be bonded to the aryl group moiety through an oxygen atom) ;
(X) a nitro group;
(Xi) a cyclo-lower alkyloxy group optionally substituted with a mono- or di-lower alkylamino group;
(Xii) a lower alkenyl group optionally substituted with a group selected from a mono- or di-lower alkylamino group and a nitrogen-containing aliphatic heteromonocyclic group;
(Xiii) a lower alkynyl group optionally substituted with a group selected from a nitrogen-containing aliphatic heteromonocyclic group and a mono- or di-lower alkylamino group;
(Xiv) a lower alkylthio group optionally substituted with a mono- or di-lower alkylamino group; and (xv) a cyclo-lower alkyl lower alkoxy group (the cyclo-lower alkyl portion of the group is a mono- or di-lower alkylamino lower alkyl group). May be substituted),
(B) a nitrogen-containing aliphatic heteromonocyclic group which may be substituted with a group selected from the following (i) to (ix):
(I) a lower alkyl group;
(Ii) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkanoyl group;
(Iii) mono- or di-lower alkylamino lower alkanoyl group;
(Iv) a lower alkoxy lower alkyl group;
(V) a mono- or di-lower alkylamino lower alkyl group;
(Vi) a cyclo-lower alkyl group;
(Vii) a heteroaryl group;
(Viii) a group that may be substituted with a group selected from a lower alkanoylamino group, a lower alkyl group, a carbamoyl group, and a lower alkoxy lower alkyl group, and that may have one or more double bonds in the ring. Nitrogen aliphatic heteromonocyclic groups; and (ix) lower alkyl groups, mono- or di-lower alkylamino lower alkyl groups, cyclo-lower alkylcarbonyl groups, lower alkenoyl groups, heteroarylcarbonyl groups, lower alkoxy lower alkyl groups, lower alkanoyls An amino group which may be substituted with a group selected from a group and a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group,
(C) a cyclo-lower alkyl group substituted with a group selected from the following (i) to (vi):
(I) Lower alkyl group, mono- or di-lower alkylamino lower alkanoyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkanoyl group, mono- or di-lower alkylamino lower alkyl group, lower alkanoyl group, cyclo lower alkylcarbonyl group A lower alkenoyl group, a heteroarylcarbonyl group, an arylcarbonyl group (the aryl portion of the group may be substituted with a halogen atom), a lower alkylthiocarbamoyl group, a lower alkoxycarbonyl group, a cyclo-lower alkyl group,

(Wherein R ³⁴ represents a mono- or di-lower alkylamino group)
An amino group which may be substituted with a group selected from the group represented by: cyclo lower alkyl lower alkyl group and lower alkyl sulfonyl group;
(Ii) Lower alkyl group optionally substituted with a hydroxyl group, mono- or di-lower alkylamino lower alkanoyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkanoyl group, nitrogen-containing aliphatic heteromonocyclic group-substituted lower Alkyl group, mono- or di-lower alkylamino lower alkyl group, heteroaryl group-substituted lower alkyl group, lower alkoxy lower alkyl group, lower alkanoyl group, heteroarylcarbonyl group (the heteroaryl part of the group is substituted with a lower alkyl group) Or a lower alkylcarbonyl group, an aryl lower alkyl group, a cyclo lower alkyl group, a cyclo lower alkyl lower alkyl group, a lower alkyl sulfonyl group, a lower alkoxy carbonyl group, a mono or di lower alkyl carbamoyl group, an aryl carbonyl group ( The group Lumpur moiety may be substituted with a group selected from a halogen atom and lower alkoxy group), amino which may be substituted by a group selected from lower alkoxy-lower alkanoyl group and a lower alkenoyl lower alkyl group;
(Iii) a nitrogen-containing aliphatic heteromonocyclic group optionally substituted with a group selected from a hydroxyl group, a lower alkyl group, a lower alkanoyl group and a lower alkoxy lower alkyl group;
(Iv) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group (the nitrogen-containing aliphatic heteromonocyclic group is a lower alkyl group, a carbamoyl (or thiocarbamoyl) group, a hydroxyl group, a lower alkoxy lower alkyl group, a lower group, They may be substituted with a group selected from an alkanoyl group and a mono- or di-lower alkylamino group, and may be condensed with a benzene ring);
(V) a mono- or di-lower alkylamino lower alkoxy group; and (vi) a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group (the nitrogen-containing aliphatic heteromonocyclic group is substituted with a lower alkyl group). A carbamoyl group optionally substituted with a group selected from a mono- or di-lower alkylamino lower alkyl group and a lower alkyl group,
(D) an amino group optionally substituted with a lower alkyl group, or (E) a heteroaryl group substituted with a group selected from the following (i) to (vii):
(I) an amino lower alkyl group optionally substituted with a group selected from a lower alkyl group and a lower alkoxy lower alkyl group;
(Ii) a group selected from a cyclo lower alkylcarbonyl group, a mono- or di-lower alkylamino lower alkyl group, a lower alkanoyl group, a lower alkenoyl group, a mono- or di-lower alkylthiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group and a lower alkyl group An amino group optionally substituted by:
(Iii) a carbamoyl group which may be substituted with a group selected from a lower alkyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group and a mono- or di-lower alkylamino lower alkyl group;
(Iv) a lower alkyl group which may be substituted with a halogen atom;
(V) a mono- or di-lower alkylamino lower alkoxy group;
(Vi) an oxo group; and (vii) the following formula:

(Wherein ring A may be substituted by a lower alkyl group, and a benzene ring fused with nitrogen-containing aliphatic optionally heteromonocyclic group, Y ^a is a single bond, lower alkylene group or a lower Alkenylene group, p represents 0 or 1)
A group represented by
R ² is
(A) a heteroaryl group which may be substituted with 1 to 3 identical or different groups selected from a lower alkyl group, a lower alkoxy group and a mono- or di-lower alkylamino group, or (b) a lower alkyl group or a halogen atom A halogeno lower alkoxy group, a mono- or di-lower alkylamino group, a lower alkoxy group, a nitro group, a lower alkoxy lower alkyl group, a hydroxyl group, a lower alkoxycarbonyl group and a lower alkanoyl group, the same or different 1 to 3 groups The pharmaceutical composition according to claim 1, which is an aryl group which may be substituted. The pharmaceutical composition according to claim ^2, wherein the aryl group in R ¹ and R ² is a phenyl group or a naphthyl group. The pharmaceutical composition according to claim 2, wherein the nitrogen-containing aliphatic heteromonocyclic group in R ¹ and R ² is a 4- to 8-membered nitrogen-containing aliphatic heteromonocyclic group. The nitrogen-containing aliphatic heteromonocyclic group is an azetidinyl group, pyrrolidinyl group, imidazolidinyl group, pyrazolidinyl group, piperidyl group, piperazinyl group, azepinyl group, diazepinyl group, azeocinyl group, diazeosinyl group, morpholinyl group or 3-pyrrolinyl group Item 5. A pharmaceutical composition according to Item 4. The pharmaceutical composition according to claim 2, wherein the heteroaryl group in R ¹ and R ² is a 5- to 10-membered monocyclic or bicyclic heteroaryl group. Heteroaryl group is pyrrolyl group, imidazolyl group, pyrazolyl group, oxazolyl group, thiazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, dihydropyridyl group, pyrazinyl group, pyrimidinyl group, tetrahydropyrimidinyl group, furopyrimidinyl group, pyridazinyl group, imidazolidinyl Group, indolyl group, quinolyl group, isoquinolyl group, purinyl group, 1H-indazolyl group, quinazolinyl group, cinnolinyl group, quinoxalinyl group, phthalazinyl group or pteridinyl group, nitrogen-containing heteroaryl group, furyl group, pyranyl group, thienyl The pharmaceutical composition according to claim 6, which is a sulfur-containing or oxygen-containing heteroaryl group selected from a group, a benzofuryl group and a benzothienyl group. Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is —CO—, R ² is a phenyl group substituted with a group selected from a lower alkyl group, a lower alkoxy group and a halogen atom, and a lower alkoxy group-substituted heteroaryl The pharmaceutical composition according to any one of claims 2 to 7, wherein a group or a lower alkyl group-substituted heteroaryl group, q is 0. Y is a single bond, Z -CH 2 is _-, R ² is a lower alkoxyphenyl group, a pharmaceutical composition according to any one of claims 2 to 7 q is 0. R ¹ is (1) a phenyl group substituted with a group selected from the following (i) to (iii):
(I) a lower alkoxy group substituted with a group selected from a mono- or di-lower alkylamino group and a nitrogen-containing aliphatic heteromonocyclic group;
(Ii) a lower alkyl group substituted with a group selected from a mono- or di-lower alkylamino group and a nitrogen-containing aliphatic heteromonocyclic group; and (iii) a lower alkyl group, a cyclo-lower alkylcarbonyl group, a mono- or di-lower group. An amino group substituted with a group selected from an alkylamino lower alkyl group, a lower alkoxy lower alkoxycarbonyl group, a nitrogen-containing aliphatic heteromonocyclic group-substituted lower alkyl group, a lower alkanoyl group and a lower alkenoyl group,
(2) a cyclo-lower alkyl group substituted with a group selected from the following (i) to (iii):
(I) an amino lower alkyl group substituted with a group selected from lower alkyl, hydroxy lower alkyl group, mono- or di-lower alkylamino lower alkyl group, lower alkanoyl group, cyclo lower alkylcarbonyl group and lower alkoxy lower alkyl group;
(Ii) a nitrogen-containing aliphatic heteromonocyclic group optionally substituted with a hydroxyl group; and (iii) a lower alkyl group, mono- or di-lower alkylamino lower alkyl group, lower alkanoyl group, heteroarylcarbonyl group, lower alkyl An amino group substituted with a group selected from a sulfonyl group and a lower alkylthiocarbamoyl group, or (3) a nitrogen-containing aliphatic heteromonocyclic group substituted with a group selected from the following (i) to (iii):
(I) a lower alkyl group;
(Ii) an amino group substituted with a group selected from a lower alkyl group, a mono- or di-lower alkylamino lower alkyl group, and a cyclo-lower alkylcarbonyl group; and (iii) a nitrogen-containing aliphatic complex unit substituted with a lower alkyl group; Cyclic groups,
A phenyl group, a lower alkyl group-substituted heteroaryl group or a lower alkoxy group-substituted heteroaryl group, wherein R ² is substituted with a group selected from a lower alkoxy group and a halogen atom,
The pharmaceutical composition according to claim 8 or 9, wherein Q is a methylene group. The group represented by the formula: R ^1- (O) _q -YZ- is a 4- (mono- or di-lower alkylamino lower alkyl) benzoyl group; a 4- (pyrrolidino lower alkyl) benzoyl group; Lower alkylamino lower alkoxy) benzoyl group; 3- (dilower alkylamino lower alkoxy) -4- (dilower alkylamino lower alkoxy) benzoyl group; 4- (piperidino lower alkoxy) benzoyl group; 4- [N-lower alkyl -N- (di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N-lower alkanoyl-N- (di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N-lower alkenoyl-N- ( Di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N-cyclo lower alkylcarbonyl] N- (di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N- (lower alkoxy lower alkoxycarbonyl) -N- (di-lower alkylamino lower alkyl) amino] benzoyl group; 4- [N-lower alkanoyl -N- (pyrrolidino lower alkyl) amino] benzoyl group; [1- (lower alkyl) piperidin-4-yl] carbonyl group; 4- [N-lower alkyl-N- (dilower alkylamino lower alkyl) amino] pi 4- [N-cyclolower alkylcarbonyl-N- (dilower alkylaminolower alkyl) amino] piperidinocarbonyl group; 4-[(dilower alkyl) piperidino] piperidinocarbonyl group; 1- (lower alkyl) piperidin-4-yl] lower alkanoyl group; [1- (lower alkyl) L) piperidin-4-yl] lower alkenoyl group; 4- (di-lower alkylamino lower alkyl) cyclohexylcarbonyl group; 4- (mono- or di-lower alkylamino) cyclohexylcarbonyl group; 4- [N- Lower alkanoyl-N- (di-lower alkylamino lower alkyl) amino] cyclohexylcarbonyl group; 4- [N-lower alkenoyl-N- (di-lower alkylamino lower alkyl) amino] cyclohexylcarbonyl group; 4- [ N-heteroarylcarbonyl-N- (di-lower alkylamino lower alkyl) amino] cyclohexylcarbonyl group; 4- [N-lower alkylthiocarbamoyl-N- (di-lower alkylamino lower alkyl) amino] cyclohexylcarbonyl group 4- [N- (di-lower alkylamino lower alkyl); N- (lower alkylsulfonyl) amino] cyclohexylcarbonyl group; 4-[[N-lower alkyl-N- (hydroxy lower alkyl) amino] lower alkyl] cyclohexylcarbonyl group; 4-[[N-lower alkyl -N- (lower alkoxy lower alkyl) amino] lower alkyl] cyclohexylcarbonyl group; 4-[[N-lower alkanoyl-N- (dilower alkylaminolower alkyl) amino] lower alkyl] cyclohexylcarbonyl group; 4-[[N- (cycloloweralkylcarbonyl) -N- (diloweralkylaminoloweralkyl) amino] loweralkyl] cyclohexylcarbonyl group; 4- (pyrrolidinyl) cyclohexylcarbonyl group; Dinyl) cyclohexylcarbonyl group; or 4- (piperidi) ) Cyclohexyl group, and R ^2, claim 8 is 1 or 2-substituted phenyl, ethoxy pyridyl group, a propyl pyridyl group, or a propyl thiazolyl group selected from ethoxy and fluorine atom The pharmaceutical composition as described. R ² is 3-ethoxyphenyl group, 6-propylpyridin-2-yl group, 6-ethoxypyridin-2-yl group, 2-propyl-1,3-thiazol-4-yl group or 3-ethoxy-2 The pharmaceutical composition according to claim 10 or 11, which is a -fluorophenyl group. 1- (3-ethoxybenzyl) -4- [4- [4- [2- (dimethylamino) ethoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- [2- (1-piperidyl) ethoxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (dimethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (diethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (1-pyrrolidinylmethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N- (cyclopropylcarbonyl) -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-[(2-methoxyethoxy) carbonyl] -N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl ] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-isobutyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[(1-propylpiperidin-4-yl) carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [3- (1-isopropylpiperidin-4-yl) propionyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (dimethylaminomethyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[(E) -3- (1-isopropylpiperidin-4-yl) acryloyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] Pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [3- (dimethylamino) -2,2-dimethylpropyloxy] benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4 d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4- [4- [3- (dimethylamino) -2,2-dimethylpropyloxy] benzoyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-acetyl-N- [2- (1-pyrrolidinyl) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3 , 4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4- [4- (ethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4-((3S) -3-hydroxy-1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3 4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N- (2-furoyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazine-1- Yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- [N- (crotonoyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N- (methylthiocarbamoyl) -N- [2- (dimethylamino) ethyl] amino] cyclohexyl] carbonyl] piperazin-1-yl ] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4- [4- [N-crotonoyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazine -1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (1-pyrrolidinyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (diethylaminomethyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- [N-isopropyl-N- (2-methoxyethyl) aminomethyl] cyclohexyl] carbonyl] piperazine-1 -Yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4- [4- [2,2-dimethyl-3- (dimethylamino) propyloxy] benzoyl] piperazine-1 -Yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (dipropylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4- (dipropylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4 -D] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4- (1-piperidyl) cyclohexyl] carbonyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4- (ethylamino) cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [3- [2- (diisopropylamino) ethoxy] -4- [3- (dimethylamino) -2,2- (dimethyl) propyloxy] benzoyl] piperazine -1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- [N- (cyclopropanecarbonyl) -N- [2- (dimethylamino) ethyl] amino] piperidinocarbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4- [4- (3,3-dimethylpiperidino) piperidinocarbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine ;
1- (3-Ethoxybenzyl) -4- [4- [4- [N-ethyl-N- [2- (dimethylamino) ethyl] amino] piperidinocarbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N-ethylamino] methyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl) [Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl [Cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) Ethyl] amino] methyl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxybenzyl) -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (hydroxy) ethyl] amino] methyl] cyclohexyl] carbonyl] piperazine- 1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N- (methanesulfonyl) amino] cyclohexyl] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-Ethoxypyridin-2-yl) methyl] -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N- (methanesulfonyl) amino] cyclohexyl] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(2-propyl-1,3-thiazol-4-yl) methyl] -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N- (methanesulfonyl) ) Amino] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- [2- (dimethylamino) ethyl] -N-pivaloylamino] methyl] cyclohexyl] carbonyl Piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1-[(6-propylpyridin-2-yl) methyl] -4- [4-[[trans-4-[[N- (cyclopropanecarbonyl) -N- [2- (dimethylamino) ethyl] amino] Methyl] cyclohexyl] carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxybenzyl) -4- [4-[[trans-4- [N- [2- (dimethylamino) ethyl] -N-propionylamino] cyclohexyl] carbonyl] piperazin-1-yl] -1H -Pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxy-2-fluorobenzyl) -4- [4-[(trans-4-piperidin-1-ylcyclohexyl) carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] Pyrimidine;
1- (3-Ethoxy-2-fluorobenzyl) -4- [4-[[trans-4-[[N- (t-butyl) -N- [2- (methoxy) ethyl] amino] methyl] cyclohexyl] Carbonyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-ethoxy-2-fluorobenzyl) -4- [4- [4- (ethylaminomethyl) benzoyl] piperazin-1-yl] -1H-pyrazolo [3,4-d] pyrimidine;
1- (3-Ethoxy-2-fluorobenzyl) -4- [4- [4- [N-acetyl-N- [2- (dimethylamino) ethyl] amino] benzoyl] piperazin-1-yl] -1H- Pyrazolo [3,4-d] pyrimidine;
Or the pharmaceutical composition which uses those pharmacologically acceptable salt as an active ingredient. The pharmaceutical composition according to any one of claims 1 to 13, which is a SK channel blocker. The pharmaceutical composition according to any one of claims 1 to 13, which is a prophylactic / therapeutic agent for gastrointestinal motility dysfunction, central disease, myotonic dystrophy, sleep apnea or bladder dysfunction. The medicament according to claim 15, wherein the gastrointestinal dysfunction is constipation or irritable bowel syndrome, the central disease is learning memory disorder, emotional disorder or Alzheimer's dementia, and bladder dysfunction is dysuria. Composition.